WO2006094357A1 - Flavonoid compounds and uses thereof - Google Patents

Flavonoid compounds and uses thereof Download PDF

Info

Publication number
WO2006094357A1
WO2006094357A1 PCT/AU2006/000314 AU2006000314W WO2006094357A1 WO 2006094357 A1 WO2006094357 A1 WO 2006094357A1 AU 2006000314 W AU2006000314 W AU 2006000314W WO 2006094357 A1 WO2006094357 A1 WO 2006094357A1
Authority
WO
WIPO (PCT)
Prior art keywords
ester
flavone
compound
benzopyran
phenyl
Prior art date
Application number
PCT/AU2006/000314
Other languages
French (fr)
Inventor
Gregory James Dusting
Owen Llewellyn Woodman
Bevyn Jarrott
Clive Newton May
Original Assignee
Howard Florey Institute Of Experimental Physiology And Medicine
Neuprotect Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2005901214A external-priority patent/AU2005901214A0/en
Priority to CN2006800078033A priority Critical patent/CN101137639B/en
Priority to AU2006222556A priority patent/AU2006222556B2/en
Priority to KR1020077023356A priority patent/KR101397510B1/en
Priority to US11/885,736 priority patent/US8017649B2/en
Priority to NZ560633A priority patent/NZ560633A/en
Application filed by Howard Florey Institute Of Experimental Physiology And Medicine, Neuprotect Pty Ltd filed Critical Howard Florey Institute Of Experimental Physiology And Medicine
Priority to CA2601028A priority patent/CA2601028C/en
Priority to JP2008500009A priority patent/JP5380069B2/en
Priority to ES06704987.4T priority patent/ES2552108T3/en
Priority to EP06704987.4A priority patent/EP1856085B1/en
Priority to DK06704987.4T priority patent/DK1856085T3/en
Priority to BRPI0608402A priority patent/BRPI0608402B8/en
Publication of WO2006094357A1 publication Critical patent/WO2006094357A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/32—2,3-Dihydro derivatives, e.g. flavanones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/6552—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring
    • C07F9/65522—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring condensed with carbocyclic rings or carbocyclic ring systems

Definitions

  • the present application claims priority from Australian Provisional Patent Application No. 2005901214 filed on 11 March 2005, the content of which is incorporated herein by reference.
  • FIELD OF THE INVENTION The present invention relates to novel compounds, compositions containing these compounds, methods for their synthesis, and uses of these compounds.
  • the present invention relates to flavonoid compounds, methods of synthesizing the flavonoid compounds, compositions containing the flavonoid compounds and methods of their use.
  • Prompt reperfusion of ischemic tissue is critical for restoring normal function.
  • This return of blood flow can paradoxically produce a progressive destruction of reversibly damaged cells, thereby leading to tissue dysfunction and infarction.
  • This "reperfusion injury” has multifactorial causes of disease but appears to be strongly associated with, an inflammatory response; with the return of blood flow, several inflammatory processes may occur to potentiate ischemic injury, including leukocyte adhesion and infiltration and the release of reactive oxidative species (ROS) such as oxygen free radical species and peroxides, for example H 2 O 2 .
  • ROS reactive oxidative species
  • ILs interleukins
  • Leukocytes white blood cells
  • leukocytes can obstruct the microcirculation directly.
  • This leukocyte capillary plugging also may be the major mechanism of the "no-reflow phenomenon.”
  • Myocardial ischaemia in particular causes extensive capillary plugging.
  • Ischaemia, and particularly reperfusion tend to promote an increased release of ROS's from leukocytes which leads to further tissue damage.
  • One of the most damaging types of free radicals is superoxide anions which act to impair endothelial function and the activity of nitric oxide (NO). This further worsens the capillary plugging process because NO has been shown to inhibit platelet aggregation and to prevent leukocyte adherence to the endothelium.
  • the degree of tissue recovery achieved after ischaemia and reperfusion depends on the nature of the tissue and the severity of the damage.
  • Ischaemia can be caused by a variety of conditions. For example, acute incidents such as stroke, myocardial infarction or mechanical trauma, and chronic conditions such as atherosclerosis, peripheral vascular disease and diabetes can cause ischaemia. Hypertension is another type of disorder that can lead to ischaemia.
  • Flavonoids are a very large and widespread group of plant derived compounds which are thought to exhibit a number of biological effects including reducing plasma levels of low density lipoproteins, inhibiting platelet aggregation, scavenging free radicals and reducing cell proliferation as well as modulating vascular tone.
  • a vast number of flavonoids have been identified and differ from one another in the orientation of the hydroxylation or methylation, the position of the benzenoid substituent, the degree of unsaturation and the types of substituents attached.
  • the general three ring structure (A, B and C rings) of many flavonoids are based on the structure of 2-phenyl-4H-1-benzopyran-4-one.
  • the synthetic flavonoid, 3',4'-dihydroxy flavonol has a hydroxyl group at the 3,3'- and 4' positions and has been demonstrated to reduce infarct and injury associated with myocardial ischaemia and reperfusion during in vitro studies (Shen Wang, Gregory Dusting, Give May and Owen Woodman, British Journal of Pharmacology (2004) 142, 443-452).
  • the present invention provides a pharmaceutically and/or veterinary composition
  • a pharmaceutically and/or veterinarily acceptable carrier or diluent together with at least one compound of the general Formula I:
  • R 1 , R 2 , R 3 , R 4 , R 5 are independently selected from H, OH or a group according to Formula (Ia):
  • O oxygen
  • L is a linker group which is covalently linked to the oxygen and D, if present, or is covalently linked to the oxygen and E, or is absent;
  • D is a spacer group having a chain length equivalent to about 1 to 20 carbon atoms, or is absent; and E is a solubilizing group; provided that at least one of R 1 , R 2 , R 3 , R 4 , R 5 is other than H or OH.
  • E is selected from an ester, a carboxylic acid, sulfonic acid, phosphonic acid, phosphate ester, sulfamate, sulfonic ester, phosphamate, phosphonate ester, sulphonate, zwitterionic specie, amino acid, amino phosphonate, acyclic arnine, cyclic amine, quaternary ammonium cation, polyethylene glycol, oligosaccharide or dendrimer.
  • E is a selected from an ester, carboxylic acid, sulfonic acid, phosphonic acid, phosphate ester, polyethylene glycol, oligosaccharide or dendrimer.
  • E is selected from an ester, carboxylic acid or phosphate ester.
  • E is group according to Formula (Ib):
  • W is O, KH, S, O-, NH- or S-;
  • X is H, a mono- or divalent cationic salt, or an ammonium cationic salt.
  • W is O and/or X is H.
  • E is an ester according to the Formula (Ic):
  • Q is a substituted or unsubstituted alkylene, alkenylene, alkynylene, optionally interrupted by one or more heteroatom(s);
  • W is O, NH, S, O-, NH-, or S-;
  • X is H, substituted or unsubstituted alkyl, alkylbenzyl, a mono- or divalent cationic salt, or an ammonium cationic salt.
  • Q is a substituted or unsubstituted lower alkylene.
  • E is a phosphate ester according to the Formula (Id):
  • Y is O, NH, S, O-, NH-, or S-;
  • Z is O or S;
  • R 6 and R 7 are independently selected from H, substituted or unsubstituted alkyl, a mono- or divalent cationic salt, or an ammonium cationic salt.
  • Y and Z are O.
  • at least one of R 1 , R 2 , R 3 , R 4 and R 5 is phosphate ester according to the formula (Ie):
  • R 6 and R 7 are independently selected from H, a mono- or divalent cationic salt, or an ammonium cationio salt.
  • L is present and selected from -CO-, ester, phenol, phosphonate ester, carbamate, carbonate or a Mannich base. In a more preferred . embodiment, L is -CO-- In another embodiment, D present and selected from substituted or unsubstituted alkylene, alkenylene, alkynylene, optionally interrupted by one or more heteroatom(s), aryl, heteroaryl, cycloalkyl or heterocycloalkyl.
  • D is a substituted or unsubstituted alkylene, optionally interrupted by one or more heteroatom(s).
  • a lower alkylene Preferably, a pharmaceutically and/or veterinary composition
  • a pharmaceutically and/or veterinary composition comprising a pharmaceutically and/or veterinarily acceptable carrier or diluent together with at least one compound of the general Formula II:
  • R 1 , R 2 and R 3 are as specified above.
  • the present invention provides a pharmaceutically and/or veterinary composition
  • a pharmaceutically and/or veterinary composition comprising a pharmaceutically and/or veterinarily acceptable carrier or diluent together with at least one compound of the general Formula III: wherein R 3 is specified above.
  • the present invention provides a pharmaceutically and/or veterinary composition
  • a pharmaceutically and/or veterinary composition comprising a pharmaceutically and/or veterinarily acceptable carrier or diluent together with at least one compound of the general Formula IV:
  • Q is substituted or unsubstituted alkylene, optionally interrupted by one or more heteroatom(s)
  • X is H, a mono- or divalent cationic salt, or an ammonium cationic salt.
  • Q is substituted or unsubstituted lower alkylene, optionally interrupted by one or more heteroatom(s).
  • the present invention provides a compound selected from the group 3-(Benzyloxycarbonylbutylcarbonyloxy)flavone; 3-Hydro ⁇ yflavone 3- hemiadipate; 4'-(Ben3yloxy)-3-(benzyIoxycarbonylbutylcarbonyloxy)flavone; 4'- Hydroxyflavone 3-hemiadipate; 3',4'-Dibenzyloxy-3-
  • the present invention provides a pharmaceutically and/or veterinary composition
  • a pharmaceutically and/or veterinary composition comprising a pharmaceutically and/or veterinarily acceptable carrier or diluent together with at least one compound selected from the group comprising 3-(Ben 2 ylo ⁇ ycarbonylbutylcarbonyloxy)flavone; 3-Hydroxyflavone 3- hemiadipate; 4'-(Beo 2 yloxy)-3-(beiizyloxycarbonylbutylcarbonyloxy)flavo-ie; 4'- Hydroxyfiavone 3-hemiadipate; 3',4 5 -Dibenzyloxy-3- (benzyloxycarbonylbutylcarbonyloxy)fiavone; 3',4'-Dib.ydroxyflavone 3- hej ⁇ iiadipate;3,4'-DI-(beo 2 yloxycarbony3butylcarbonyloxy)flavone;
  • the present invention provides a method of preventing and/or treating a disease(s) in a subject associated with the presence of reactive oxidative species (ROS), the method comprising: administering an effective amount of at least one compound specified above.
  • the subject in need of such treatment is at risk of developing ischaemia. More preferably, the subject is suffering ischaemia and/or reperfusion injury as a result of an acute or chronic condition.
  • the chronic condition is selected from cancer, cerebrovascular, disease, pulmonary vascular disease, atherosclerosis, artery disease, congestive heart disease, coronary disease, peripheral vascular disease, diabetes, hypertension, migraine, bums, chronic obstructive pulmonary disease and retinal vascular disease.
  • the acute condition is selected from stroke, myocardial infarction, mechanical trauma resulting from crush injury or surgery.
  • the surgery is vascular surgery. More preferably, the vascular surgery is heart bypass and/or transplant surgery.
  • the compound is administered to the subject before and/Or during the surgery.
  • the present invention provides a method of preventing, delaying the onset of and/or slowing the progression of atherosclerosis and/or coronary heart disease in a subj ect comprising administering an effective amount of at least one compound specified above.
  • the present invention provides a therapeutic and/or prophylactic method of preventing and/or treating a disease(s) in a subject associated with the presence of reactive oxidative species (ROS), the method comprising: axJministering an effective amount of at least one compound specified above.
  • ROS reactive oxidative species
  • the present invention provides a method of preventing and/or at least ameliorating the damage to a subject caused by isehaemia and/or reperfusion injury, the method comprising administering an effective amount of at least one compound specified above.
  • the present invention provides a method of preventing and/or at least ameliorating damage to a subject caused by the administration of a therapeutic agent the method comprising co-administering to a subject: i) a therapeutic agent: and ii) administering an effective amount of at least one compound specified above.
  • the therapeutic agent is an oxidative therapeutic agent
  • the therapeutic agent is an anticancer agent
  • the anticancer agent is anthiacycline and its derivatives.
  • the compound is administered orally, topically, subcutaneous, parenterally, intramuscular, intra-arterial and/or intravenously.
  • the present invention provides for the use of a compound as Specified above for the preparation of a medicament.
  • the present invention provides a compound of the general Formula I:
  • R 1 , R z , R 3 , R 4 , R s are independently selected from H, OH or a group according to Formula (Ia):
  • O oxygen
  • L is a linker group which is covalently linked to the oxygen and D, if present, or is covalently linked to the oxygen and E, or is absent;
  • D is a spacer group having a chain length equivalent to about 1 to 20 carbon atoms, or is absent;
  • E is a solubilizing group; provided that at least one of R 1 , R 2 , R 3 , R 4 , R 5 is other than H or OH, with the proviso that the compound is not flavone, 3 '-hydroxy-, acetate; Flavone.,
  • R 1 , R 2 , R 3 , R 4 and R 5 are as specified above.
  • the present invention provides a compound according to the general Formula (II):
  • R 1 , R 2 and R 3 are as specified above.
  • the present invention provides a compound according to the general Formula (III):
  • Q is substituted or unsubstituted alkylene, optionally interrupted by one or more heteroatom(s)
  • X is H, a mono- or divalent caiionic salt, or an ammonium cationic salt.
  • Q is substituted or unsubstituted lower alkylene, optionally interrupted by one or more heteroaiom(s).
  • the present invention provides a compound according to the general Formula V:
  • the present invention provides a method for synthesizing compounds as specified above.
  • the present invention provides compounds of general Formula:
  • R 1 , R 2 , R 3 , R 4 , R 5 which are independently selected from H, OH, substituted or unsubstituted alkoxy. aryloxy, esters, carbonate esters, ethers, phosphate esters and ⁇ - acyloxyalkyl ethers provided that at least one of R 1 , R 2 , R 3 , R 4 , R 5 is other than H or OH; and pharmaceutically acceptable salts or solvates thereof,
  • At least R 3 is selected from substituted or unsubst ⁇ t ⁇ ted esters, carbonate esters, ethers, phosphate esters and ⁇ -acyloxyalkyl ethers.
  • At least one of R 1 , R 2 , R 3 , R 4 or R 5 is selected from: i) phosphate having the general formula
  • R 6 and R 7 are independently selected from substituted or unsubstituted alkyl, H, a mono- or divalent cationic salt, or an ammonium cationic salt; ii) ester having the general formula
  • R 8 is a substituted or unsubstituted lower alkyl, lower alkyla ⁇ koxy; iii) ester having the general formula
  • Q is a substituted or unsubstituted lower alkylene, lower alkenyl, and alkynyl
  • W is O. NH, S, O; NH-, or S-;
  • X is H, substituted or unsubstituted alkyl, alkylbenzyl, a mono- or divalent cationic salt, or an ammonium catiooic salt, and pharmaceutically acceptable salts or solvates thereof.
  • Y and Z are both O-
  • the present invention provides compounds of general Formula:
  • R 1 , R 2 or R 3 which are independently selected from H, OH, substituted or unsubstituted alkoxy, aryloxy, esters, carbonate esters, ethers, phosphate esters and ⁇ - acyloxyalkyl ethers provided that at least one of R 1 , JR 2 or R 3 is other than H or OH; . and pharmaceutically acceptable salts or solvates thereof.
  • R 1 , R 2 or R 3 is selected from: i) phosphate having the general formula
  • Y is O, NH, S, O-, NH-, or S-;
  • Z is O or S; and each of R 6 and R 7 ate independently selected from substituted or unsubstituted alkyl, H, a mono- or divalent cationic salt, or an ammonium cationic salt; ii) ester having the general formula
  • R 8 is a substituted or unsubstituted lower alkyl, lower alkylalkoxy; iii) ester having the general formula
  • Q is a substituted or unsubstituted lower alkylene, lower alkenylene, alkynylene, optionally interrupted by one or more heteroatom(s);
  • W is O, NH, S, O-, NH-, or S-; and X is H, substituted or unsubstituted alkyl, alkylbenzyl, a mono- or divalent cationic salt, or an ammonium cationic salt; and pharmaceutically acceptable salts or solvates thereof.
  • R 1 is H or OH;
  • R 2 is H or OH; and
  • R 3 is selected from
  • the present invention provides a compound of general
  • R 9 is substituted or unsubstituted alkoxy, aryloxy, ester, carbonate ester, ether,
  • U is substituted or unsubstituted alkylene, optionally interrupted by one of more heteroatom(s).
  • the present invention provides a compound of general Formula:
  • n is an integer from 2 to 6, preferably n is 4.
  • the present invention provides methods for synthesizing compounds in accordance with Formula I, Formula II, Formula III or Formula IV, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 8 , U, Q, W, X, Y, Z, n have title same meaning as above, or a pharmaceutically acceptable salt or solvates thereof.
  • the present invention provides a pharmaceutical and/or a veterinary composition
  • a pharmaceutical and/or a veterinary composition comprising & pharmaceutically anchor veteriuarily acceptable carrier or diluent together with at least one compound in accordance with Formula I, Formula H, Formula III or Formula IV, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R s , U, Q, W, X, Y, Z, n have the same meaning as above, or a pharmaceutically acceptable salt Or solvates thereof.
  • a method of preventing and/or at least ameliorating damage to a subject caused by the administration of a therapeutic agent comprising co-administering to a subject: i) a therapeutic agent; and ii) an effective amount of at least one compound in accordance with Formula I, Formula 33, Formula IH, Formula IV, or 'Formula V, wherein R 1 , R 2 , R 3 , R 4 . R 5 , R 6 , R 7 , R 8 , R 8 , U, Q, W, X, Y, Z, ii have the same meaning as above, or a pharmaceutically acceptable salt or solvates thereof.
  • the present invention provides a method of preventing and/or treating a disease(s) associated with the presence of reactive oxidative species (ROS), the method comprising administering an effective amount of at least one compound in accordance with Formula I, Formula 11, Formula UI , Formula FV, or Formula V, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R s , R s , U, Q, W, X, Y, Z, n have the same meaning as above, or a pharmaceutically acceptable salt or solvates thereof.
  • ROS reactive oxidative species
  • the present invention provides a method of preventing and/or treating a disease(s) associated with the presence of reactive oxidative species (ROS), the method comprising administering an effective amount of at least one compound in accordance wjth Formula I, Formula II, Formula m or Formula IV, wherein R 1 , R 2 , R 3 , R*, R s , R 6 , R 7 , R 8 , R 8 , U, Q, W, X, Y, Z, n have the same meaning as above, or a pharmaceutically acceptable salt oi solvates thereof.
  • ROS reactive oxidative species
  • the subject in. need of such treatment will be a person at risk of developing ischaemia.
  • the subject may be a person who is currently suffering ischaemia and/or reperfusion as a result of an acute or chronic condition.
  • the present invention provides a method of preventing and/or at least ameliorating the damage to a subject caused by ischaemia and/or reperfiision, the method comprising administering an effective amount of at least one compound an effective amount of at least one compound in accordance with Formula I, Formula II, Formula III or Formula IV, wherein R 1 , R 2 . R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 8 , U, Q, ' W, X, Y, Z, n have the same meaning as above, or a pharmaceutically acceptable salt or solvates thereof.
  • the solubilizing group renders the compound at least partially soluble, and more preferably, totally soluble in aqueous solution, preferably water.
  • the compounds of the invention have at least one in vivo enzyme cleavable substituent.
  • the in vivo enzyme cleavable substituent is an ionisable group at physiological pH.
  • BREEF DESCRIPTION OF THE DRAWINGS Figure 1 illustrates the synthetic scheme for the synthesis of 3-hydroxyflav ⁇ ne-
  • Figure 2 illustrates the synthetic scheme for the synthesis of 3',4'- dihydroxyflavone-3 -phosphate (10).
  • Figure 3 illustrates the synthetic scheme for the synthesis of 3-hydroxyflavone- 3-hemisuccinate (15) via the succinic acid monobenzyl ester.
  • Figure 4 illustrates the synthetic scheme for the synthesis of 3-bydroxyflavone- 3-hemiadipate (19) via adipic acid monobenzyl ester.
  • FIG 5 illustrates Hie synthetic scheme .for the synthesis of 3',4'- dihydroxyilavone-3-herniadipate (21).
  • Figure 6 illustrates the effects of vehicle CdH 2 O), Flavone-3-hemiadipate (19)
  • F3HA in the presence and absence of butyryl cholmesterase (BuCHE, 1000 U/L) and DiOHF (10 -4 M) on the level of superoxide anions generated in rat aorta in the presence of NADPH expressed as a percentage of control.
  • Figure 7 illustrates the effects of Vehicle CdH 2 O), 3 ⁇ 4'-dihydroxyflavone-3- hemiadipate (21) (DiOHFSHA, 10 -6 M- 10 -4 M) in the presence and absence of butyryl choHnesterase (BuCHE, 1000 U/L) and DiOHF (10 -4 M) on the level of superoxide anions generated in rat aorta in the presence of NADPH expressed as a percentage of control.
  • DiOHFSHA 3 ⁇ 4'-dihydroxyflavone-3- hemiadipate
  • Figure 8 illustrates the concentration response curves to Ca 2+ in the presence of vehicle or 3',4'-dmydroxyflavone-3-hemiadipate (21) (DiOHF3HA, 10 -4 M), in the presence and absence of BuCHE, compared to DiOHF in endothelium intact aortic rings isolated from rats.
  • the contractions are expressed as a percentage of the initial response to Ca 2+ (3x10 -3 M) observed before treatment with DiOHF3HA.
  • Figure 9 illustrates the effects of vehicle CdH 2 O), Flavone-3-phosphate (F3P, 10 -8 M to 10-* M) in the presence phosphatase (1000 U/L) and DiOHF (10 -4 M) on the level of superoxide anions generated in rat aorta in the presence of NADPH expressed as a percentage of control.
  • F3P Flavone-3-phosphate
  • DiOHF 10 -4 M
  • Figure 10 illustrates the concentration response curves to Ca 2+ in the presence of vehicle or flavone-3-phosphate (F3P, 10 -8 M to 10 -4 M) in the presence and absence of phosphatase (P, 1000 U/L) in endothelium intact aortic rings isolated from rats.
  • the contractions are expressed as a percentage of the initial response to Ca 2+ (3x10 -3 M) observed before treatment with flavone-3 -phosphate.
  • Figure 11 illustrates the direct relaxing effect of vehicle, 1000U/L BuCHE
  • DiOHF3HA (10 -4 M) plus 1000U/L BuCHE had a marked effect on vascular tone in rat aorta precontracted with PE.
  • Figure 12(a) illustrates the dose-dependent decrease in MAP (mm Hg) indicating vasodilatation in response to DiOHF3HA in anaesthetised rats.
  • Figure 12(b) illustrates the dose-dependent decrease in HR (beats/min) in response to DiOHF3HA.
  • Figure 13 illustrates the decrease in MAP (mm Hg) indicating vasodilatation in response to ACh in anaesthetised rats, dilator response to ACh was enhanced by 30 min pre-treatment with 3 mg/kg DiOHF3HA.
  • Figure 14 illustrates the concentration response curves to PE generated in the presence of control, DiOHF3HA with and without BuCHE and DiOHF in rat aortic rings.
  • DiOHF3HA in the presence of BuCHE and DiOHF both appeared to inhibit the response to PE in a concentration dependent manner.
  • Figure 15 illustrates the effect of phosphatase(1000U/L) and flavone-3- phosphate, (F3P) (10 -5 M-10 -4 M) with phosphatase on concentration response curves to
  • Figure 16a illustrates the dose-dependent decreases in, MAP (mm Hg) in response to F3P and DiOHF in anaesthetised rats.
  • Figure 16b illustrates the dose-dependent decrease in, HR (beats/min) in response to F3P and DiOHF in anaesthetised rats.
  • Figure 17 illustrates the area of myocardium at risk (left panel) and myocardial infarct size (right panel) in.
  • AR/LV% area at risk expressed as a percentage of total left ventricular volume.
  • IS/AR% infarct size expressed as a percentage of the area of myocardium at risk * indicates significant difference in infarct size between Control and Adipate (6.6 mg/kg)-treated animals.
  • Figure 18 illustrates the latency to touch (A & C) and remove (B & D) a stimulus on the contralateral forelimb compared with the ipsilateral forelimb assessed 24, 48, and 72 hours after ET-1-induced stroke and treatment with vehicle (A & B) or DiOHF3HA (15 mg/kg/day) (C & D) in mild to moderate stroke rats.
  • Figure 19 illustrates the effect of delayed administration of DiOHF3HA (15 mg/kg/day) or vehicle on infarct area in cortex (A) and striatum (B) in mild to moderate stroke rats.
  • alkyl includes branched or unbranched hydrocarbon chains, such as, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tertbutyl, octa-decyl and 2-methylpentyl. These groups can be substituted or unsubstituted with one or more functional groups which are attached commonly to such chains, such as, hydxoxyl, bromo, fluoro, chloro.
  • alkylthio iodo, mercapto or thio, cyano, alkylthio, heterocyclyl, aryl, heteroaryl, carboxyl, carbalkoyl, alkyl, alkenyl, nitro, amino, alkoxyl, amido, and the like to form alkyl groups such as trifluoromethyl, 3- hydroxyhexyl.2-carboxypropyl, 2-fluoroethyl, carboxymethyl, cyanobutyl and the like.
  • lower herein includes a linear or branched chain of 1 to 6 carbon atoms-
  • alkylene refers to a divalent alkyl as defined above, such as methylene (-CH 2 -), propylene (-CH 2 CH 2 CH 2 -), chloroethylene (-CHCICH 2 -), 2- thiobutene -CH 2 CH(SH)CH 2 CH 2 , l-bromo-3-hydroxyl-4H ⁇ iemylpenterie (- CHBrCH 2 CH(OH)CH(CH 3 )CH 2 -), .methylethylene, trimethylene, 1-propytene, 2- propyleiie, teirarnethylene, l-msthyltrimethylene, 2-methyltritnethylene, 3- methyltrimethylene , l-ethylethylene, 2-ethylethylene , pentamethylene, 1- methyltetramethylene, 2-memyltetramethylene, 3-methyltetramethyIene, 4- methyltetramethylene and hexamethylene and the like.
  • alkenyl includes branched or unbranched hydrocarbon chains containing one or more carbon-carbon double bonds.
  • alkynyl includes branched or unbranched hydrocarbon chains containing one or more carbon-carbon triple bonds.
  • aryl is meant an aromatic carbocyclic group having a single ring (e.g., phenyl), multiple rings (e.g., biphenyl), or multiple condensed rings in which at least one is aromatic, (e.g., 1,2,3,4-tetrahydronaphthyl, naphthyl), which is optionally mono-, di-, or tri-substituted.
  • the aryl groups herein are unsubstituted or, as specified, substituted in one or more substitutable positions with various groups.
  • cycloalkyl refers to saturated carbocyclic radicals having three to twelve carbon atoms.
  • the cycloalkyl can be monocyclic, or a polycyclic fused system. Examples of such radicals include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.
  • the cycloalkyl groups herein are unsubstituted or, as specified, substituted in one or more substitutable positions "with various groups.
  • such cycloalkyl groups may be optionally substituted with C 1 -C 6 alkyl, C 1 -C 6 alkoxy, halogen, hydroxy, cyano, nitro, amino, mono(C 1 -C 6 )alkylamino, di(C 1 - C 6 )alkylamino, C 1 -C 6 alkenyl, C 1 -C 6 alkynyl, C 1 -C 6 haloalkyl, C 1 -C 6 haloalkoxy, amino(C 1 -C 6 )alkyl, mono(C 1 -C 6 )alkylamino(C 1 -C 6 )alkyl or di(C 1 -C 6 )alkylamino(C 1 - C 6 )alkyl.
  • acyl includes an -C(O)R group, wherein R is alkyl or aryl as defined above, such as formyl, acetyl, propionyl, or
  • alkoxy includes -OR-. wherein R is alkyl.
  • lower alkoxy radicals there may be mentioned linear and branched alkoxy groups of 1 to 6 carbon atoms, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, tert-butoxy, pentyloxy, isopentyloxy, hexyloxy and isohexyloxy groups.
  • amido includes an amide linkage: -C(O)NR- (wherein R is hydrogen or alkyl).
  • amino indicates an amine linkage: -NR-, wherein R is hydrogen or alkyl.
  • carboxyl indicates -C(O)O-, and the term “carbonyt” indicates -
  • carbonate indicates -OC(O)O-.
  • sulfonate indicates -S(O) 2 O-.
  • phosphonate ester indicates The term “carboxylic acid” indicates -C(O)OH.
  • sulfonic acid indicates -S(O) 2 OH.
  • phosphonic acid indicates -P(O)(OH) 2 .
  • phosphamate indicates -Ar-NHPO 4 -.
  • phosphate ester indicates -O-P(O)(OR) 2 *
  • sulfamate indicates -Ar-NHSO 3 -.
  • sulfonic esters indicates -S(O) 2 -OR.
  • sulfonate indicates -S(O) 2 O-.
  • phosphonate ester indicates R-P(O)(OR) 2 .
  • carboxylic acid indicates -C(O)OH.
  • sulfonic acid indicates -S(O) 2 OH
  • phosphonic acid indicates -P(O)(OH) 2 .
  • phosphamate indicates -Ar-NHPO 4 -
  • the hydrocarbon chains can be optionally interrupted by one or more heteroatoms.
  • the linker group may be any of a number of such molecules known in the area described herein.
  • the spacer group D may be absent. It is also clear from the above description that the linker group may be absent. DESCRIPTION OF THE EMBODIMENTS
  • the present invention provides flavonoid derivatives and compositions containing tlavonoid derivatives, and methods of using same.
  • ROS reactive oxidative species
  • Some examples of ROS molecules include singlet O 2 , H 2 O 2 , free radicals such a$ OH : , O 2 -' , NO ' , and ROO-. Many of these species are formed during normal metabolic activity, but their concentration levels can be elevated under conditions of oxidative stress associated with chronic infJatmmation, infections and other diseases. Many ROS molecules are the result of naturally occulting processes such as oxygen metabolism and inflammatory processes. For example, when cells use oxygen to generate energy, free radicals are created as a consequence of ATP production by the mitochondria.
  • Exercise can increase the levels of free radicals a$ can environmental stimuli such as ionizing radiation (from industry, sun exposure, cosmic rays, and medical X-rays), environmental toxins, altered atmospheric conditions (e,g. hypoxia and hyperoxia), • ozone and nitrogen oxide (primarily from automobile exhaust, therapeutics). Lifestyle stressors such as cigarette smoking and excessive alcohol consumption are also known to affect levels of free radicals. Radical species may combine to form other more damaging Or toxic species such as peroxymtrite ONOO-, a product of superoxide and nitric oxide radical reaction.
  • ROS species Another source of ROS species is some therapeutic agents, such as ami-cancer drugs.
  • Anthracycline derivatives are highly useful anti-cancer agents in the treatment of neoplastic diseases such as acute leukemia, malignant lymphoma, etc.
  • neoplastic diseases such as acute leukemia, malignant lymphoma, etc.
  • an undesirable feature of their administration can be oxidative damage to tissue, which can lead to cardiomyopathy and possible heart failure.
  • the presence of the therapeutic agent can therefore cause the development of congestive heart failure (CHF).
  • CHF congestive heart failure
  • a method of preventing and/or at least ameliorating damage to a subject caused by the administration of a therapeutic agent comprising co-administering to a subject: i) a therapeutic agent; and ii) an effective amount of at least one compound in accordance with Formula I, Formula II, Formula in or Formula TV, wherein R 1 . R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 8 , U, Q, W, X, Y, Z, n have the same meaning as above, or a pharmaceutically acceptable salt or solvates thereof.
  • the present invention provides a method of preventing and/or at least ameliorating UV damage to the skin of a subject, comprising administering a therapeutically effective amount of the composition of the invention.
  • the composition is formulated into a sunscreen.
  • the composition may be topically applied to the skin.
  • the composition may contain emollients and moisturisers.
  • the present invention provides a method of preventing and/or reversing the effects of ageing, of reducing apparent wrinkling and or/or treating or preventing dry skin.
  • the present invention provides a method of treating a subject having a disease or disorder involving oxidative damage, comprising administering a therapeutically effective amount of the composition of the invention.
  • the disease or disorder involving oxidative damage is selected from the group consisting of cancer, heart disease, neurological disorders, auto-immune disoiders, ischaemia-reperfusion injury, diabetic complications, septic shock, hepatitis, atherosclerosis, Alzheimer's disease and complications arising from HIV or Hepatitis, including Hepatitis B.
  • the present invention provides a
  • the subject is an animal.
  • the animal may be selected from the group consisting of humans, non-human primates, cattle, horses, pigs, sheep, goats, dogs, cats, birds, chickens or other poultry, ducks, geese, pheasants, turkeys, quails, guinea pigs, rabbits, hamsters, rats and mice.
  • the one or more flavonoid derivatives are administered simultaneously, separately or sequentially with the one or more therapeutic agent(s).
  • the one or more therapeutic agent(s) and the one or more flavonoid derivative(s) according to the present invention can. be administered as separate agents at the same or different times or they can be formulated as a single composition comprising both compounds.
  • ROS reactive oxygen species
  • ischaemia reperfusion stroke, myocardial infarction or mechanical trauma, such as a crush injury or surgery.
  • Some forms of surgery such as heart bypass or transplant surgery necessarily cause ischaemia and reperfusion of tissue.
  • one or more flavonoid derivatives according to the present invention are administered to the subject before and/or during surgery.
  • Chronic disorders may be chosen from the group including cancer, cerebrovascular disease, atherosclerosis, artery disease including coronary disease, peripheral vascular disease (including damage caused by diseases such as diabetes), hypertension, pulmonary hypertension, chronic obstructive airways disease, emphysema, neurological disorders, auto-immune disorders, diabetic complications, septic and hypovolemic shock, burns, hepatitis, and complications arising from hepatitis and HIV.
  • Another chronic disorder may be chosen from the complications resulting from administration, of hyperbaric or high oxygen tension atmospheres, often applied to assist breathing particularly in a premature infant human., including retinal or other eye damage.
  • Subjects at risk of relevant chronic disorders may be diagnosed by analysis of symptoms, diagnostic testing, enzymatic markers, or by genetic testing to identify a genetic predisposition.
  • Predisposition to certain acute disorders such as heart attack or stroke may also be identified by genetic testing and may prompt the prophylactic application of one or more flavouoid derivatives to the subject at risk.
  • Drug-induced disorders due to ROS eg drug induced congestive heart disease. If the disease or disorder is stroke or risk or stroke, the composition described above is preferably administered before the stroke occurs as a prophylactic to reduce the risk of stroke occurrence, or within twelve hours (preferably within four hours) of stroke occuance.
  • ROS involved pathological condition is ischaemia where a deficiency of blood flow to part of a body results in inadequate tissue perfusion with oxygen. Ischaemia causes tissue damage, the severity of the damage depending on the length of time the tissue is deprived of oxygen and whether adequate reperfusion of oxygen occurs after the ischaemic event.
  • At least one compound in accordance with the present invention may be administered via a number of different routes, for example, topically, orally, subcutaneous, intramuscular, intra-arterially and/or intravenously.
  • the present invention provides flavonoid compounds according to Formula I, II, III or IV, V and methods of synthesizing such compounds. Derivatives of Flavonoids
  • Flavonoid phosphate derivatives are produced by a selective protection / deprotection synthetic strategy, 3-Hydroxyflavone-3-phosphate disodium salt (5)
  • 3-Hydroxyflavone (1) underwent phosphitylatkm when, treated with dibenzyl N,N-diisopropylphosphoramidite and the intermediate phosphate was directly oxidised by m-chloroperbenzoic acid (mCPBA) to its corresponding protected phosphate.
  • mCPBA m-chloroperbenzoic acid
  • the phosphate ester was purified by flash chromatography followed by recrystallization, yield 45%.
  • the phosphate ester underwent hydrogenolysis in ethanol with palladium hydroxide to form the phosphate, which was immediately converted to its disodium salt by addition of a slight excess of 0.1 M sodium hydroxide solution. Deprotection. by hydrogenolysis provided a pure sample of 3-hydroxyflavone-3-phosphate disodium salt in a 73% yield.
  • the corresponding diammoniurn salt was produced by ion exchange chromatography using a diethylaminoethyl column (DEAE) of (5).
  • DEAE diethylaminoethyl column
  • 3',4'-dibenzyloxy-3-hydroxyflavone (6) underwent phosphitylation by diisopropyl N,N-dibenzyloxyphosphoramidite in the presence of 1H-tetrazole to form the 3',4'-dibenzyloxy-flavone-3-phospbite dibenzyloxy ester (7), which was oxidized by mCPBA to the protected phosphate ester, 3',4'-dibenzyloxy-flavone-3-phosphate dibenzyloxy ester (8) .
  • These two steps produced the desired compound in a 40% yield after recrystallisation.
  • 3-Hydroxyflavone-3-hemisuccinate (15) was produced according to the reaction outlined in Figure 3. Reaction of succinic anhydride (11) and benzyl alcohol (12) in the presence of 4-dimethylaminopyridine (DMAP) and pyridine in dichloromethane produced the succinic acid monobenzyl esteT (13) as white crystalline flakes in 77% yield. This protected succinic acid derivative was coupled to 3-hydroxyflavone (1) in the presence of DCC and DMAP, forming flavone-3-hemisuccinate monobenzyi ester
  • 3-Hy ⁇ oxyflavone-3-hemiadipate (19) was synthesized .following a similar procedure to that discussed above for the hemisuecinate, as shown in Figure 4.
  • Adipic acid monobenzyl ester (17) was produced from adipic acid and benzyl alcohol in the presence of p-TsOH to yield the desired product as a colourless oil in 34% yield.
  • the protected adipic acid then underwent a DCC coupling with 3- hydroxyflavone (1) to form flavone-3-hemiadipate monobenzyl ester as a yellow/brown gum in 59% yield.
  • Hydrogenation of this compound in the presence of Pd(OH) 2 catalyst, using a THF-based solvent system (9:1 THFrEtOH + 0.05% acetic acid) resulted in hydrogenolysis of the monobenzyl ester, forming flavone-3-hemiad ⁇ pate as a yellow solid in 89% yield.
  • 3 ', 4 '-dihvdroxyftavone-3-hemiadmate (21 )
  • compositions and Methods The compounds of this invention can be formulated in a variety of carriers and delivery systems.
  • the amount of the therapeutic compound to be administered and the compound's concentration is dependent on the vehicle or device selected, the clinical condition of the patient, the side effects and the stability of the compound in the formulation.
  • the physician employs the appropriate preparation containing the appropriate concentration of the therapeutic compound and selects the amount of formulation administered, depending upon clinical experience with the patient in question or with similar patients.
  • excipients can be included in the formulation.
  • examples include co-solvents, surfactants, oils, humectants, emollients, preservatives, stabilizers and antioxidants.
  • Any pharmacologically acceptable buffer may be used, e.g., Tris or phosphate buffers.
  • Effective amounts of diluents, additives and excipients are those amounts which are effective to obtain a pharmaceutically acceptable formulation in terms of solubility, biological activity, etc.
  • composition of the invention includes a therapeutic compound which can be formulated with conventional, pharmaceutically acceptable, vehicles for topical, oral or parenteral administration, Formulations can also include small amounts of adjuvants such as buffers and preservatives to maintain isotonicity, physiological and pH stability.
  • adjuvants such as buffers and preservatives to maintain isotonicity, physiological and pH stability.
  • the compounds of the invention may be adrninistered to both human and animal subjects.
  • the compounds of this invention may be administered in compositions wherein the active compound is intimately admixed with one or more inert ingredients and optionally including one or more additional active ingredients.
  • the compounds may be used in any composition known to those skilled in the art for administration to humans and animals.
  • the composition of the invention may be administered through a proper route according to the dosage form.
  • the injection can be administered intravenous, intra-arterial, subcutaneous, intramuscular and the like.
  • either solid or fluid unit dosage forms can be prepared.
  • the water soluble forms can be dissolved in an aqueous vehicle together with sugar, aromatic flavouring agents and preservatives to form syrup.
  • An elixir is prepared by using a hydro-alcoholic (e.g., ethanol) vehicle with suitable sweeteners such as sugar and saccharin, together with an aromatic flavouring agent.
  • Suspensions can be prepared with an aqueous vehicle with the aid of a suspending agent such as acacia, tragacanth, methylcellulose and the like.
  • the synthetic flavonoid compounds of the present invention may also be formulated with stabilizing agents, for example metal chelator reducing agents such as ethylenediaminetetracetic acid (EDTA) or a reducing agent such as sodium metabisufite.
  • the therapeutic compound is prepared in an aqueous solution in a concentration of from about 1 to about 100 mg/mL. More typically, the concentration is from about 10 to 60 mg/mL or about 20 mg/mL. Concentrations below 1 mg/mL may be necessary in some cases depending on the solubility and potency of the compound selected for use.
  • the formulation which is sterile, is suitable for various parenteral routes including intra-dermal, intra-articular, intramuscular, intravascular, intravenous, inhalation and subcutaneous.
  • compositions according to the present invention may be formulated into sunscreens, skin care compositions, emollient of moisturizers.
  • Slow or extended-release delivery systems including any of a number of biopolymers (biological-based systems), systems employing- liposomes, and polymeric delivery systems, for example dendrimers, can be utilized with, the compositions described herein to provide a continuous or long term source of therapeutic compound.
  • Such slow release systems are applicable to formulations for topical, ophthalmic, oral, and parenteral use.
  • the synthetic flavonoid compound(s) of the present invention may also be formulated as a nutrapharmaceutical or a nutraceutical.
  • the synthetic flavonoid compound(s) may be formulated into a food, such as a cereal, beverages such as fruit juice, alcoholic drinks, bread, etc, for oral consumption.
  • the flavone-3-hemiadipate did not effect Ca 2+ contraction of the aortic ring.
  • the flavone-3 - hemiadipate has some inhibitory effect, most likely due to the presence of an esterase in the aortic tissue of the rat.
  • the concentration response curves to Ca 2 * in the presence of vehicle or increasing concentrations of 3',4'-dihydroxyflavone-3-herniadipate (21) (DiOHF3HA, 10" 6 M - ICC 4 M) in endothelium intact aortic rings isolated from rats.
  • the contractions are expressed as a percentage of the initial response to Ca 2+ (3x10 -3 M) observed before treatment with DiOHF3HA.
  • D1OHF3HA appears to have slight Ca 2+ inhibitory action at 10 -4 M. This effect is possibly due to the presence of some esterase in. the aortic tissue of the rat.
  • the concentration response curves to Ca 2+ in the presence of vehicle or flavone-3 -phosphate (F3P, 10 -8 M-I0 -4 M) in the presence and absence of phosphatase (P, 1000 U/L) in endothelium intact aortic rings isolated from rats is shown.
  • the contractions are expressed as a percentage of the initial response to Ca 2+ (3x10 -3 M) observed before treatment with flavone-3-phosphate.
  • the presence of phosphatase markedly enhanced the inhibitory effects of flavone-3 ⁇ phosphate.
  • 3-Hydroxyflavone (0.105 g, 0.442 mmol), dicyclohexylcarbodiimide (0.193 g, 0.933 mmol) and 4-dimethylaminopyridine (9.80 tag, 0.0802 mmol) was added to a solution of adipic acid monobenzyl ester (0.168 g, 0,754 mmol) in dichloromethane (10 mL) and the mixture was stirred under N 2 at room temperature for 19 h. Water (50 ⁇ L) was added and the resultant mixture was stirred for 10 rain, then diethyl ethex (10 mL) was added.
  • Ethylene dichloride (843 mg, 4,40 mmol) was added to a solution of 4'- benzyloxy-3-hydroxyflavone (1.00 g, 2.90 mmol), adipic acid monobenzyl ester (1.30 g, 5.50 mmol) and DMAP (354 mg, 2.89 mmol) in dichloromethane (110 mL) and the mixture was stirred at rt overnight. The reaction mixture was then concentrated and the residue dissolved in ethyl acetate. The organic-phase was washed with water (x 3), 1 M HCl ( ⁇ 3), sat NaHCO 3 (x 3), brine (x 3), dried (MgSO 4 ) and concentrated.
  • Adipic acid monobenzyl ester (1.91 g, 5.04 mmol) followed by EDC hydrochloride (0.764 g, 3.98 mmol) and DMAP (0.324 g, 2.65 mmol) were added to a stirring solution of 3',4'-dibenzyloxyflavonol (1.21 g, 2.68 mmol) in dry dichloromethane (100 mL) and the resultant mixture was stirred at room temperature under N 2 for 3 h. The reaction mixture was concentrated under reduced pressure and resuspended in ethyl acetate (100 mL).
  • Ethylene dichloride (EDC) (517 mg, 2.7 mmol) was added to a solution of 3,7- dihydroxyflavone (250 mg, 0.983 mmol), adipic acid monobenzyl ester (921 mg, 3.90 mmol) and DMAP (220 mg, 1.80 mmol) in dichlororoethane (25 mL) and the mixture was stirred at rt for 1 h. The reaction mixture was then concentrated and the residue dissolved in ethyl acetate. The organic phase was washed with water (x 2), 1 M HCI (x 2), sat NaHCO 3 (x 2), brine (x 2), dried (MgSO 4 ) and concentrated.
  • reaction mixture was then cooled to -78 °C and m-CPBA (3.00 g, 12.1 mmol, 70% w/w) was added.
  • m-CPBA 3.00 g, 12.1 mmol, 70% w/w
  • the reaction was then warmed to rt and stirred for 45 min.
  • the organic layer was washed with 0.25 M Na 2 S 2 O 3 (x 3), sat NaHCO 3 (x 3), brine (x 3), dried (MgSO.*) and concentrated.
  • Cumulative concentration-response curves in the range 10 -8 — 10 -4 M were conducted for 3',4'-dihydroxyflavoriol, 3-hydroxyflavone-3-hemiadipate, 3',4'- dihydroxy-3-hemiadipate, 3-hydroxyflavone-3-phosphate- Experiments were conducted in the presence of an esterase, butyryl cholinesterase (BuCHE, 1000 U/L) for the hemiadipate derivates and a phosphatase (1000 U/L) in the case of the phosphate derivatives.
  • BuCHE butyryl cholinesterase
  • Aortic rings were pre-incubated for 45 minutes at 37°C with a pH 7.4, in Krebs-HEPES buffer containing diethylthiocarbamic acid (DETCA, 10 -3 M) to inactivate superoxide dismutase and ⁇ -nicotinamide adenine dinucleotide phosphate (NADPH, 10 -4 M) as a substrate for NADPH oxidase and either 3',4'-dihydroxyflavonol (10 ⁇ * M) as a positive control, vehicle, 3 -hydroxyflavone-3 -hemiadipate, 3 ',4'-dihydroxy-3 -hemiadipate, 3- hydroxyflavone-3 -phosphate (10 -S — 10 ⁇ M).
  • DETCA diethylthiocarbamic acid
  • NADPH ⁇ -nicotinamide adenine dinucleotide phosphate
  • a unit dosage of an aqueous solution of 3-hydroxyflavone-3-he ⁇ adipate (15) was administered to a group of male anesthetized Sprague Dawiey iats intravenously and the blood pressure monitored over a period of time.
  • the descending thoracic aorta fiom rats was rapidly dissected and placed in Krebs-bicarbonate solution. Superficial connective tissue and fat surrounding the aorta was removed and the aorta was cut into segments of 2-3 mm length and mounted in, organ baths.
  • the aortic rings were then submaximally precontracted with PE and U46619, which were used to produce an active tension of 45-60% of the KPSS-induced maximum contraction.
  • flavonoids flavonol, flavone-3-hemiadipate (f 3HA), 3', 4'-dihydroxyflavone, 3', 4'-dihydroxyflavonol- 3', 4--dihydroxyflavone-3-hemiadipate (DiOHF3HA), and flavone-3- phosphate (F3P) on vasorelaxant responses
  • rings were incubated with one of the compounds for 20 mins before they were precontracted submaximally, followed by a cumulative-concentration response curve to ACh (100 nM - 10 ⁇ M) or SNP (10 pM -1 ⁇ M).
  • Ca 2+ , contractile responses to exogenous application of Ca 2+ were examined in the . presence of flavonoids in Ca 2+ - free high-K + solution (60 mM, K+-PSS). Aortic rings were initially equilibrated at a resting tension of 1 g in Ca 2+ -free PSS for 45 minutes. The bath medium was then replaced with Ca 2+ - free K + -PSS for 45 minutes to determine a reference contraction to added Ca 2+ (3 mM). Following a 30 minute re- equilibration period with.
  • Ca 2+ -free PSS the cumulative contractile responses to Ca 2+ (10 -5 - 3 x 10 -3 M) were determined in K + PSS in the presence of vehicle (0.1% DMSO), or a range of concentrations (10 -7 - 10 -4 M) of 3'-hydroxyflavonol, F3HA, DiOHF3HA or F3P. A 20 minute incubation period was allowed for the flavonoids before examining the responses to Ca 2+ . Experiments were conducted in the presence and absence of BuCHE (1000U/L) to cleave the adipate in F3HA and DiOHF3HA. In experiments using F3P, phosphatase ( ⁇ 000U/L) was used in some experiments to cleave the phosphate.
  • the right carotid artery was cannulated and connected with a heparinised saline filled cannula (O,D. 0.75, LD, 0.58 mm) and connected to a pressure transducer. Mean and phasic arterial pressure were continuously measured and recorded on a polygraph. The heart rate was derived from the phasic arterial pressure using a tachometer.
  • Flavonol and dihydroxyflavone caused concentration dependent decreases in superoxide levels generated by rat aortic rings. At the highest concentration tested (0J mM) flavonol and DiOHFne both reduced the superoxide levels to 36 ⁇ 3% of control. Flavonol did not affect the relaxant effects of ACh or SNP. DiOHFne caused concentration-dependent relaxation of rat aorta which was weaker than the effect of DiOHF. Flavonol caused concentration dependent decreases in calcium-induced contraction of rat aortic rings which, were relatively weak in comparison to previous observations with DiOHF.
  • F3HA (10 ⁇ 7 M-I0 -4 M) had no inhibitory effect on superoxide generation by rat aorta but the presence of butyryl choHnesterase (BuCHE, 100- 1000 U/ml) caused a concentration dependent increase in the inhibitory effect of F.3HA ( Figure 6-). F3HA only inhibited contractile responses to increasing concentrations of extracellular calcium at the highest concentration tested (0.1 mM).
  • DiOHF3HA Antioxidant and vascular effects ofdihydroxy ilavone-3-hemiad ⁇ pate.
  • DIQHF3HA (10 -7 M-IC 4 M) had no inhibitory effect on superoxide generation by rat aorta but the presence of butyryl cholitiesterase (BuCHE, 1000 U/ml) ⁇ evealed a concentration dependent inhibitory effect.
  • BuCHE butyryl cholitiesterase
  • DiOHF3HA alone had no effect on relaxant responses to ACh or SNP.
  • DiOHF3HA In contrast, in the presence of BuCHE (1000 U/ml) DiOHF3HA significantly increased the sensitivity of the relaxant response to SNP, Similarly DiOHF3HA alone had little effect on calcium-induced contraction of rat aorta, but in the presence of BuCHE (1000 U/ml) DiOHF3HA (0.1 mM) had an equivalent inhibitory effect to DiOHF. This suggests that when the adipate was removed by the esterase the hemiadipate was equally active to the parent DiOHF. DiOHF3HA was also found to cause direct relaxation of pre-contracted rat aortic rings only in the presence of the esterase (Figure 11).
  • DiOHF3HA (0.1, 0.3, 1, 3 mg/kg) was injected intravenously, allowing at least 30 min between injections, and the peak changes in mean arterial pressure and heart rate measured.
  • DiOHF3HA caused dose-dependent decreases in arterial pressure ( Figure 12a) and heart rate ( Figure 12b),
  • ACh (0.3 r ⁇ g/kg iv) and phenylephrine (PE, 30 rng/kg W) were injected before and 30 minutes after DiOHF3HA (3 mg/kg iv), a time when arterial pressure and heart rate had returned to control levels.
  • D1OHF3HA significantly enhanced the depressor response to ACh and attenuated the PE-induced increase in arterial pressure (Figure 13).
  • F3P or phosphatase had no effect on superoxide generation by rat aortic segments whereas F3P caused a concentration -dependent inhibition of superoxide levels in the presence of phosphatase.
  • F3P in the presence of phosphatase, increased the sensitivity of rat aortic rings to relaxation by ACh but not SNP, Oxidant stress, caused by the presence of pyrogallol (2x10 -5 M), significantly reduced the maximum response to ACh but the response was restored by the ' presence of F3 P plus phosphatase. Responses to SNP were unaffected by any of those treatments.
  • F3P caused a small inhibition of calcium-induced contraction but the effect was significantly enhanced by the presence of phosphatase.
  • F3P (0-1, 0.3, 1, 3, 10 mg/kg) was injected intravenously, allowing at least 30 minutes between injections, and the peak changes in mean arterial pressure and heart rate measured (Figure 16a).
  • DiOHF3HA caused dose-dependent decreases in arterial pressure and heart rate ( Figure 12 a and 12b) but the depressor response was small compared to DiOHF (1 mg/kg iv).
  • Flavone-3-herniadipate alone had no antioxidant or vascular activity when applied alone but the presence of a cholinesterase to cleave the adipate substitution revealed the ability of F3HA to inhibit calcium-induced contraction.
  • Dihydroxy fiavone-3-hemiadipate (D1OHF3HA) had no antioxidant or vascular activity when applied alone but the presence of a cholinesterase to cleave the adipate substitution revealed the ability of DIOHF3HA to inhibit superoxide levels produced by ' rat aorta, to inhibit calcium-induced contraction and to cause direct relaxation of rat aortic rings.
  • the level of activity of D1OHF3HA was similar to DiOI-IF.
  • Flavone-3-phosphate alone had no antioxidant or vascular activity but the presence of a phosphatase to cleave the phosphate substitution revealed the ability of F3P to inhibit superoxide levels produced by rat aorta, to inhibit calcium-induced contraction and to enhance endothelium-dependent relaxation in the presence of oxidant stress.
  • the level of activity of F3P was similar to DiOHF.
  • the anaesthetized rat F3P caused only small concentration dependent decreases in arterial pressure and heart rate. The effects were much smaller than seen with DiOHF.
  • the ability of the synthetic flavonol, 3 ',4' dihydroxy flavonol adipate (DiOHF3HA) to prevent myocardial ischaemia and reperfusion injury in anaesthetised sheep was assessed.
  • the adipate derivative was soluble in. aqueous solution, particularly water.
  • DiOHF3HA administered in aqueous solution caused a dose-related reduction in infarct size, which was similar to that caused by a similar molar dose of DiOHF when dissolved an DMSO.
  • Intravenous DiOHFSHA infusion did not alter haemodynamic indices (arterial blood pressure, heart rate, left ventricular-end diastolic pressure (LV-EDP).
  • Anaesthesia was induced by intravenous thiopentone sodium (15 mg/kg) and following tracheal intubation was maintained by isoflurane (1.5-2%).
  • a catheter was • inserted in the right facial artery for arterial blood sampling and monitoring arterial pressure.
  • Intravenous infusions were made via a catheter insetted into the jugular vein.
  • the heart was exposed through a left thoracotomy performed at the fourth intercostal space.
  • a 4F catheter-tipped manometer was inserted through the left atrium into the left ventricle to measure left ventricular pressure (LVP).
  • An additional silastic cannula was inserted into the left atrial appendage for the injection of lignocaine and for infusion of Evans Blue.
  • the left anterior descending coronary artery was dissected from, the epicardixiTH immediately distal to its second diagonal branch, and a transit-time 2 mm flow probe was placed around it to monitor the LAD blood flow.
  • a silk suture was passed under the LAD proximal to the probe and both ends of the silk were threaded through a plastic tube to form a vascular snare.
  • DiOHF was dissolved in 2 ml DMSO plus 14 ml polyethylene glycobwater (1:1).
  • DiOHF3HA was dissolved in 20 ml 0.1 M Na 2 C ⁇ 3 - The drugs were given at 1 rr ⁇ Vmin i.v..
  • the two doses of DiOHF3HA (2.7 mg/kg and 6.6 mg/kg) were chosen to achieve equivalent molar do$es to the parent DiOHF compound (at 2 mg/kg and 5 mg/kg, respectively). Control animals did not receive any intravenous solutions. Lignocaine was used, as required, to ameliorate arrhythmias.
  • the area of myocardium at risk and infarct size were delineated by Evan's blue and triphenyltetra ⁇ olium chloride (TTC) staining. After 3 hours of reperfusion, the LAD was re-occluded at the original occlusion site. Immediately after intravenous injection of pentobarbitone (100 mg kg -1 ) to arrest the heart, Evan's blue dye (1.5%, 40 ml) was injected into the left atrium to define the myocardium at risk. The heart was rapidly xemoved and the left ventricle was sliced into transverse sections about 1 cm thick. The unstained risk area was traced onto the same transparencies.
  • TTC triphenyltetra ⁇ olium chloride
  • the sections were then incubated in 0.1 M sodiuro phosphate buffer containing 1% TTC for 20 min (37"C, pH 7.4).
  • the infarcted area was traced onto transparencies.
  • the area of myocardium, at risk, and infarct size, were measured by computerised planimetry. The former was expressed as a percentage of total left ventricular volume (AR/LV%) and infarct size was expressed as a percentage of the area of myocardium at risk (IS/AR%).
  • Plasma markers for myocardial infarction Arterial blood samples (5 ml) were collected into chilled heparinised tubes at baseline, during ischaemia and at three time points during the reperfusion period (1 hour, 2 hour and 3 hour). Following centrifugation at 4°C, plasma samples were stored at -20°C until measurement to determine levels of lactate dehydrogenase and creatinine kinase. Results
  • LV-EDP Resting LV-EDP was not different between the two groups of sheep (-11 mmHg) but the maximal positive value of the first derivative of LVP (dP/dt max ) was lower (P ⁇ 0.05) in the control sheep (1454 ⁇ 62 mmHg/s) compared to DiOHF3HA- treated sheep (1967 ⁇ 103 mmHg/s). This difference remained throughout the course of the experiment. Both LV-EDP and dP/dt max were unchanged during the 20-min infusion period of DiOHF3HA administration. Moreover, no marked change in LV-EDP and dP/dt max was observed in either group of sheep during myocardial ischaemia reperfusion. Haemodynamic benefits of the drug showed up more clearly after 24 hours of reperfusion.
  • Plasma markers for myocardial infarction Ischaemic stroke was studied in conscious rats, with daily monitoring of neurological function and post mortem morphological assessment of cerebral infarcts at 72 hours after stroke.
  • Unilateral, transient cerebral ischaemia and reperfusion was induced in conscious rats by injection of the potent vasoconstrictor endothelin-1 outside but close to the right middle cerebral artery MCA, (via a pre-implanted guide tube).
  • the ensuing stroke was graded on a scale of 0 to 5 by immediate behaviour, and potential neuroprotective compounds were injected intravenously 3 h after the stroke, and at 24 hour intervals thereafter.
  • mice Male Hooded Wistar rats (280-340 g) were anaesthetised with pentobarbitone sodium in a volume of 0.6 ml (60 mg/kg i.p.) for insertion of an intravenous (i.v.) catheter into the jugular vein for acute drug administration, A 23-gauge stainless steel guide cannula was then stereotaxically implanted into the piriform cortex 2 mm dorsal to the right MCA (0-2 mm anterior, -5.2 mm lateral and -5.9 mm ventral). The cannula was secured with dental acrylate cement and two small screws inserted into the skull.
  • Rats were housed individually on a 12h daytaight cycle at a temperature of 18-22°C and allowed to recover for 5 days before induction of stroke.
  • Vaso constriction of the right middle cerebral artery was induced in conscious rats by administration of the potent vasoconstrictor agent endothelin-1 (ET- 1) (60 pmol in 3 ⁇ l of saline over 10 min) via a 30-gauge injector that protruded 2mm beyond the end of the previously implanted stereotaxic guide cannula.
  • the injector was held in place by a poly-tubing cuff and the rat was placed in a clear Plexiglass box for observation during ET-1 injection.
  • stroke induction we observed counterclockwise circling, clenching and dragging of the contralateral forepaw, validating the correct placement of the cannula.
  • Rats were decapitated 72h after ischemia and their brains were removed and frozen in liquid nitrogen, and stored at -80°C.
  • Coronal cryostat sections (16 ⁇ m) were cut at eight pre-determined coronal planes throughout the brain from -3.2 to 6.8 mm relative to Bregma.
  • Infarct was measured in triplicate unstained sections based on the observation that damaged areas in unstained slide-mounted brain sections are visible to the naked eye as clearly defined frosted or dark areas, while normal tissue is essentially translucent.
  • Rats showed neurological behavioural deficits indicative of stroke within 2-10 minutes of ET- 1 injection but not after an equal volume of saline alone. These deficits included specific behavioural responses such as clenching and failure to extend the contralateral forepaw, and circling in the direction contralateral to the occlusion. Grooming behaviour preceded circling and was observed in almost all rats. Grooming occurred in a stereotypical manner with facial grooming being followed by -Roll body grooming in one continuous movement. Other behaviours such as teeth chattering, biting of the cage and bedding or tongue poking, were observed less frequently. These behavioural responses observed at the time of stroke could be ranked based on their degree and severity.
  • DiOHF (10 mg/kg) treatment in mild to moderate stroke rats significantly reduced the area of infarct throughout the cortex and the striatum compared with vehicle treatment.
  • DiOHF treatment also significantly improved neurological outcome in mild to moderate stroke rats, in comparison to vehicle treated rats.
  • Each rat received 3 bolus doses of DiOHF3HA (15mg/kg/day i.v.) dissolved in a Na 2 CO 3 buffered saline (0.1M, pH 7.8) for injection.
  • DiOHF3HA (15mg/kg) treatment significantly improved neurological function in the hemineglect test, and also reduced the area of damage in the striatum following stroke compared with vehicle treatment. Effect of DiOHF3HA in mild to moderate strokes
  • a selected group of rats were studied with mild to moderate strokes.
  • Rats did not lose weight following mild to moderate stroke in either treatment group. Core temperature prior to stroke in both treatment groups was within normal physiological limits. Following mild to moderate stroke there was a significant increase in temperature at 30 minutes in both treatment groups, but temperature returned to within normal levels after this time. Following mild to moderate strokes, rats in both treatment groups exhibited significantly higher neurological deficit scores pre-stroke and 24, 48 and 72h post- stroke when compared to pre-surgery scores. Treatment with DiOHF3HA (15 mg/kg/day) had no effect on neurological deficit scores when compared with vehicle treated rats.
  • DiOHF3HA treatment also significantly reduced the area of infarct through the striatum.
  • DiOHF3HA (15 mg/kg) treatment in mild to moderate stroke rate significantly reduced the area of infarct through the cortex and the striatum compared with -vehicle treatment
  • DiOHF3HA treatment also significantly restored neurological function in the hemineglect test

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

Novel flavonoid compounds having anti-oxidant activity are described. The compounds and compositions have been shown to exhibit anti-oxidant properties and are particularly useful in the treatment of ischemia and reperfusion injuries. The invention also describes a method to chemically synthesize such flavonoid compounds and test their efficacy. Such compounds and corresponding pharmaceutically acceptable derivatives and/or salts have uses in the areas of pharmaceuticals, nutraceutical, and veterinary applications.

Description

FLAVONOID COMPOUNDS AND USES TMEREOF CROSS-REFERENCE TO RELATED APPLICATIONS
The present application claims priority from Australian Provisional Patent Application No. 2005901214 filed on 11 March 2005, the content of which is incorporated herein by reference. FIELD OF THE INVENTION The present invention relates to novel compounds, compositions containing these compounds, methods for their synthesis, and uses of these compounds. In particular, the present invention relates to flavonoid compounds, methods of synthesizing the flavonoid compounds, compositions containing the flavonoid compounds and methods of their use. BACKGROUND OF THE INVENTION
Prompt reperfusion of ischemic tissue is critical for restoring normal function. However, this return of blood flow can paradoxically produce a progressive destruction of reversibly damaged cells, thereby leading to tissue dysfunction and infarction. This "reperfusion injury" has multifactorial causes of disease but appears to be strongly associated with, an inflammatory response; with the return of blood flow, several inflammatory processes may occur to potentiate ischemic injury, including leukocyte adhesion and infiltration and the release of reactive oxidative species (ROS) such as oxygen free radical species and peroxides, for example H2O2.
Much of lids inflammatory response appears to be mediated by interleukins (ILs), a multifunctional subclass of cytokines. Leukocytes (white blood cells) also appear to play a critical role in reperfusion. injury. In addition to injuring endothelium and neurons, leukocytes can obstruct the microcirculation directly. This leukocyte capillary plugging also may be the major mechanism of the "no-reflow phenomenon." Thus areas of parenchyma that are still viable when blood flow returns are not reperfused adequately and ultimately die. Myocardial ischaemia in particular causes extensive capillary plugging.
Ischaemia, and particularly reperfusion, tend to promote an increased release of ROS's from leukocytes which leads to further tissue damage. One of the most damaging types of free radicals is superoxide anions which act to impair endothelial function and the activity of nitric oxide (NO). This further worsens the capillary plugging process because NO has been shown to inhibit platelet aggregation and to prevent leukocyte adherence to the endothelium. The degree of tissue recovery achieved after ischaemia and reperfusion depends on the nature of the tissue and the severity of the damage.
Ischaemia can be caused by a variety of conditions. For example, acute incidents such as stroke, myocardial infarction or mechanical trauma, and chronic conditions such as atherosclerosis, peripheral vascular disease and diabetes can cause ischaemia. Hypertension is another type of disorder that can lead to ischaemia.
Following an acute incident such as a heaxt attack caused by a blocked coronary artery, various drugs are delivered intravenously to the heart attack victim to assist in removing any blood vessel obstruction thus re-establishing blood flow leading to reberfusion of tissues. However, this type of treatment is not directed to preventing or ameliorating the tissue damage associated with reperfusion, Creating an environment for reperfusion to occur and re-establish the supply of oxygen to tissue can lead to increased tissue damage by increasing free radical production.
In this respect the conventional treatments for subjects exhibiting ischaemia or at risk of ischaemia are inadequate.
It has been suggested that various substances improve vascular health and function, and that in populations with a diet high in fruits and vegetables there is a lower incidence of coronary arterial disease, This effect has been linked to the beneficial effects of flavonoids, which are polyphenols compounds that are found in both fruits and vegetables.
Flavonoids are a very large and widespread group of plant derived compounds which are thought to exhibit a number of biological effects including reducing plasma levels of low density lipoproteins, inhibiting platelet aggregation, scavenging free radicals and reducing cell proliferation as well as modulating vascular tone. A vast number of flavonoids have been identified and differ from one another in the orientation of the hydroxylation or methylation, the position of the benzenoid substituent, the degree of unsaturation and the types of substituents attached. The general three ring structure (A, B and C rings) of many flavonoids are based on the structure of 2-phenyl-4H-1-benzopyran-4-one.
Figure imgf000003_0001
For example, the synthetic flavonoid, 3',4'-dihydroxy flavonol (DiOHF) has a hydroxyl group at the 3,3'- and 4' positions and has been demonstrated to reduce infarct and injury associated with myocardial ischaemia and reperfusion during in vitro studies (Shen Wang, Gregory Dusting, Give May and Owen Woodman, British Journal of Pharmacology (2004) 142, 443-452).
However, the pharmacokinetics of many flavonoids has severely limited their therapeutic usefulness. Synthetic flavonoids tend to be highly lipid soluble molecules and therefore tend to have poor water solubility leading to a difficulty in administration. as a therapeutic agent. These characteristics limit their applicability to therapies where acuta parenteral administration is desirable, for example in vasodilation therapies.
Given the above identified problems, there remains a need for the development of synthetic flavonoid derivatives with improved aqueous solubility and pharmacokinetics when compared to known flavonoids. SUMMARY OF THE INVENTION According to a first aspect, the present invention provides a pharmaceutically and/or veterinary composition comprising a pharmaceutically and/or veterinarily acceptable carrier or diluent together with at least one compound of the general Formula I:
Figure imgf000004_0001
in which:
— denotes a single or double bond; and
R1, R2, R3, R4, R5 are independently selected from H, OH or a group according to Formula (Ia):
Figure imgf000004_0002
in which
O is oxygen;
L is a linker group which is covalently linked to the oxygen and D, if present, or is covalently linked to the oxygen and E, or is absent; D is a spacer group having a chain length equivalent to about 1 to 20 carbon atoms, or is absent; and E is a solubilizing group; provided that at least one of R1, R2, R3, R4, R5 is other than H or OH. Preferably, E is selected from an ester, a carboxylic acid, sulfonic acid, phosphonic acid, phosphate ester, sulfamate, sulfonic ester, phosphamate, phosphonate ester, sulphonate, zwitterionic specie, amino acid, amino phosphonate, acyclic arnine, cyclic amine, quaternary ammonium cation, polyethylene glycol, oligosaccharide or dendrimer. In one preferred embodiment, E is a selected from an ester, carboxylic acid, sulfonic acid, phosphonic acid, phosphate ester, polyethylene glycol, oligosaccharide or dendrimer.
Preferably E is selected from an ester, carboxylic acid or phosphate ester. In a particular preferred embodiment, E is group according to Formula (Ib):
Figure imgf000005_0001
wherein
W is O, KH, S, O-, NH- or S-; and
X is H, a mono- or divalent cationic salt, or an ammonium cationic salt. Preferably, W is O and/or X is H. Ia another embodiment, E is an ester according to the Formula (Ic):
Figure imgf000005_0002
wherein
Q is a substituted or unsubstituted alkylene, alkenylene, alkynylene, optionally interrupted by one or more heteroatom(s); W is O, NH, S, O-, NH-, or S-; and
X is H, substituted or unsubstituted alkyl, alkylbenzyl, a mono- or divalent cationic salt, or an ammonium cationic salt.
Preferably, Q is a substituted or unsubstituted lower alkylene.
In another embodiment, E is a phosphate ester according to the Formula (Id):
Figure imgf000005_0003
wherein
Y is O, NH, S, O-, NH-, or S-; Z is O or S; and
R6 and R7 are independently selected from H, substituted or unsubstituted alkyl, a mono- or divalent cationic salt, or an ammonium cationic salt. Preferably Y and Z are O. In another embodiment, at least one of R1, R2, R3, R4 and R5 is phosphate ester according to the formula (Ie):
Figure imgf000006_0002
wherein R6 and R7 are independently selected from H, a mono- or divalent cationic salt, or an ammonium cationio salt.
In one embodiment, L is present and selected from -CO-, ester, phenol, phosphonate ester, carbamate, carbonate or a Mannich base. In a more preferred . embodiment, L is -CO-- In another embodiment, D present and selected from substituted or unsubstituted alkylene, alkenylene, alkynylene, optionally interrupted by one or more heteroatom(s), aryl, heteroaryl, cycloalkyl or heterocycloalkyl.
In a preferred embodiment, D is a substituted or unsubstituted alkylene, optionally interrupted by one or more heteroatom(s). Preferably, a lower alkylene. In another aspect, the present invention provides a pharmaceutically and/or veterinary composition comprising a pharmaceutically and/or veterinarily acceptable carrier or diluent together with at least one compound of the general Formula II:
Figure imgf000006_0001
wherein — denotes a single or double bond; and
R1 , R2 and R3 are as specified above.
In yet another aspect, the present invention provides a pharmaceutically and/or veterinary composition comprising a pharmaceutically and/or veterinarily acceptable carrier or diluent together with at least one compound of the general Formula III:
Figure imgf000007_0001
wherein R3 is specified above.
In yet another aspect, the present invention provides a pharmaceutically and/or veterinary composition comprising a pharmaceutically and/or veterinarily acceptable carrier or diluent together with at least one compound of the general Formula IV:
Figure imgf000007_0002
wherein
Q is substituted or unsubstituted alkylene, optionally interrupted by one or more heteroatom(s) X is H, a mono- or divalent cationic salt, or an ammonium cationic salt.
Preferably Q is substituted or unsubstituted lower alkylene, optionally interrupted by one or more heteroatom(s).
Ia another aspect, the present invention provides a compound selected from the group 3-(Benzyloxycarbonylbutylcarbonyloxy)flavone; 3-Hydroκyflavone 3- hemiadipate; 4'-(Ben3yloxy)-3-(benzyIoxycarbonylbutylcarbonyloxy)flavone; 4'- Hydroxyflavone 3-hemiadipate; 3',4'-Dibenzyloxy-3-
(ben2yloxycarbon.ylbutylcarbonyloxy)flavone; 3 ',4'-Dihydroxyflavone 3-hemiadipaιt'e; 3=4'-Di-(berizyloxycarbonylbutylcarbonylo>ζy)ilavone; Flavone 3,4'-bisGiemiadipate); 3,7-Di-(benzyloxycarboo.ylbutylcarbonyloxy)flavone; 3,7-Diliydroxyflavone 3,7- bis(hemiadipate); 4'-Hydroxy-3-Hydroxyflavone-3-quaternary ammounium ester; 4'- (Benzyloxy)-3-(dibenzyloxyphosplioryloxy)flavone and 3-Hydroxyflavone-3- phosphate disodium salt. •
In another aspect, the present invention provides a pharmaceutically and/or veterinary composition comprising a pharmaceutically and/or veterinarily acceptable carrier or diluent together with at least one compound selected from the group comprising 3-(Ben2yloκycarbonylbutylcarbonyloxy)flavone; 3-Hydroxyflavone 3- hemiadipate; 4'-(Beo2yloxy)-3-(beiizyloxycarbonylbutylcarbonyloxy)flavo-ie; 4'- Hydroxyfiavone 3-hemiadipate; 3',45-Dibenzyloxy-3- (benzyloxycarbonylbutylcarbonyloxy)fiavone; 3',4'-Dib.ydroxyflavone 3- hejϊiiadipate;3,4'-DI-(beo2yloxycarbony3butylcarbonyloxy)flavone; flavone 3,4'- bis(hemiadipate); S^'Di-CbenzyloxycarbonylbutylcarbonyloxyJ-lavone; 3- (Diberizyloxyphosphoryloxy)flavone; 3,7-Dihydτoxyflavon.e 3,7~bis(hemiadipate); 41- I-Iydroxy-3-Hydroxyflavone-3 -quaternary ammounium ester; Flavone-3 -phosphate disQdiunα salt; 4'-(Benzyloxy)-3-(dibenzyloxyphosphoiyloxy)flavone or 3- Hydroxyflavonej3 -phosphate disodium salt.
In yet a further aspect, the present invention provides a method of preventing and/or treating a disease(s) in a subject associated with the presence of reactive oxidative species (ROS), the method comprising: administering an effective amount of at least one compound specified above. Preferably, the subject in need of such treatment is at risk of developing ischaemia. More preferably, the subject is suffering ischaemia and/or reperfusion injury as a result of an acute or chronic condition.
In a particular embodiment, the chronic condition is selected from cancer, cerebrovascular, disease, pulmonary vascular disease, atherosclerosis, artery disease, congestive heart disease, coronary disease, peripheral vascular disease, diabetes, hypertension, migraine, bums, chronic obstructive pulmonary disease and retinal vascular disease.
.In another embodiment, the acute condition is selected from stroke, myocardial infarction, mechanical trauma resulting from crush injury or surgery. Preferably the surgery is vascular surgery. More preferably, the vascular surgery is heart bypass and/or transplant surgery.
In a particular embodiment, the compound is administered to the subject before and/Or during the surgery.
In another aspect, the present invention provides a method of preventing, delaying the onset of and/or slowing the progression of atherosclerosis and/or coronary heart disease in a subj ect comprising administering an effective amount of at least one compound specified above.
In yet a further aspect, the present invention provides a therapeutic and/or prophylactic method of preventing and/or treating a disease(s) in a subject associated with the presence of reactive oxidative species (ROS), the method comprising: axJministering an effective amount of at least one compound specified above. In yet a further aspect, the present invention provides a method of preventing and/or at least ameliorating the damage to a subject caused by isehaemia and/or reperfusion injury, the method comprising administering an effective amount of at least one compound specified above. In yet a further aspect, the present invention provides a method of preventing and/or at least ameliorating damage to a subject caused by the administration of a therapeutic agent the method comprising co-administering to a subject: i) a therapeutic agent: and ii) administering an effective amount of at least one compound specified above.
Preferably the therapeutic agent is an oxidative therapeutic agent
In a particular embodiment, the therapeutic agent is an anticancer agent Preferably the anticancer agent is anthiacycline and its derivatives.
In particular embodiments, the compound is administered orally, topically, subcutaneous, parenterally, intramuscular, intra-arterial and/or intravenously.
In another aspect, the present invention provides for the use of a compound as Specified above for the preparation of a medicament.
In another further aspect, the present invention provides a compound of the general Formula I:
Figure imgf000009_0001
wherein: .
— denotes a single or double bond; and
R1, Rz, R3, R4, Rs are independently selected from H, OH or a group according to Formula (Ia):
Figure imgf000009_0002
wherein: O is oxygen;
L is a linker group which is covalently linked to the oxygen and D, if present, or is covalently linked to the oxygen and E, or is absent; D is a spacer group having a chain length equivalent to about 1 to 20 carbon atoms, or is absent; and
E is a solubilizing group; provided that at least one of R1, R2, R3, R4, R5 is other than H or OH, with the proviso that the compound is not flavone, 3 '-hydroxy-, acetate; Flavone.,
4'-hydroxy-, acetate; Flavone, 3-hydroxy-, acetate; (±)41-Acetoxyflavanone; Flavanone, 3,4',7-trihydroxy-, 3-acetats; 4H~l-Benzopyran-4-one, 3,7-bis(acetyloxy)- 2,3-dihydro--2-phenyl-, (2R-trans)-; 4H-1-Benzopyran-4-one, 7-(acetyloxy)-2-[4- (acetyloxy)phenyl]-2,3-dihydro-, (±); (+)4',7-Diacetoxyflavanone; (2S, 3S)-3,7- Dihydroxyflavanone diacetate; Flavanone, 3 ,4'-dihydroxy-, diacetate; Flavanone, 3 ',4'- dihydroxy-, diacetate; Plavanone, 3,7-dihydroxy-, diacetate; 4H-1-Benzopyran.-4-one, 3,7-bis(acetyloxy)-2-(3,4-dihydroxyphenyl)-2,3-dihydro-, (2Ji-trans)-; Flavone, 3,3'- dihydroxy-, diacetate; Flavone, 4',7-dihydroxy-, diacetate; Flavone, 3,7-dihydroxy-, diacetate; Flavone, 3,3',7-trihydroxy-, triacetates; Flavone, 3,3',4'-trihydroxy-, triacetate; 4H-1-Benzopyran-4-on.e, 7-(acetyloxy)-2-[3,4-bis(acetyloxy)phenyl]-;
Flavone, 3,4',7-trihydroxy-, triacetate; Flavanone, 3',4',7-trihydroxy-, triacetate; 4H-1- Benzopyran-4-one, 7-(acetyloxy)-2-[3,4-bis(acetyloxy)phenyl]-2,3-dihydro-, (S)-; Flavanone, 3,4',7-trihydroxy-, triacetate; Flavanone, 3,4'.7-trihydxoxy , triacetate, trans- (t)-ι 4H-1-Benzopyran-4-orie, 3 ,7-bis(acetyloxy)-2-[3-4-bis(acetyloxy)phenyl]-; Fustin, tetraacetate; 4H-1-Benzopyran-4-one, 3,7-bis(acetyloxy)-2-[3,4-bis(acetyloxy)pheriyl]- 2,3-dihydro-, (2R-trans)-; 4H-1-Benzopyran-4-oue, 3,7-bis(acetyloxy)-2-[3,4- bis(acetyloxy)phenyl]-2,3-dihydro-, trans-; Flavanone, 3,3',4',7-tetrahydroxy-, tetraacetate; 4H-1-Benzopyran-4-one, 3-(1-oxopropoxy)-2-phenyl-; Propanoic acid, 2- methyl-, 4-oxo-2-phenyl-4H-1-benzopyran-3-yl ester; Propanoic acid, 2,2-dimethyl-, 4- oxo-2-phenyl-4H-1-benzopyran-3-yl ester; Benzeneacetic acid, 4-oxo-2-phenyl-4H-1- benzopyτan-3-yl ester; Benzenepropanoic acid, 4-oxo-2-phenyl-4H-1-benzopyran-3-yl ester; Benzeneacetic acid, a-phenyl-, 4-oxo-2-phenyl-4H-1-benzopyran-3 yl ester; Phosphorothioic acid, o-[4-[3-[(diethoxyphosphinothioyl)oxy3-4-oxo-4H-1- benzopyτan-2-yl]phenyl] o,o-diethyl ester; Phosphorothioic acid, o-[3-[3- [(diethoxyphosphinothioyl)oxy]-4-oxo-4H-1-betizopyran-2-yl]phenyl] o,o-diethyl ester; Phosphoric acid, diethyl 4-(4-oxo-4H-1-benzopyran-2-yl)phenyl ester; 4H-1- Benzopyran-4-one, 2-phenyl-3-(phosphonooxy)-; Flavone, 3 -hydroxy-, dihydrogen phosphate diammonium salt; 4H-1-Benzopyran-4-one, 2-phenyl-3-(phosphonooxy)-, magnesium salt (1:1), pentahydrate; 4H-1-Benzopyran-4-one, 2-[3-hydroxy-4- (phosphonooxy)phenyl]-; 3',4'-dihydroxyflavone--4'-phospliate; 3',4'-dihydroxyflavone- 4'-β-D-glucopyranoside sodium salt; 3', 4'-dihydroxyflavone-4'-β-D-ribofluranoside sodium salt; and pharmaceutically and/or veterinarily acceptable salts or solvates thereof.
Preferably, R1, R2, R3, R4 and R5 are as specified above. In another aspect, the present invention provides a compound according to the general Formula (II):
Figure imgf000011_0001
wherein
= denotes a single or double bond; and R1, R2 and R3 are as specified above.
In yet another aspect, the present invention provides a compound according to the general Formula (III):
Figure imgf000011_0002
wherein R3 is specified above. In yet a further aspect, the present invention provides a compound according to the general Formula (IV):
wherein
Figure imgf000011_0003
Q is substituted or unsubstituted alkylene, optionally interrupted by one or more heteroatom(s) X is H, a mono- or divalent caiionic salt, or an ammonium cationic salt. Preferably, Q is substituted or unsubstituted lower alkylene, optionally interrupted by one or more heteroaiom(s).
In another aspect, the present invention provides a compound according to the general Formula V:
Figure imgf000012_0001
wherein R3 and R5 are specified above.
In. another aspect, the present invention provides a method for synthesizing compounds as specified above.
According to yet another aspect, the present invention provides compounds of general Formula:
Figure imgf000012_0002
in which:
= denotes a single or double bond; and
R1, R2, R3, R4, R5 which are independently selected from H, OH, substituted or unsubstituted alkoxy. aryloxy, esters, carbonate esters, ethers, phosphate esters and α- acyloxyalkyl ethers provided that at least one of R1, R2, R3, R4, R5 is other than H or OH; and pharmaceutically acceptable salts or solvates thereof,
Preferably at least R3 is selected from substituted or unsubstϊtαted esters, carbonate esters, ethers, phosphate esters and α-acyloxyalkyl ethers.
Preferably at least one of R1, R2, R3, R4 or R5 is selected from: i) phosphate having the general formula
Figure imgf000012_0003
wherein Y is O, NH, S, O-, NfT, or S-; Z is O or S; and each of R6 and R7 are independently selected from substituted or unsubstituted alkyl, H, a mono- or divalent cationic salt, or an ammonium cationic salt; ii) ester having the general formula
Figure imgf000013_0002
where R8 is a substituted or unsubstituted lower alkyl, lower alkylaϊkoxy; iii) ester having the general formula
Figure imgf000013_0003
where Q is a substituted or unsubstituted lower alkylene, lower alkenyl, and alkynyl;
W is O. NH, S, O; NH-, or S-; and
X is H, substituted or unsubstituted alkyl, alkylbenzyl, a mono- or divalent cationic salt, or an ammonium catiooic salt, and pharmaceutically acceptable salts or solvates thereof.
In particular embodiments of the invention, Y and Z are both O- In one embodiment, the present invention provides compounds of general Formula:
Figure imgf000013_0001
in which-.
— denotes a single or double bond; and
R1, R2 or R3 which are independently selected from H, OH, substituted or unsubstituted alkoxy, aryloxy, esters, carbonate esters, ethers, phosphate esters and σ- acyloxyalkyl ethers provided that at least one of R1, JR2 or R3 is other than H or OH; . and pharmaceutically acceptable salts or solvates thereof.
Preferably at least one of R1, R2 or R3 is selected from: i) phosphate having the general formula
Figure imgf000014_0001
wherein Y is O, NH, S, O-, NH-, or S-; Z is O or S; and each of R6 and R7 ate independently selected from substituted or unsubstituted alkyl, H, a mono- or divalent cationic salt, or an ammonium cationic salt; ii) ester having the general formula
Figure imgf000014_0002
where R8 is a substituted or unsubstituted lower alkyl, lower alkylalkoxy; iii) ester having the general formula
Figure imgf000014_0003
where Q is a substituted or unsubstituted lower alkylene, lower alkenylene, alkynylene, optionally interrupted by one or more heteroatom(s);
W is O, NH, S, O-, NH-, or S-; and X is H, substituted or unsubstituted alkyl, alkylbenzyl, a mono- or divalent cationic salt, or an ammonium cationic salt; and pharmaceutically acceptable salts or solvates thereof. Preferably R1 is H or OH; R2 is H or OH; and R3 is selected from
Figure imgf000015_0001
In another embodiment, the present invention provides a compound of general
Formula:
Figure imgf000015_0002
in which
R9 is substituted or unsubstituted alkoxy, aryloxy, ester, carbonate ester, ether,
or a group according to formula where U is substituted or
Figure imgf000015_0004
unsubstituted alkylene, optionally interrupted by one of more heteroatom(s).
In another embodiment, the present invention provides a compound of general Formula:
Figure imgf000015_0003
where n is an integer from 2 to 6, preferably n is 4.
The formulae given herein axe intended to extend to all possible geometric and optical isomers as well as racemic mixtures thereof.
In another aspect, the present invention provides methods for synthesizing compounds in accordance with Formula I, Formula II, Formula III or Formula IV, wherein R1, R2, R3, R4, R5, R6, R7, R8, R8, U, Q, W, X, Y, Z, n have title same meaning as above, or a pharmaceutically acceptable salt or solvates thereof. In another .aspect, the present invention, provides a pharmaceutical and/or a veterinary composition comprising & pharmaceutically anchor veteriuarily acceptable carrier or diluent together with at least one compound in accordance with Formula I, Formula H, Formula III or Formula IV, wherein R1, R2, R3, R4, R5, R6, R7, R8, Rs, U, Q, W, X, Y, Z, n have the same meaning as above, or a pharmaceutically acceptable salt Or solvates thereof.
According to another, aspect of the present invention, there is provided a method of preventing and/or at least ameliorating damage to a subject caused by the administration of a therapeutic agent, the method comprising co-administering to a subject: i) a therapeutic agent; and ii) an effective amount of at least one compound in accordance with Formula I, Formula 33, Formula IH, Formula IV, or 'Formula V, wherein R1, R2, R3, R4. R5, R6, R7, R8, R8, U, Q, W, X, Y, Z, ii have the same meaning as above, or a pharmaceutically acceptable salt or solvates thereof.
In yet a further aspect, the present invention provides a method of preventing and/or treating a disease(s) associated with the presence of reactive oxidative species (ROS), the method comprising administering an effective amount of at least one compound in accordance with Formula I, Formula 11, Formula UI , Formula FV, or Formula V, wherein R1, R2, R3, R4, R5, R6, R7, Rs, Rs, U, Q, W, X, Y, Z, n have the same meaning as above, or a pharmaceutically acceptable salt or solvates thereof.
In yet a further embodiment, the present invention provides a method of preventing and/or treating a disease(s) associated with the presence of reactive oxidative species (ROS), the method comprising administering an effective amount of at least one compound in accordance wjth Formula I, Formula II, Formula m or Formula IV, wherein R1, R2, R3, R*, Rs, R6, R7, R8, R8, U, Q, W, X, Y, Z, n have the same meaning as above, or a pharmaceutically acceptable salt oi solvates thereof.
Typically the subject in. need of such treatment will be a person at risk of developing ischaemia. Alternatively, the subject may be a person who is currently suffering ischaemia and/or reperfusion as a result of an acute or chronic condition.
IB yet a further aspect, the present invention provides a method of preventing and/or at least ameliorating the damage to a subject caused by ischaemia and/or reperfiision, the method comprising administering an effective amount of at least one compound an effective amount of at least one compound in accordance with Formula I, Formula II, Formula III or Formula IV, wherein R1, R2. R3, R4, R5, R6, R7, R8, R8, U, Q, ' W, X, Y, Z, n have the same meaning as above, or a pharmaceutically acceptable salt or solvates thereof.
Preferably the solubilizing group renders the compound at least partially soluble, and more preferably, totally soluble in aqueous solution, preferably water. Preferably the compounds of the invention have at least one in vivo enzyme cleavable substituent.
Preferably the in vivo enzyme cleavable substituent is an ionisable group at physiological pH. BREEF DESCRIPTION OF THE DRAWINGS Figure 1 illustrates the synthetic scheme for the synthesis of 3-hydroxyflavσne-
3-phosphate disodium salt (5).
Figure 2 illustrates the synthetic scheme for the synthesis of 3',4'- dihydroxyflavone-3 -phosphate (10).
Figure 3 illustrates the synthetic scheme for the synthesis of 3-hydroxyflavone- 3-hemisuccinate (15) via the succinic acid monobenzyl ester.
Figure 4 illustrates the synthetic scheme for the synthesis of 3-bydroxyflavone- 3-hemiadipate (19) via adipic acid monobenzyl ester.
Figure 5 illustrates Hie synthetic scheme .for the synthesis of 3',4'- dihydroxyilavone-3-herniadipate (21). Figure 6 illustrates the effects of vehicle CdH2O), Flavone-3-hemiadipate (19)
(F3HA), in the presence and absence of butyryl cholmesterase (BuCHE, 1000 U/L) and DiOHF (10-4 M) on the level of superoxide anions generated in rat aorta in the presence of NADPH expressed as a percentage of control.
Figure 7 illustrates the effects of Vehicle CdH2O), 3^4'-dihydroxyflavone-3- hemiadipate (21) (DiOHFSHA, 10-6 M- 10-4 M) in the presence and absence of butyryl choHnesterase (BuCHE, 1000 U/L) and DiOHF (10-4 M) on the level of superoxide anions generated in rat aorta in the presence of NADPH expressed as a percentage of control.
Figure 8 illustrates the concentration response curves to Ca2+ in the presence of vehicle or 3',4'-dmydroxyflavone-3-hemiadipate (21) (DiOHF3HA, 10-4 M), in the presence and absence of BuCHE, compared to DiOHF in endothelium intact aortic rings isolated from rats. The contractions are expressed as a percentage of the initial response to Ca2+ (3x10-3 M) observed before treatment with DiOHF3HA.
Figure 9 illustrates the effects of vehicle CdH2O), Flavone-3-phosphate (F3P, 10-8 M to 10-* M) in the presence phosphatase (1000 U/L) and DiOHF (10-4 M) on the level of superoxide anions generated in rat aorta in the presence of NADPH expressed as a percentage of control.
Figure 10 illustrates the concentration response curves to Ca2+ in the presence of vehicle or flavone-3-phosphate (F3P, 10-8 M to 10-4 M) in the presence and absence of phosphatase (P, 1000 U/L) in endothelium intact aortic rings isolated from rats. The contractions are expressed as a percentage of the initial response to Ca2+ (3x10-3 M) observed before treatment with flavone-3 -phosphate.
Figure 11 illustrates the direct relaxing effect of vehicle, 1000U/L BuCHE,
DiOHF3HA (10-4M), DiOHF3HA (10-4M) plus 1000U/L BuCHE. vehicle, 1000U/L BuCHE and DiOHF3HA (10-4M) had no effect on PE precontracted vessels.
DiOHF3HA (10-4M) plus 1000U/L BuCHE had a marked effect on vascular tone in rat aorta precontracted with PE.
Figure 12(a) illustrates the dose-dependent decrease in MAP (mm Hg) indicating vasodilatation in response to DiOHF3HA in anaesthetised rats. Figure 12(b) illustrates the dose-dependent decrease in HR (beats/min) in response to DiOHF3HA.
Figure 13 illustrates the decrease in MAP (mm Hg) indicating vasodilatation in response to ACh in anaesthetised rats, dilator response to ACh was enhanced by 30 min pre-treatment with 3 mg/kg DiOHF3HA. A increase in MAP (mm Hg) indicating vasoconstriction in response to PE in anaesthetised rats, constrictor responses to PE were diminished by 30 min pre-treatment of 3 mg/kg DiOHF3HA.
Figure 14 illustrates the concentration response curves to PE generated in the presence of control, DiOHF3HA with and without BuCHE and DiOHF in rat aortic rings. DiOHF3HA in the presence of BuCHE and DiOHF both appeared to inhibit the response to PE in a concentration dependent manner.
Figure imgf000018_0001
Figure 15 illustrates the effect of phosphatase(1000U/L) and flavone-3- phosphate, (F3P) (10-5M-10-4M) with phosphatase on concentration response curves to
ACh in endothelium intact aortic rings from rats (n=5). The relaxant response to ACh did not appear to be effected by the phosphatase alone, however relaxant responses to ACh were enhanced in the presence of the F3P with phosphatase at both concentrations tested when compared to control rings.
PEC50 Rmax
Control 7.31±0.03 100±3
Phosphatase 10-4M (P) 7.30±0,04 100 ±1
F3P 10-5M + P 7.80±0.06 100 ±1
F3P 10-4M + P 7.70±0.07 100±1
Figure 16a illustrates the dose-dependent decreases in, MAP (mm Hg) in response to F3P and DiOHF in anaesthetised rats. Figure 16b illustrates the dose-dependent decrease in, HR (beats/min) in response to F3P and DiOHF in anaesthetised rats.
Figure 17 illustrates the area of myocardium at risk (left panel) and myocardial infarct size (right panel) in. Control ( n=4), DiOHF (2 mg/kg, n=2 and 5 mg/kg, n =3) and DiOHF3HA (2-7 mg/kg, n=3 and 6.6 mg/kg, n=4) treated groups of anaesthetised sheep. AR/LV% = area at risk expressed as a percentage of total left ventricular volume. IS/AR% = infarct size expressed as a percentage of the area of myocardium at risk * indicates significant difference in infarct size between Control and Adipate (6.6 mg/kg)-treated animals.
Figure 18 illustrates the latency to touch (A & C) and remove (B & D) a stimulus on the contralateral forelimb compared with the ipsilateral forelimb assessed 24, 48, and 72 hours after ET-1-induced stroke and treatment with vehicle (A & B) or DiOHF3HA (15 mg/kg/day) (C & D) in mild to moderate stroke rats.
Figure 19 illustrates the effect of delayed administration of DiOHF3HA (15 mg/kg/day) or vehicle on infarct area in cortex (A) and striatum (B) in mild to moderate stroke rats.
Definitions
As used herein, the term "alkyl" includes branched or unbranched hydrocarbon chains, such as, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tertbutyl, octa-decyl and 2-methylpentyl. These groups can be substituted or unsubstituted with one or more functional groups which are attached commonly to such chains, such as, hydxoxyl, bromo, fluoro, chloro. iodo, mercapto or thio, cyano, alkylthio, heterocyclyl, aryl, heteroaryl, carboxyl, carbalkoyl, alkyl, alkenyl, nitro, amino, alkoxyl, amido, and the like to form alkyl groups such as trifluoromethyl, 3- hydroxyhexyl.2-carboxypropyl, 2-fluoroethyl, carboxymethyl, cyanobutyl and the like. The term "lower" herein includes a linear or branched chain of 1 to 6 carbon atoms-
The term "alkylene" refers to a divalent alkyl as defined above, such as methylene (-CH2-), propylene (-CH2CH2CH2-), chloroethylene (-CHCICH2-), 2- thiobutene -CH2CH(SH)CH2CH2, l-bromo-3-hydroxyl-4Hαiemylpenterie (- CHBrCH2CH(OH)CH(CH3)CH2-), .methylethylene, trimethylene, 1-propytene, 2- propyleiie, teirarnethylene, l-msthyltrimethylene, 2-methyltritnethylene, 3- methyltrimethylene , l-ethylethylene, 2-ethylethylene , pentamethylene, 1- methyltetramethylene, 2-memyltetramethylene, 3-methyltetramethyIene, 4- methyltetramethylene and hexamethylene and the like.
The term "alkenyl" includes branched or unbranched hydrocarbon chains containing one or more carbon-carbon double bonds.
The term "alkynyl" includes branched or unbranched hydrocarbon chains containing one or more carbon-carbon triple bonds. By "aryl" is meant an aromatic carbocyclic group having a single ring (e.g., phenyl), multiple rings (e.g., biphenyl), or multiple condensed rings in which at least one is aromatic, (e.g., 1,2,3,4-tetrahydronaphthyl, naphthyl), which is optionally mono-, di-, or tri-substituted. The aryl groups herein are unsubstituted or, as specified, substituted in one or more substitutable positions with various groups. As used herein, the term "cycloalkyl" refers to saturated carbocyclic radicals having three to twelve carbon atoms. The cycloalkyl can be monocyclic, or a polycyclic fused system. Examples of such radicals include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl. The cycloalkyl groups herein are unsubstituted or, as specified, substituted in one or more substitutable positions "with various groups. For example, such cycloalkyl groups may be optionally substituted with C1-C6 alkyl, C1-C6 alkoxy, halogen, hydroxy, cyano, nitro, amino, mono(C1-C6)alkylamino, di(C1- C6)alkylamino, C1-C6 alkenyl, C1-C6 alkynyl, C1-C6 haloalkyl, C1-C6 haloalkoxy, amino(C1-C6)alkyl, mono(C1-C6)alkylamino(C1-C6)alkyl or di(C1-C6)alkylamino(C1- C6)alkyl. The term "acyl" includes an -C(O)R group, wherein R is alkyl or aryl as defined above, such as formyl, acetyl, propionyl, or butyryl,
The term "alkoxy" includes -OR-. wherein R is alkyl. The term "lower alkoxy radicals" there may be mentioned linear and branched alkoxy groups of 1 to 6 carbon atoms, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, tert-butoxy, pentyloxy, isopentyloxy, hexyloxy and isohexyloxy groups. The term "amido" includes an amide linkage: -C(O)NR- (wherein R is hydrogen or alkyl).
The term "amino" indicates an amine linkage: -NR-, wherein R is hydrogen or alkyl. The term "carboxyl" indicates -C(O)O-, and the term "carbonyt" indicates -
C(O)-.
The term "carbonate" indicates -OC(O)O-.
The term "sulfonate" indicates -S(O)2O-.
The term "phosphonate ester" indicates The term "carboxylic acid" indicates -C(O)OH.
The term "sulfonic acid" indicates -S(O)2OH.
The term "phosphonic acid" indicates -P(O)(OH)2.
The term "phosphamate" indicates -Ar-NHPO4-.
The term "phosphate ester" indicates -O-P(O)(OR)2* The term "sulfamate" indicates -Ar-NHSO3-.
The term "sulfonic esters" indicates -S(O)2-OR.
The term "sulfonate" indicates -S(O)2O-.
The term "phosphonate ester" indicates R-P(O)(OR)2.
The term "carboxylic acid" indicates -C(O)OH. The term "sulfonic acid" indicates -S(O)2OH
The term "phosphonic acid" indicates -P(O)(OH)2.
The term "phosphamate" indicates -Ar-NHPO4-,
The term "carbamate" indicates -NHC(O)O-.
The hydrocarbon chains can be optionally interrupted by one or more heteroatoms.
When present, the linker group may be any of a number of such molecules known in the area described herein.
As is clear from the above description, the spacer group D may be absent. It is also clear from the above description that the linker group may be absent. DESCRIPTION OF THE EMBODIMENTS
The present invention provides flavonoid derivatives and compositions containing tlavonoid derivatives, and methods of using same.
The presence of reactive oxidative species (ROS) in living tissue has been shown to be associated with many disorders in animals. Reactive oxidative species can contain both nitrogen, and oxygen, or only oxygen atoms. Some examples of ROS molecules include singlet O2, H2O2, free radicals such a$ OH:, O2 -', NO', and ROO-. Many of these species are formed during normal metabolic activity, but their concentration levels can be elevated under conditions of oxidative stress associated with chronic infJatmmation, infections and other diseases. Many ROS molecules are the result of naturally occulting processes such as oxygen metabolism and inflammatory processes. For example, when cells use oxygen to generate energy, free radicals are created as a consequence of ATP production by the mitochondria. Exercise can increase the levels of free radicals a$ can environmental stimuli such as ionizing radiation (from industry, sun exposure, cosmic rays, and medical X-rays), environmental toxins, altered atmospheric conditions (e,g. hypoxia and hyperoxia), • ozone and nitrogen oxide (primarily from automobile exhaust, therapeutics). Lifestyle stressors such as cigarette smoking and excessive alcohol consumption are also known to affect levels of free radicals. Radical species may combine to form other more damaging Or toxic species such as peroxymtrite ONOO-, a product of superoxide and nitric oxide radical reaction.
Another source of ROS species is some therapeutic agents, such as ami-cancer drugs. Anthracycline derivatives are highly useful anti-cancer agents in the treatment of neoplastic diseases such as acute leukemia, malignant lymphoma, etc. However, an undesirable feature of their administration can be oxidative damage to tissue, which can lead to cardiomyopathy and possible heart failure. The presence of the therapeutic agent can therefore cause the development of congestive heart failure (CHF). This feature of some therapeutic agents can limit their effectiveness and it would be useful to develop an appropriate co-administration regime.
Thus in one aspect of the present invention, there is provided a method of preventing and/or at least ameliorating damage to a subject caused by the administration of a therapeutic agent, the method comprising co-administering to a subject: i) a therapeutic agent; and ii) an effective amount of at least one compound in accordance with Formula I, Formula II, Formula in or Formula TV, wherein R1. R2, R3, R4, R5, R6, R7, R8, R8, U, Q, W, X, Y, Z, n have the same meaning as above, or a pharmaceutically acceptable salt or solvates thereof.
In another aspect, the present invention provides a method of preventing and/or at least ameliorating UV damage to the skin of a subject, comprising administering a therapeutically effective amount of the composition of the invention. With this aspect, preferably the composition is formulated into a sunscreen. The composition may be topically applied to the skin. The composition may contain emollients and moisturisers.
In another aspect the present invention provides a method of preventing and/or reversing the effects of ageing, of reducing apparent wrinkling and or/or treating or preventing dry skin.
In another aspect, the present invention provides a method of treating a subject having a disease or disorder involving oxidative damage, comprising administering a therapeutically effective amount of the composition of the invention.
Preferably, the disease or disorder involving oxidative damage is selected from the group consisting of cancer, heart disease, neurological disorders, auto-immune disoiders, ischaemia-reperfusion injury, diabetic complications, septic shock, hepatitis, atherosclerosis, Alzheimer's disease and complications arising from HIV or Hepatitis, including Hepatitis B.
In another aspect, the present invention provides a In a particular embodiment, the subject is an animal. The animal may be selected from the group consisting of humans, non-human primates, cattle, horses, pigs, sheep, goats, dogs, cats, birds, chickens or other poultry, ducks, geese, pheasants, turkeys, quails, guinea pigs, rabbits, hamsters, rats and mice.
In some aspects of the invention, the one or more flavonoid derivatives are administered simultaneously, separately or sequentially with the one or more therapeutic agent(s).
When used in such a combination the one or more therapeutic agent(s) and the one or more flavonoid derivative(s) according to the present invention can. be administered as separate agents at the same or different times or they can be formulated as a single composition comprising both compounds.
Free radicals react with key organic substrates in cells such as lipids, proteins, and DNA. Oxidation of these biomolecules can damage them, disturbing normal functions and may contribute to a variety of disease states. It has been noted that certain organ systems are predisposed to greater levels of oxidative stress or nitrosative stress. Those organ systems most susceptible to damage are the pulmonary system (exposed to high levels of oxygen), the brain (exhibits intense metabolic activity yet has lower levels of endogenous antioxidants), the eye (constantly exposed to damaging UV light), circulatory system (victim to fluctuating oxygen and nitric oxide levels) and reproductive systems (at risk from the intense metabolic activity of sperm cells). Examples of relevant acute disorders causing the production of ROS include ischaemia reperfusion, stroke, myocardial infarction or mechanical trauma, such as a crush injury or surgery. Some forms of surgery such as heart bypass or transplant surgery necessarily cause ischaemia and reperfusion of tissue. Typically one or more flavonoid derivatives according to the present invention are administered to the subject before and/or during surgery. Chronic disorders may be chosen from the group including cancer, cerebrovascular disease, atherosclerosis, artery disease including coronary disease, peripheral vascular disease (including damage caused by diseases such as diabetes), hypertension, pulmonary hypertension, chronic obstructive airways disease, emphysema, neurological disorders, auto-immune disorders, diabetic complications, septic and hypovolemic shock, burns, hepatitis, and complications arising from hepatitis and HIV. Another chronic disorder may be chosen from the complications resulting from administration, of hyperbaric or high oxygen tension atmospheres, often applied to assist breathing particularly in a premature infant human., including retinal or other eye damage. Subjects at risk of relevant chronic disorders may be diagnosed by analysis of symptoms, diagnostic testing, enzymatic markers, or by genetic testing to identify a genetic predisposition. Predisposition to certain acute disorders such as heart attack or stroke may also be identified by genetic testing and may prompt the prophylactic application of one or more flavouoid derivatives to the subject at risk. Drug-induced disorders due to ROS eg drug induced congestive heart disease. If the disease or disorder is stroke or risk or stroke, the composition described above is preferably administered before the stroke occurs as a prophylactic to reduce the risk of stroke occurrence, or within twelve hours (preferably within four hours) of stroke occuance.
An example of an ROS involved pathological condition is ischaemia where a deficiency of blood flow to part of a body results in inadequate tissue perfusion with oxygen. Ischaemia causes tissue damage, the severity of the damage depending on the length of time the tissue is deprived of oxygen and whether adequate reperfusion of oxygen occurs after the ischaemic event.
At least one compound in accordance with the present invention may be administered via a number of different routes, for example, topically, orally, subcutaneous, intramuscular, intra-arterially and/or intravenously.
Compound Synthesis
The present invention provides flavonoid compounds according to Formula I, II, III or IV, V and methods of synthesizing such compounds. Derivatives of Flavonoids
Flavonoid phosphate derivatives are produced by a selective protection / deprotection synthetic strategy, 3-Hydroxyflavone-3-phosphate disodium salt (5) With reference to Figure 1 the approach to the synthesis of 3-hydroxyflavone-3- phosphate disodium salt is shown. 3-Hydroxyflavone (1) underwent phosphitylatkm when, treated with dibenzyl N,N-diisopropylphosphoramidite and the intermediate phosphate was directly oxidised by m-chloroperbenzoic acid (mCPBA) to its corresponding protected phosphate. The phosphate ester was purified by flash chromatography followed by recrystallization, yield 45%.
The phosphate ester underwent hydrogenolysis in ethanol with palladium hydroxide to form the phosphate, which was immediately converted to its disodium salt by addition of a slight excess of 0.1 M sodium hydroxide solution. Deprotection. by hydrogenolysis provided a pure sample of 3-hydroxyflavone-3-phosphate disodium salt in a 73% yield.
The corresponding diammoniurn salt was produced by ion exchange chromatography using a diethylaminoethyl column (DEAE) of (5). 3'4'-Dϊhydroxyflavone-3-phosphate (as disodium salt) (10)
An identical procedure was implemented for the synthesis of the trihydroxyflavone analogue as shown in Figure 2.
Thus 3',4'-dibenzyloxy-3-hydroxyflavone (6) underwent phosphitylation by diisopropyl N,N-dibenzyloxyphosphoramidite in the presence of 1H-tetrazole to form the 3',4'-dibenzyloxy-flavone-3-phospbite dibenzyloxy ester (7), which was oxidized by mCPBA to the protected phosphate ester, 3',4'-dibenzyloxy-flavone-3-phosphate dibenzyloxy ester (8) . These two steps produced the desired compound in a 40% yield after recrystallisation.
The phosphate ester was then subjected to hydrogenolysis in ethanol with palladium to form the desired 3',3'-dihydroxyl-fIavone-3-phosphate (9) which was converted to the corresponding disodium salt, 3'.4'-dihydroxyl-flavone-3-phosphate disodium salt (10) by addition of ΝaOΗ. Ester Derivatives of Flavonoids
3-Hyάroxyflavone-3-hemi$uccinate fl 5)
3-Hydroxyflavone-3-hemisuccinate (15) was produced according to the reaction outlined in Figure 3. Reaction of succinic anhydride (11) and benzyl alcohol (12) in the presence of 4-dimethylaminopyridine (DMAP) and pyridine in dichloromethane produced the succinic acid monobenzyl esteT (13) as white crystalline flakes in 77% yield. This protected succinic acid derivative was coupled to 3-hydroxyflavone (1) in the presence of DCC and DMAP, forming flavone-3-hemisuccinate monobenzyi ester
(14) as yellow or brown oil that solidified upon standing, with yields of up to 96% produced.
The deprotection of the monobenzyl ester to form the corresponding hemisuccinate using a Pd(OAc)2 in the THF:EtOH;acetic acid solvent system, a larger scale reaction was undertaken to yield the requiτed 3-hydrosyflavone-3-hernisuccinate (15). 3-HydroxyfIavone-3-hemiadiøate (19)
3-Hyάχoxyflavone-3-hemiadipate (19) was synthesized .following a similar procedure to that discussed above for the hemisuecinate, as shown in Figure 4.
Adipic acid monobenzyl ester (17) was produced from adipic acid and benzyl alcohol in the presence of p-TsOH to yield the desired product as a colourless oil in 34% yield.
The protected adipic acid then underwent a DCC coupling with 3- hydroxyflavone (1) to form flavone-3-hemiadipate monobenzyl ester as a yellow/brown gum in 59% yield. Hydrogenation of this compound in the presence of Pd(OH)2 catalyst, using a THF-based solvent system (9:1 THFrEtOH + 0.05% acetic acid) resulted in hydrogenolysis of the monobenzyl ester, forming flavone-3-hemiadάpate as a yellow solid in 89% yield. 3 ', 4 '-dihvdroxyftavone-3-hemiadmate (21 )
The scheme for the synthesis of 3',4'-dihydroxyflavone-3- hemiadipate (21) is illustrated in Figure 5. Following the methodology established above, 3',4'- dibenzyloxγ-3-hydroxyflavone (6) and adipic acid moribenzyl ester (17) underwent a
DCC coupling to produce the hemiadipate monobenzyl ester as a brown gum in 59% yield. Deprotection by hydrogenolysis on a small scale (100-500 mg) proceeded smoothly to completion in 3-5 hours to give the 3',4'-dihydroxyflavone-3-hemiadipate (21) in 33% yield
III Compositions and Methods The compounds of this invention can be formulated in a variety of carriers and delivery systems. The amount of the therapeutic compound to be administered and the compound's concentration is dependent on the vehicle or device selected, the clinical condition of the patient, the side effects and the stability of the compound in the formulation. Thus, the physician employs the appropriate preparation containing the appropriate concentration of the therapeutic compound and selects the amount of formulation administered, depending upon clinical experience with the patient in question or with similar patients.
Furthermore, excipients can be included in the formulation. Examples include co-solvents, surfactants, oils, humectants, emollients, preservatives, stabilizers and antioxidants. Any pharmacologically acceptable buffer may be used, e.g., Tris or phosphate buffers. Effective amounts of diluents, additives and excipients are those amounts which are effective to obtain a pharmaceutically acceptable formulation in terms of solubility, biological activity, etc.
Thus, a composition of the invention includes a therapeutic compound which can be formulated with conventional, pharmaceutically acceptable, vehicles for topical, oral or parenteral administration, Formulations can also include small amounts of adjuvants such as buffers and preservatives to maintain isotonicity, physiological and pH stability.
IV Administration The compounds of the invention may be adrninistered to both human and animal subjects.
The compounds of this invention may be administered in compositions wherein the active compound is intimately admixed with one or more inert ingredients and optionally including one or more additional active ingredients. The compounds may be used in any composition known to those skilled in the art for administration to humans and animals.
The composition of the invention may be administered through a proper route according to the dosage form. For example, the injection can be administered intravenous, intra-arterial, subcutaneous, intramuscular and the like. For oral administration, either solid or fluid unit dosage forms can be prepared. The water soluble forms can be dissolved in an aqueous vehicle together with sugar, aromatic flavouring agents and preservatives to form syrup. An elixir is prepared by using a hydro-alcoholic (e.g., ethanol) vehicle with suitable sweeteners such as sugar and saccharin, together with an aromatic flavouring agent. Suspensions can be prepared with an aqueous vehicle with the aid of a suspending agent such as acacia, tragacanth, methylcellulose and the like. The synthetic flavonoid compounds of the present invention, may also be formulated with stabilizing agents, for example metal chelator reducing agents such as ethylenediaminetetracetic acid (EDTA) or a reducing agent such as sodium metabisufite.
Appropriate formulations for parenteral use are apparent to the practitioner of ordinary skill. Usually, the therapeutic compound is prepared in an aqueous solution in a concentration of from about 1 to about 100 mg/mL. More typically, the concentration is from about 10 to 60 mg/mL or about 20 mg/mL. Concentrations below 1 mg/mL may be necessary in some cases depending on the solubility and potency of the compound selected for use. The formulation, which is sterile, is suitable for various parenteral routes including intra-dermal, intra-articular, intramuscular, intravascular, intravenous, inhalation and subcutaneous.
Compositions according to the present invention may be formulated into sunscreens, skin care compositions, emollient of moisturizers.
Slow or extended-release delivery systems, including any of a number of biopolymers (biological-based systems), systems employing- liposomes, and polymeric delivery systems, for example dendrimers, can be utilized with, the compositions described herein to provide a continuous or long term source of therapeutic compound. Such slow release systems are applicable to formulations for topical, ophthalmic, oral, and parenteral use.
The synthetic flavonoid compound(s) of the present invention may also be formulated as a nutrapharmaceutical or a nutraceutical. For example, the synthetic flavonoid compound(s) may be formulated into a food, such as a cereal, beverages such as fruit juice, alcoholic drinks, bread, etc, for oral consumption.
V Vasorelaxant and Antioxidant Activity of Flavonoid Derivatives
The effects of vehicle, flavone-3-hemiadipate (10-8 to 10-4 M) and DiOHF (10-4 M) on the level of superoxide anions generated in rat aorta in the presence of NADPH were determined and expressed as a percentage of control. The presence of the flavone-3-h.emiadipate appeared to have no effect on- the superoxide production at any concentration.
With reference to Figure 6, the effects of vehicle, FlavoDe-3-heπriadipate (F3HA), in the presence and absence of butyτyl cholinesterase (BuCHE, 1000 U/L) and DiOHF (1 Q"4 M) on the level of superoxide anions generated in rat aorta in the presence of NADPH expressed as a percentage of control is illustrated. In the absence of the esterase there appears to be no effect on the superoxide production. The presence of cholinesterase reveals a concentration-dependent inhibitory effect of flavone-3- hsmiadipate. This is consistent with the hemiadipate group being removed in vitro to form the free hydroxyl derivative, 3-hydroxy flavone. The suppression of superoxide production by inclusion of both the flavone-3 -hemiadipate (19) and esterase compares favourably to the activity of DiOHF O'^'-dihydroxy flavonol). A reduction in the superoxide and other ROS concentrations has been linked to a possible reduction in myocardial damage induced by the presence of these radicals. The concentration response curves to Ca2+ in the presence of vehicle or increasing concentrations of flavone-3-herniadipate (15) (F3HA, 10-8 M - IQF* M) in endothelium intact aortic rings isolated from rats was determined. At the lower concentrations (10-S to 10-3 M), the flavone-3-hemiadipate did not effect Ca2+ contraction of the aortic ring. At the higher level tested, 10-4 M, the flavone-3 - hemiadipate has some inhibitory effect, most likely due to the presence of an esterase in the aortic tissue of the rat.
The effects of vehicle CdH2O), 3',4'-dihydroxyflavone-3-hemiadipate (21) (D1OHF3HA, 10-8M - IQ-4 M) and DiOHF (10-4 M) on the level of superoxide anions generated in rat aorta in the presence of NADPH expressed as a percentage of control. The superoxide concentration remained constant throughout the DiOHF3HA concentration range studied, thus DiOHF3HA had no effect on superoxide generation.
Referring to Figure 7, the effects of vehicle, ^'^'-dihydroxyflavone-S- . hemiadipate (21)- (DiOHFSHA, 10-6 M - 10-4M) in the presence and absence of buryryl cholinesterase (BuCHE, 1000 U/L) on the level of superoxide anions generated in rat aorta in the presence of NADPH expressed as a percentage of control is illustrated- For comparison the results using DiOHF (10-4 M) on the level of superoxide anions generated in rat aorta in the presence of NADPH expressed as a percentage of control are also shewn. The presence of the cholinesterase revealed a concentration dependent inhibition of superoxide levels. The concentration response curves to Ca2* in the presence of vehicle or increasing concentrations of 3',4'-dihydroxyflavone-3-herniadipate (21) (DiOHF3HA, 10"6 M - ICC4 M) in endothelium intact aortic rings isolated from rats. The contractions are expressed as a percentage of the initial response to Ca2+ (3x10-3 M) observed before treatment with DiOHF3HA. D1OHF3HA appears to have slight Ca2+ inhibitory action at 10-4 M. This effect is possibly due to the presence of some esterase in. the aortic tissue of the rat.
Turning to Figure 8, the concentration response curves to Ca2+ in the presence of vehicle or 3',4'-dIhydτoxyflavone-3-hemiadipate (21) (DiOHF3HA, 10-4 M), in the presence and absence of BuCHE was compared to DiOHF in endothelium intact aortic rings isolated from rats is illustrated. The contractions are expressed as a percentage of the initial response to Ca2+ (3x10~3 M) observed before treatment with D1OHF3HA. The presence of cholinesterase markedly enhanced the inhibitory effect of DiOHF3HA.
Referring to Figure θ, the effects of vehicle, flavone-3-ph.osphate (F3P, 10-B M- 10-4 M) in the presence phosphatase (1000 U/L) and DiOHF (10-4 M) on the level of superoxide anions generated in iat aorta in the presence of NADPH expressed as a percentage of control. The presence of the flavone-3 -phosphate caused a concentration dependent decrease in the levels of superoxide. This effect is contrary to previous studies that have shown that the presence of the S'^'-dihydroxyl group in the B ring is determinative in decreasing the levels of superoxide.
The concentration response' curves to Ca2+ in the presence of vehicle or. increasing concentrations of flavone-3-phosphate (F3P, 10-6M- 10"* M) in endothelium intact aortic rings isolated from rats was determined. Flavone-3-phosphate caused partial inhibition of the calcium-induced contraction at the highest concentration.
Referring to Figure 10, the concentration response curves to Ca2+ in the presence of vehicle or flavone-3 -phosphate (F3P, 10-8 M-I0-4 M) in the presence and absence of phosphatase (P, 1000 U/L) in endothelium intact aortic rings isolated from rats is shown. The contractions are expressed as a percentage of the initial response to Ca2+ (3x10-3 M) observed before treatment with flavone-3-phosphate. The presence of phosphatase markedly enhanced the inhibitory effects of flavone-3~phosphate.
The invention is illustrated by the following non-limiting examples.
Synthesis of Flavonoid Derivatives
3- (Benzyloxycarbonylbutylcarbonyloxy)flavone
Figure imgf000031_0001
3-Hydroxyflavone (0.105 g, 0.442 mmol), dicyclohexylcarbodiimide (0.193 g, 0.933 mmol) and 4-dimethylaminopyridine (9.80 tag, 0.0802 mmol) was added to a solution of adipic acid monobenzyl ester (0.168 g, 0,754 mmol) in dichloromethane (10 mL) and the mixture was stirred under N2 at room temperature for 19 h. Water (50 μL) was added and the resultant mixture was stirred for 10 rain, then diethyl ethex (10 mL) was added. The mixture was filtered, the filtrate concentrated and purified by flash chromatography (15-40% EtOAc in toluene) to yield the monobenzyl ester as a yellow gum (0.16 g, 80%). A small portion was recrystallized from EtQ Ac/petroleum spirits to give a colourless powder; mp = 74-76°C; 1H NMR (399.7 MHz, CDCl3) δ 1.60 - 1.75 (m, 4H, CO2CH2CH2); 2.31 (t, J = 6.8 Hz, 2H, CO2CH2); 2.55 (t, J = 6.8 Hz, 2H, CO2CH2); 5.02 (s, 2H, CH2Ph); 7.20 - 7.28, 7.39 - 7.45 (2m, H, PhCH2, H3', 4', 5'); 7.34 (dd, 1H, J5,6 = 8.0 Hz, J6,7 - 7.6 Hz, H6); 7.46 (d, 1H, J7,8 = 8.0 Hz, H8); 7.62 (ddd, 1H, J5,7 = 1.6 Hz, J6,7 = 7.6 Hz, J7,8 = 8.0 Hz, H7); 7.73 - 7.77 (m, 2H, H2', 6'); 8.16 (dd, 1H- J5,7 = 1.6 Hz, H5). 13C KMR (100.5 MHz, CDCl3) δ 25.29 (2C, CO2CHiCH2); 34.62, 34.91 (2C, CO2CH2); 67.30 (1C, CH2Ph); 119,21, 124.68, 126-29, 127.17, 129.29, 129.40, 129.63, 129.75, 131.05, 132.36, 134.72, 135.06. 137.03, 156.7I, 157.45 (20C, Ar); 171.54, 173.27, 174.16 (3C, C-O). Anal. Found: C, 73.54; H, 5.27; C42H36O8 requires C, 73.67; H, 5.30%. HRMS (ESI+) ra/z 479.1469, C28H24NaO6 [M + Na]+ requires 479.1471. 3-Hydroxyflavone 3-hemiadipate
Figure imgf000031_0002
A mixture of 3-(benzyloxycarbonylbutylcarbonylox.y)flavone (312 mg, 0,7 mmol) and Pd(OH)2 (49,4 mg) in 9:1 THF:EtOH + 0.05% acetic acid (15 mL) was treated with H2 for 5 h. The crude product was filtered (Celite), the filtrate was concentrated and the residue was purified by flash chromatography (10-25% EtOAc in toluene + 1% acetic acid) to give the hemiadipate as a light yellow solid (0.211 g, 89%), A small portion was crystallized from EtOAc/petroleum spirits; mp = 118- 12I°C; 1H NMR (399.7 MHz, CDCl3) δ 1.66 - 1.83 (m, 4H, CH2CH2CO2): 2.38 (t, J = 6.8 Hz, 2H, CH2CO2); 2.63 (t, J = 6.8 Hz, 2H, CH2CO2); 7.42 (dd, 1H, J5,6 = 8.0 Hz, J6,7 = 8.0 Hz, H6); 7,47 - 7.53 (m, 3H, H3', 4', 5'); 7.54 (d, 1H, J7,8 = 8.4 Hz, H8); 7.70 (ddd, 1H, J5,7 = 1.6 Hz, J6,7 = 8.0 Hz, J7,8 = 8.4 Hz, H7); 7.81 - 7.86 (m, 2H, H2', 6'); 8.24 (dd, 1H, J5,6 = 8.0 Hz, J5,7 = 1.6 Hz, H5). 13C NMR (100.5 MHz, CDCl3) δ 25.01, 25.20 (2C, CO2CH2CH2); 34.57 (2C, CO2CH2); 119.20, 124.66, 126.33, 127.21, 129.41, 129.76, 131-04, 132.40, 134.70, 135.10, 156.74, 157.60 (14C, Ar); 171.52, 173.38, 179.36 (3C, C=O). Anal. Found: C, 68.89; H, 4.91; C21H18O6 requires C, 68.85; H, 4.95%. HRMS (ESI+) m/z 389.1000, C21H18NaO6 [M + Na]+ requires 389.1001).
4 '-(Benzyloxy)-3-(benzyloxycarbonylbutylcarbonyloxy)flavone
Figure imgf000032_0001
Ethylene dichloride (EDC) (843 mg, 4,40 mmol) was added to a solution of 4'- benzyloxy-3-hydroxyflavone (1.00 g, 2.90 mmol), adipic acid monobenzyl ester (1.30 g, 5.50 mmol) and DMAP (354 mg, 2.89 mmol) in dichloromethane (110 mL) and the mixture was stirred at rt overnight. The reaction mixture was then concentrated and the residue dissolved in ethyl acetate. The organic-phase was washed with water (x 3), 1 M HCl (κ 3), sat NaHCO3 (x 3), brine (x 3), dried (MgSO4) and concentrated. The residue was purified by flash chromatography (50% EtOAc/petrol) to give the benzyl ester as a brown oil, which was crystallized from EtOAc/petrol to give a colourless solid (900 mg, 55%); mp 93 °C; 1H NMR (500 MHz, CDCl3) δ 1.77-1.83 (m , 4H, CH2CH2), 2.42 (t, 2H, J = 7.5 Hz, CH2CO), 2,67 (t, 2H, J = 6.5 Hz, CH2CO), 5.13 (s, 2H, CH2Ph), 5.15 (s, 2H, CH2Ph), 7.09 (d, 1H, J7,8 = 8.5 Hz, H8), 7.35 (app. d, 2H, J = 8.5 Hz, H2',6'), 7.40-7.46 (m, IIH, 2 X Ph, H6). 7.69 (ddd, 1H, J5,7 = 1-5, J6,7 = 7-0, J7,8 = 8.5 Hz, H7), 7.85 (app. d, 2H, J = 8-5 Hz, H3',5'), 8.25 (4 1H, % = 8 Hz, H5); 13C NMR (125 MHz, CDCl3) δ 24.2 (x 2), 33.6, 33.8 (4C, CH2), 66.2, 70.1 (2C, CH2Ph), 115.0, 117,9, 122.4, 123.5, 125.0, 126.0, 127.4, 128.1, 12S.2, 128.5, 128.7, 130.0, 133.0. 133.7, 135.9, 136.2, 155.5, 156.1, 161.1 (AT), 170.4, 172,0- 173.0 (3C, C=O); IR (thin film) 2937, 1760, 1730, 1646, 1602, 1507, 1468, 899 cm-1; Anal. Found C, 74,67; H, 5.29, C35H30O7 requires C, 74.72; H, 5.37%. 4'-Hydroxyflavone 3-hemiadipate
Figure imgf000033_0001
A mixture of the 4'-(benzyloxy)-3-(benzyloxycarbonyl butylcarbonyloxy) flavone (400 mg, 0.711 mmol) and Pd(OH)2 (56 mg) in THF (10 mL), ethanol (1.2 mL) and AcOH (100 μL) was treated with hydrogen (50 psi) for 18 h. The reaction mixture was then filtered (Celite) and the pad washed with THF. The filtrate was concentrated and the solid residue was purified by flash chromatography (70% THF/toluene + 1%
AcOH) and the resultant solid recrystallised from THF/petrol to afford the acid as a colourless solid (150 mg, 55%); mp 177-180°C; 1H HMR (500 MHz, d6-DMSO) δ 1.56-1.66 (m, 4H, CH2CH2), 2.25 (t, 2H, J = 7.0 Hz, CH2CO), 2.64 (t, 2H, J = 7.0 Hz,
CH2CO), 6.96 (app. d, 2H, J = 8.5 Hz, H2',6'), 7.52 (t, 1H, J6,7 = J7,8 = 7.5 Hz,. H7),
7.80 (app. d, 2H, J = 7.5 Hz, H3',5'), 7.78 (m, 1H, H8), 7.85 (t, 1H, J5,6 = J6,7 = 7.5 Hz,
H6), 8.06 (d, 1H, J5,6 = 8.0 Hz, H5); 13C NMR (125 MHz, d6-DMSO) δ 23.8, 23,9,
32,9, 33.3 (4C, CH2), 115.9, 118.5, 119.7, 122.7, 125.0, 125-6, 130.1, 131.9, 134.5, 154.9, 155.8 160.6 (Ar), 170.4 170.9, 174.3 (3C, C=O); IR 3257, 2944, 2869, 1765,
1706, 1595, S54 cm-1; HRMS (ESI+) m/z 383.1123, C21H19O7 (M + H]+ requires
383.H31.
3 ', 4 '-Dibenzyloxy-3-(benzyloxycarbonylbutylcarbonyIoxy)flavone
Figure imgf000033_0002
Adipic acid monobenzyl ester (1.91 g, 5.04 mmol) followed by EDC hydrochloride (0.764 g, 3.98 mmol) and DMAP (0.324 g, 2.65 mmol) were added to a stirring solution of 3',4'-dibenzyloxyflavonol (1.21 g, 2.68 mmol) in dry dichloromethane (100 mL) and the resultant mixture was stirred at room temperature under N2 for 3 h. The reaction mixture was concentrated under reduced pressure and resuspended in ethyl acetate (100 mL). The suspension was then washed with water (3 x 50 mL), 1M HCl (3 x 50 mL), saturated NaHCO3 (3 x 50 mL) and brine (3 x 50 mL). The organic extract was dried (MgSO4), filtered, concentrated under reduced pressure and the yellow residue crystallized from EtOAc/ petroleum spirits to yield the benzyl ester as a fluffy yellow solid (1.58 g, 88%); mp = 84-85 °C; 1H NMR (399.8 MHz, CDCl3); δ 1.70- 1.80 (m, 4H, CH2CH2); 2,38 (t, 2H, J = 6.8 Hz, CH2CO); 2.55 (m, 2H, CH2CO); 5.10 (s, 2H, CH2Ph); 5.20 (s, 2H, CH2Ph); 5.24 (s, 2H, CH2Ph); 7.01 (d, 1H, J7,8 = 8.4 Hz, H8); 7.26 - 7.49 (m, 19H, Ar, H6, 2', 5 6'); 7.62 (ddd, 1H, J5,7 = 1.2 Hz, J6,7 = 7.2 Hz, J7,8 = 8.4 Hz, H7); 8.22 (dd, 1H, J5,5 = 7.6 Hz, J5,7 = 1.2 Hz, H5). 13C NMR (100.5 MHz, CDCl3) 6 25.33 (2C, CH2CH2CO2); 34.59, 34,93 (2C, CH2CO2); 67.30, 71,91, 72.59 (2C, CH2Ph); 114.77, 115.84, 119.06, 123.76, 123.84, 124.60, 126.19, 127.12, 128.25, 128.36, 129.15, 129.29, 129-64, 129.73, 130.12, 134.23, 134.89, 137.05, 137.54, 137.85, 149.61, 152.64, 156.53, 157.00 (32C, Ar); 171.49, 173.12, 174.18 3C, C=O). Anal. Found: C, 75.39; H, 5.47; C42H36O8 requires C, 75.43; H, 5.43%. HRMS (ESI+) m/z 691.2303, C42H36NaO8 [M + Na]+ requires 691.2308. 3 ',4'-Dihydroxyflavone 3-hemiadipate
Figure imgf000034_0001
A mixture of 3",4'-dibenzyloxy'-3-(benzyloxycarbonylbutylcarbonyloxy)flavone (2.12 g, 3.16 mmol) and Pd(OH)2 (107 mg) in 9: 1 THF:EtOH containing 0.05% acetic acid (50.0 mL) was treated with H2 under high pressure for 5 h. The reaction mixture was filtered (Celite) and concentrated to give a dark green solid. The green residue was purified by flash chromatography (30 - 90% THF/toluene + 1% acetic acid) followed by crystallization from THF/petroleum spirits to yield the pure hemiadipate as a pale brown solid (0.70 g, 56%); mp = 194-197°C; 1H NMR (399-8 MHz, CDCl3); δ 1.44 - 1.62 (m, 4H, CH2CH2); 2.10 (t, 2H, J = 6.8 Hz, CH2CO); 2.44 (t, 2H, J = 6.8 Hz, CH2CO); 6.73 (d, 1H, J5',6' = 8.4 Hz, H5'); 7.09 (dd, 1H, J2',6' = 2.0 Hz, J5',6' = 8.4 Hz, H6'); 7.16 - 7.22 (m, 2H, H6, 2'); 732 (d, 1H, J7,8 = 8.0 Hz, H8); 7.48 (ddd, 1H, J5,7 = 1.6 Hz, J6,7 = (5.8 Hz, J7,8 = 8.0 Hz, H7); 7.94 (dd, 1H, h,6 = 8.4 Hz, J5,7 = 1.6 Hz, H5). 13C NMR (100.5 MHz d6-DMSO) δ 25-30, 25.62 (2C- CH2CH2CO2); 34.43, 34.81 (2C, CH2CO2); 116.59, 117,42, 119.98, 121.41, 122.06, 124.13, 126.51 , 127.07, 133.32, 136.04, 146.97, 150.65, 156.35, 157.27 (14C, Ar); 171.97, 173.46, 179.95 (3C, C=O). Anal. Found; C, 68.89; H, 4.91; C21H18O6 requires C, 68.85; H, 4.95 %. HRMS (ESf) m/z 389.1000, C21H18NaO6 [M + Na]+ requires 389-1001. 3,4 '-Di-(benzyloxycarhonylbutylcarbonyloxy)flavone
Figure imgf000035_0001
Ethylene dichloride (1.13 g, 5.91 mmol) was added to a solution of 3,4'- dihydroxyflavone (500 rag, 1.97 mmol), adipic acid monobenzyl ester (1.86 g, 7,88 mmol) and DMAP (481 mg, 3.94 mmol) in dichloromethane (30 mL) and the mixture stirred at rt for 50 min. The reaction mixture was then concentrated and the residue dissolved in ethyl acetate. The organic phase washed with water (x 3), 1 M HCl (x 3), sat NaHCO3 (x 3), brine (x 3), dried (MgSO4) and concentrated. The residue was purified by flash chromatography (50% EtOAc/petrol) to give the diester as a colourless oil, which was crystallized from EtO Ac/petrol to afford a colourless solid (850 mg, 62%); mp 79°C; 1H NMR (500 MHz, CDCl3) δ 1.76-1.82 (m, 8H, 2 x CH2CH2), 2.42 (t, 2H. J = 7.0 Hz, CH2CO), 2.45 (t, 2H, J = 7-0 Hz, CH2CO), 2.62 (t, 2H, J = 7.0 Hz, CH2CO), 2.65 (t, 2H, J = 7.0 Hz, CH2CO), 5.12 (s, 2H, CH2Ph), 5.14 (S, 2H, CH2Ph), 7.25 (d, 2H, J = 8.5 Hz, H2',6'), 7.31-7.37 (m, 10H, 2 x Ph), 7.44 (t, 1H, J5,6 = J6,7 = 8.5 Hz, H6), 7.55 (d, 1H, J7,8 = 8.5 Hz, H8), 7.72 (td, 1H, J6,7 = J7,8 = 8.5, J7,5 = 1.5 Hz, HT). 7.89 (d, 2H, J = 8.5 Hz, H3',5'), 8.25 (dd, 1H, J5,6 = 8.5, J5,7 = 1.5 Hz, H8); 13C NMR (125 MHz, CDCl3) 6 24.16, 24.17, 24.21, 33.5, 33,8, 33.9, 66.1, 66.3 (CH2), 118.0, 121.9, 123.5, 125.2, 126.1, 127.4, 128.-1, 128.18, 128.22. 128.49, 128.53, 129.7, 133.7, 134.0, 135.9, 136.0, 152.8, 155.4, 155.5 (Ar), 170.3, 171.2, 172.1, 173.97, 173.0 (5C, C=O); IR 2943, 1765, 1732, 1652, 1501, 1465, 902 cm-1; Anal. Found C, 71.30; H, 5.56, C41H38O10 requires C, 71.29; H, 5.55%. Flσvone 3,4'-bis(hemiadwate)
Figure imgf000035_0002
A mixture of 3,4'-di-(benzyloxycarbonylbutylcarbonyloxy)fIavone (435 mg, 0.629 mmol) and Pd(OH)2 (50 mg) in EtOAc (5 mL) was treated with hydrogen for 2 h resulting in a grey precipitate. THF was added to dissolve the precipitate and the mixture was filtered (Celite). The pad washed with THF, and the filtrate concentrated. The solid residue was recrystallised from THF/petrol to afford the bis(hemiadipate) as a colourless solid (183 mg, 50%); mp 133°C; 1H NMR (500 MHz, d6-DMSO) δ 1.55- 1.70 (m, 8H, CH2CH2), 2.24 (t, 2H, J = 7.0 Hz, CH2CO), 2.27 (t, 2H, J = 7.0 Hz, CH2CO), 2.63 (t, 2H, J = 7.0 Hz, CH2CO), 2.64 (t, 2H, J = 7.0 Hz, CH2CO), 7.37 (app. d, 2H, J = 9.0 Hz, H3',5'), 7-55 (dd, 1H, J5.6 = 8.5, J6.7 = 7-5, Hz, H6), 7.80 (d, 1H, J7,8 = 8.5 Hz, H8), 7.88 (ddd, 1H, J6,7 = 7.5, J7,8= 8.5, J5,7 = 1.5 Hz, H7), 7.96 (app. d, 2H, J = 9.0 Hz, H2',6'), 8.08 (dd, 1H, J5.6 = 8.5, J5,7 = 1.5 Hz, H5); 13C NMR (125 MHz, d6- DMSO) δ 23.77, 23.82, 32.6, 33.2, 33.3; 44.3 (CH2), 118.7, 122.5, 122.6, 122.7, 125.1, 126.8, 129.7, 132.9, 134.8, 152.7, 154.9, 155.1 (Ar), 170.4, 171.1, 171.4, 174.3, 174.3 (5C, C=O); IR 3059, 2940, 2873, 1768, 1706, 1504, 759 cm-1; HRMS (ESI-) m/z 509.1441, C27H25O10 [M -H]- requires 509.1442. 3,7-Di-(benzyloxycarbonylbutylcarbonyloxy)flavone
0
Figure imgf000036_0001
O Ethylene dichloride (EDC) (517 mg, 2.7 mmol) was added to a solution of 3,7- dihydroxyflavone (250 mg, 0.983 mmol), adipic acid monobenzyl ester (921 mg, 3.90 mmol) and DMAP (220 mg, 1.80 mmol) in dichlororoethane (25 mL) and the mixture was stirred at rt for 1 h. The reaction mixture was then concentrated and the residue dissolved in ethyl acetate. The organic phase was washed with water (x 2), 1 M HCI (x 2), sat NaHCO3 (x 2), brine (x 2), dried (MgSO4) and concentrated. The residue was filtered through a pad of silica eluting with 50% EtOAc/petrol to give a solid, which was recrystallized from EtOAc/petrol to give the diester as a colourless solid (565 mg, 91%); mp 58 °C; 1H NMR (500 MHz, CDC13) δ 1.74-1.82 (m, 8H, CH2CH2 x 2), 2.39 (t, 2H, J = 7.0 Hz, CH2CO), 2.45 (t, 2H, J = 7.0 Hz, CH2CO), 2,62-2.64 (m, 4H, CH2CO x 2), 7.15-7.17 (m, 2H, H2', 6 ') ,7.30-7.36 (m, 10H, 2 x Ph), 7.39 (d, 1H, J6,8 = 1.6 Hz, H8), 7.48-7.51 (m, 2H, H3', 5'), 7.81-7.83 (m, 2H, 4' H6) 8.25 (d, 1H, J5,6 =9, H5); 13C NMR (125 MHz, CDCl3) δ 24.1, 24.20, 24.21, 33.5, 33,80, 33.82. 34.0, 44.7, 66.2, 66.3, (CH2), 111.0, 119.5, 121.5, 172.5. 128.19, 128.22, 128.3, 128.5, 128.6, 128.7, 129.8, 131.3, 133.7, 135.9, 136.0, 154.8, 156.1, 156.6 (Ar), 170.3, 170.8, 171.5, 172.96, 173,0 (5C, C=O) IR 3071, 3035, 2944, 2876, 1760, 1726, 1615, 848 cm-1; Anal. Found C, 71.34; H, 5.60%, C41H38O10 requires C, 71.29; H, 5.55%. 3.7-Dihydroxyflavone 3, 7-bis(hemiadipate)
Figure imgf000037_0001
6
A mixture of 3,7-di-(benzyloxycarbonylbutylcarbonyloxy)flavone (565 mg, 0.818 mmol) and Pd(OH)2 (65 mg) in EtOAc (10 mL) was treated with hydrogen for 3 h. A grey precipitate formed and THF was added until it dissolved. The mixture was filtered (Celite) and the pad washed with THF, and the filtrate was concentrated. The solid residue was recrystallised from THF/petrol to afford the diacid as a colourless solid (311 mg, 76%); mp 128 °C; 1H NMR (400 MHz, d6-DMSO) δ 1.55-1.74 (m, 8H, CH2CH2 x 2), 2.23 (t, 2H, J = 7.0 Hz, CH2CO), 2.28 (t, 2H, J = 7.0 Hz, CH2CO), 2.61- 2.68 ( m, 4H, CH2CO x 2), 734 (m, 1H. H4'), 7.58-7.61 (m, 3I-I, H6, H2', 6'), 7.68 (cL 1H, J6,8 = 1.6 Hz, H8), 7.87-7.89 (m, 2H, H3', 5'), 8.12 (d, 1H, J5,6 = 8.8, H5); 13C NMR (100 MHz, d6-DMSO) δ 23.7, 23.76, 23.78, 23.9, 32.9, 33.19, 33-24, 33.28 (CH2), 111.9, 120.5, 120.6, 126.6, 128.1, 129.0, 129.2, 131.7, 133.0, 154.9, 155.6, 155.9 (Ar), 170.4, 170.6, 171.1, 174.2, 174.3 (5C, C=O); IR 3035, 2952, 2920, 1762, 1708, 1112 cm-1; Anal. Found C, 63.64; H, 5.14%, C27H26O10 requires C, 63,53; H, 5.13%.
Preparation of flavonol phosphates
3-(Dibenzyloxyphosphoryloxy)flavone
Figure imgf000037_0002
Dibenzyl diisopropylphosphoramidite (12.5 mL, 38.0 mmol) and 1H-tetrazoIe
(74.0 mL, 31.7 mmol) was added to a solution of 3-hydroxyflavone (3.00 g, 12.6 mmol) in dry dichloromethane (150 mL). The reaction mixture was stirred under N2 at room temperature for 2 h. The mixture was then cooled to -78 °C and m-CPBA (8.72 g, 50.6 mmol) was added. The mixture was allowed to return to room temperature and stirred for a further 45 min. The reaction mixture was washed with 0.25 M Na2S2O4 (3 x 100 mL). saturated NaHCO3 (3 x 100 mL) and water (2 x 100 mL). The organic extract was dried. (MgSO4), filtered and concentrated under reduced pressure to yield a crude white solid. The crude material was purified by flash chromatography (20-50% EtOAc in toluene) followed by crystallization for EtOAc/petroleum spirits to give the protected phosphate as a white fluffy solid (5.28 g, 84 %); mp = 85-88°C; 1H NMR (399.7 MHz, CDCl3); δ 5.09 - 5.17 (m, 4H, CH2Ph); 7.22 - 7.30, 7,38 - 7.47 (2 x m, 14H, Ar, H3', 4', 5',6'); 7.51 (d, J7,8 = 8.5 Hz, H8); 7.69 (ddd, J5,7 = L5 Hz, J6,7 = 7.2 Hz, J7,8 = 8.5 Hz, 1H, H7); 7.93 - 7.96 (m, 2H, H2',6'); 8.29 (dd, J5,6 = 7.5 Hz, J5,7 = 1.5 Hz, 1H, H5), 13C NMR (100.5 MHz, CDCl3); δ 78,13 (2C, CH2Ph); 119.13, 124.86, 126.23, 127.22, 128.90, 129.36, 129.48, 129.62, 130.06, -131.03, 132.29, 135.06, 157.03, 157,10 (25C, Ar); 136,89 (1C, JC,P = 8.0 Hz, C-O-phosphate); 173.87 (1C, C=O). 31P NMR (161.8 MHz, CDCl3); δ -7.45 (s, P=O). Anal. Found: C, 69.81; H, 4.60; C2S)H23OeP requires C, 69.88; H, 4.65%. HRMS (ESf) m/z 521.1126, C29H23NaO6P [M + Na]+ requires 521.1130]. 3-Hydraxyflavone-3-phosphate disodium salt
Figure imgf000038_0001
A solution of 3-(dibenzyioxyphosphoryloxy)flavone (2,05 g, 4.09 mmol) and palladium on carbon (10%, 0.25 g) in EtOH:water (4:1. 250 mL) was treated with H2 at atmospheric pressure for 3.5 h. The reaction mixture was filtered (Celite) and the filttate treated with NaOH (0.50 g in 100 mL water). The aqueous mixture was concentrated under reduced pressure then crystallized from water/acetone to yield the phosphate as pale yellow crystals (1.03 g, 87% yield). 1H NMR (499.7 MHz, D2O) δ 7.33 (dd, 1H, J5,6 - 8.0 Hz, J5,7 = 1.2 Hz, H6); 7.40 - 7.46 (m, 3H, H3', 4', 5'); 7.52 (d, 1H, J7,8 = 8.5 Hz, H8); 7.64 (ddd, 1H, J5,7 = 1.2 Hz, J6,7 = 7.5 Hz, J7,8 = 8.5 Hz, H7); 7.97 (dd, 1H, J5,6 = 8.0 Hz, J5,7 - 1.2 Hz, H5); 8.10 (in, 2H, H2', 6'). 13C NMR (100.5 MHz, D2O) 5 118.29, 122.92, 124.97, 125.06, 128.50, 129.15, 130.92, 131.33, 134.22, 155.06, 156.68 (13C, Ar); 136.11 (1C, JC, P = 6.8 Hz, C-O-P); 177.15 (1C, C=O). 31P NMR (161.8 MHz, D2O) 5 2.98 (s, P). Anal.: Found: C, 49.68; H, 2.51; C15H11Na2O6P requires C, 49.74; H, 2.50%. 4 '-(Benzyloxy)-3~{dibenzyloxyphosphoryloxy)flavone
Figure imgf000039_0001
1H-Tetrazole (483 mg, 6.89 mmol) was added to a mixture 4'-benzγloxy-3- hydroxyflavone (1.00 g, 2.72 mmol), dibenzyl N,N-dnsopropylphosphoramidite (1.5 mL, 1.6 g, 4.4 mmol) in dichloromethane (30 mL) and the reaction, was stirred at rt for 2 h. Additional dibenzyl N,N-diisopropylphosphoramidite (L0 mL, 1.1 g, 1.5 mmol) was added and the reaction stirred for a further 1 h. The reaction mixture was then cooled to -78 °C and m-CPBA (3.00 g, 12.1 mmol, 70% w/w) was added. The reaction was then warmed to rt and stirred for 45 min. The organic layer was washed with 0.25 M Na2S2O3 (x 3), sat NaHCO3 (x 3), brine (x 3), dried (MgSO.*) and concentrated. The residue was purified by flash chromatography (50% EtOAc/petrol) to give a yellow solid, which was recrystallized from EtOAc/petrol to afford the phosphate as a colourless solid (1.01 g, 58%); mp 101°C; 1H NMR (500 MHz, CDCl3) δ 5.02 (s, 2H, CH2Ph), 5.16 (s, 2H, CH2Ph), 5.17 (s, 2H, CH2Ph), 6.97 (app. d, 2H, J = 8.8 Hz, H3',5'). 7.29-7-36 (m, 15H, 3 x Ph), 7.41 (t, 1H, J5,6 = J6,7 = 8.0 Hz, H6), 7.51 (d, J7,8 = 8.5 Hz, H8), 7.68 (dd, 1H, J6,7 - 8.0, J7,8 = 8.5 Hz, H7), 7.96 (app. d, 2H, J = 8.8, H2',6'), 8.30 (dd, 1H, J7,8 = 8-5, J^8 =1.5 Hz, H8); 13C NMR (100 MHz, CDCl3) δ 69.9, 70.0 (CH2), 144.7, 117.9, 122,3, 123.7, 125-0, 126.1, 127.4, 127.8, 128.2, 128.4, 128.7, 130.7, 133.8, 135.8, 135.9, 136.1, 155.2, 155.7, 161.0 (Ar), 172.6 (1C, C=O); 31P NMR (162 MHz, CDCl3) δ -5.3 (s. P); IR 3063, 3031, 1647, 160I, 1506, 983 cm-1; Anal. Found C, 72.60; H, 5.05%, C35H29O7P requires C, 71.52; H, 4.83%. Flavone-3-phosphate dϊsodium salt
Figure imgf000039_0002
A mixture of 4'-(ben2yloxy)-3-(dibenzyloxyphosphoryloxy)flavDne (1.00 g, 1.65 mmol) and Pd(OH)2 (120 rag) in THF (10 mL) and water (15 mL) was treated with hydrogen for 3 d. The mixture was filtered (Celite) and the pad washed with THF and water, and the filtrate was concentrated- The solid residue was dissolved in THF (20 mL) and water (10 mL) and triethylamine (600 μL, 4.3 mmol) added and stirred at rt for 30 min. The mixture was concentrated and the residue was dissolved in water. Insoluble material was removed by filtration and the solution passed through an ion exchange column. The eluant was concentrated to afford a solid, which was recrystallised from acetone/water to afford the phosphate as a brown solid (226 mg, 36%); mp 182-184°C; 1H NMR (500 M-Iz, D2O) δ 7.07 (app. d, 2H, J = 8.5 Hz, H3',5'). 7.62 (t, 1H, % = J6,7 = 7.5 Hz, H6), 7.72 (d, J7ι8 = S.5 Hz, H8), 7.92 (t, 1H, J6,? = J7,s - 7.5 H7), 8.18 (d, 1H, J5,6 = 7.5 Hz, H5) 8.19 (app. d, 2H, J = 8.5, H2',6'); 13C NMR (100 MHz, D2O) δ 118.4, 122.5, 122.6, 124.9, 125.3, 131.2, 134.4, 155.0, 157.1, 157.2, 15S.5 (Ar), 176.3 (1C, C=O); 31P NMR (162 MHz, CDCl3) δ 0.60 (s, P); IR 3281, 1597, 1579, 1542, 1393, 903 cm-1; HRMS (ESI-) mix 333.0160, C15H10O7P [M + H]- requires 333.0159.
4 '-(Ben∑yloxy) -3-(trimethylammomumylpropylcarbonyloxy)flavone chloride
Figure imgf000040_0001
A mixture of carboxypropyliiiinethylaiπinonium chloride (0.5 g, 2.7 mmol) and thionyl chloride (2 mL), 3.26 g, 27 mmol) was stirred at room temperature overnight The solvent was evaporated and the residue dissolved in nitrobenzene (2 mL) and 4*- benzyloxyfl&vQnol (344 mg- 1.00 mmol) was added. The solution was stirred at room temperature for 30 min, then at 65 C for 5 h. The nitrobenzene was removed under reduced pressure (80 C water bath) and the residue was purified by filtration through a plug of silica (7:2:1 EtOAc:MeOH:H2O). The residue was washed with THF and recrystallized from ethanol/pet spirits to afford a yellow powder (30 mg); 1H NMR (399.7 MHz, CDCl3) S 2.01-2.13 (2H, m, CH2), 2.78 (2H, d, J6.8 Hz, CH2), 3.09 (9H, 5, NMe3), 3.25-3.35 (2H, m, CH2N), 5.21 (2H, m, CH2Pb), 7.24 (2HS app. d, J9.2 Hz, H2',6'), 7.33-7.49 (m, 5H, Ph), 7.54 (1H, dd, J 8.0, 8.0 Hz, H6)> 7.81 (1H, d, J7i8 8.4 Hz, H8), 7.88 (1H, d. J 8.0. 8.4 Hz, H7), 7.92 (2H, app. d, J9.2 Hz, H3',5'), 8.07 (1H, d, _/5>6 8.0 Hz, H5). 4 '- (Hydroxy) -3-(trimethylammoniumylpropylcarhonyloxγ)flavone chloride
Figure imgf000041_0001
A mixture of the flavone (30 mg) and Pd/C (5%, 5 mg) in EtOH (5 mL) was stirred under an atmosphere of hydrogen for 2 h. The mixture was filtered and the solvent evaporated to afford a yellow solid.
Vasorelaxant and Antioxidant Activity of Flavonoid Derivatives
Effect of Flavonoid Derivatives on Ca2+ -Induced Contraction
To determine the effect of flavonoids on responses to the influx of extracellular Ca2+., contractile responses to exogenous application of Ca2+ were examined in the presence of flavonoids in Ca2+-free high-K+ solution (60 mM, KPSS). Aortic rings were initially equilibrated at a resting tension of 1 g in normal Ca2+-free PSS for 45 minutes. The bath medium was then replaced with Ca2+-free KPSS for 45 minutes to determine a reference contraction to Ca2+ (3 x 1(T3 M). Following a 30 minute re- equilibration period with Ca2+-free PSS, the cumulative contractile responses to Ca2+ (10-5 - 3 x 10-3 M) were determined in KPSS in the presence of a range of concentrations (10-8 - 10-4 M) of vehicle, 3',4'-dihydroxyflavonol, 3-hydroxyflavone- 3-hemiadipate, 3',4'-dihydroxy-3-hemiadipate, 3-hydroxyflavone-3-phosphate. A 20 minute incubation period was allowed for the flavonoids before examining the responses to Ca2+-. Relaxation by Flavonoid Derivatives
Following testing of endothelial integrity, rings were repeatedly washed and re- equilibrated for 30 minutes before the addition of PE (10-s - 2 x 10-7 M) and 9,11- dideoxy-9α, 11α-epoxymethano-prostaglandin F2α. (U46619. 10-9 - 10-8 M) to produce an active force in the range of 40-60% of KPSS-induced contraction. The level of precontraction was matched between the various groups by adjusting the concentrations of PE and U46619. Cumulative concentration-response curves in the range 10-8 — 10-4 M were conducted for 3',4'-dihydroxyflavoriol, 3-hydroxyflavone-3-hemiadipate, 3',4'- dihydroxy-3-hemiadipate, 3-hydroxyflavone-3-phosphate- Experiments were conducted in the presence of an esterase, butyryl cholinesterase (BuCHE, 1000 U/L) for the hemiadipate derivates and a phosphatase (1000 U/L) in the case of the phosphate derivatives. Effects ofFlavonϋid Derivatives on Superoxide Levels in an In Vitro Assay Superoxide anion production in rat isolated aortic segments was determined using lucigenin chemiluminescence. Aortic rings were prepared as described above and theti placed in ice-cold Kxebs-(N-[2-Hydroxyetbyl]pipera2ine-N'-[2-ethanesulfonie acid] (HBPBS buffer) (composition QaM); NaCl 99.0, KCl 4.7, KH2PO4 1.0, MgSO4JH2O L2, D-glucose 11.0, NaHCO3 25.0, CaCl2.2H2O 2.5, Na-HEPES 20.0). Aortic rings were pre-incubated for 45 minutes at 37°C with a pH 7.4, in Krebs-HEPES buffer containing diethylthiocarbamic acid (DETCA, 10-3 M) to inactivate superoxide dismutase and β-nicotinamide adenine dinucleotide phosphate (NADPH, 10-4 M) as a substrate for NADPH oxidase and either 3',4'-dihydroxyflavonol (10~* M) as a positive control, vehicle, 3 -hydroxyflavone-3 -hemiadipate, 3 ',4'-dihydroxy-3 -hemiadipate, 3- hydroxyflavone-3 -phosphate (10-S — 10^ M). Background photon emission was measured for 12 cycles in a 96-well Optiplate containing 0.3 ml per well of Krebs- HEPES buffer together with hicigenin (5 x 10~5 M) and vehicle or flavonoid (10-s - 10-4 M). Each cycle was counted every one minute. After background reading was completed the incubated aortic rings were transferred to the appropriate wells and photon emission was recounted as described above. The tissue was then placed in a 65βC oven for 48 hours to allow superoxide production to be normalised to dry tissue weight.
Effects of Flavonoid Derivatives on Superoxide Levels in an In Vitro Assay in the wesence or absence of an Esterase The effects of vehicle, 3',4'-dihydroxyflavone-3-hemiadipate (21) (DiOHF3HA.
10-8 M - 10-4 M) and DiOHF (10-4 M) in the presence and absence of Butyryl cholinesterase (BuCHE), 100, 300 and 1000 U/L) on the level of superoxide anions generated in rat isolated aortic segments in the presence of NADPH was expressed as a percentage of control. The method used was as described above except for the addition of the butyryl cholinesterase.
Effects of Plavonoid Derivatives on Superoxide Levels in an In Vitro Assay in the presence or absence of a phosphatase
The effect of vehicle, 3 -hydroxy flavone-3 -phosphate (10~8 to 10-4 M) in the presence or absence of phosphatase (1000 U/L) on the level of superoxide anions generated in rat aorta in the presence of NADPH expressed as a percentage of control was determined as described above for the 3',4'-dihydro3cyflavone-3-liemiadipate. A measurable effect on the superoxide anion generation was observed using the 3-hydroxyflavone-3 -phosphate in the absence of the phosphatase. This was thought to occur due to the presence of natural phosphatases in the isolated rat tissue. In vivo study of the Effects of Flavonoid Derivatives on the vascular function of a rat
A unit dosage of an aqueous solution of 3-hydroxyflavone-3-heπύadipate (15) was administered to a group of male anesthetized Sprague Dawiey iats intravenously and the blood pressure monitored over a period of time.
A significant reduction in the blood pressure of rats was observed which is indicative of the in vivo vasorelaxation caused by the flavonoid derivative. No effect was observed when an aqueous solution was administered to a second group of rats.
The experiment was repeated with aqueous solutions of the other synthesized flavonoid derivatives which also resulted in distinct reductions in the blood pressures of the rats. Screening for Activity and Pharmacokinetics
Preparation of rat aorta
The descending thoracic aorta fiom rats was rapidly dissected and placed in Krebs-bicarbonate solution. Superficial connective tissue and fat surrounding the aorta was removed and the aorta was cut into segments of 2-3 mm length and mounted in, organ baths.
Effect of Flavonoids on ACh and SNP relaxation
After wash out and re-equilibration for 30 min, the aortic rings were then submaximally precontracted with PE and U46619, which were used to produce an active tension of 45-60% of the KPSS-induced maximum contraction. When investigating the effects of the flavonoids, flavonol, flavone-3-hemiadipate (f 3HA), 3', 4'-dihydroxyflavone, 3', 4'-dihydroxyflavonol- 3', 4--dihydroxyflavone-3-hemiadipate (DiOHF3HA), and flavone-3- phosphate (F3P) on vasorelaxant responses, rings were incubated with one of the compounds for 20 mins before they were precontracted submaximally, followed by a cumulative-concentration response curve to ACh (100 nM - 10 μM) or SNP (10 pM -1 μM). In experiments using F3P 1000U/L phosphatase was used in some experiments to cleave the phosphate- Some expeiiments were conducted in the presence and absence of butyryl cholinesterase (BuCHE, 1000U/L) to cleave the adipate in DiOHF3HA and F3HA.
Effect of Flavonols and Flavones on PE-Induced Contraction
Rings were incubated for 20 initiates with DiOHF3HA at a range of concentrations (10-7 - 10-4 M) or vehicle (0.1% dimethyl sulphoxide, DMSO). A concentration response curve to PE (10-9 -10-5 M) in endothelium-intact (EI) aortic rings was then performed. Experiments were conducted in the presence and absence of BuCHE ( 1000U/L) to cleave the adipate in DJOHF3HA.
Effect of Flavonols on Ca2+ -Induced Contraction To determine the effect of flavonoids on responses to the influx of extracellular
Ca2+, contractile responses to exogenous application of Ca2+ were examined in the . presence of flavonoids in Ca2+ - free high-K+ solution (60 mM, K+-PSS). Aortic rings were initially equilibrated at a resting tension of 1 g in Ca2+-free PSS for 45 minutes. The bath medium was then replaced with Ca2+- free K+-PSS for 45 minutes to determine a reference contraction to added Ca2+ (3 mM). Following a 30 minute re- equilibration period with. Ca2+-free PSS, the cumulative contractile responses to Ca2+ (10-5 - 3 x 10-3 M) were determined in K+ PSS in the presence of vehicle (0.1% DMSO), or a range of concentrations (10-7 - 10-4 M) of 3'-hydroxyflavonol, F3HA, DiOHF3HA or F3P. A 20 minute incubation period was allowed for the flavonoids before examining the responses to Ca2+. Experiments were conducted in the presence and absence of BuCHE (1000U/L) to cleave the adipate in F3HA and DiOHF3HA. In experiments using F3P, phosphatase (Ϊ000U/L) was used in some experiments to cleave the phosphate.
Relaxation by Flavonoids Following testing of endothelial integrity, rings were repeatedly washed and re- equilibrated for 30 minutes before the addition of PE (10-s -2 x 10-7 M) and 9,11- dideoxy-9α, 11α- epoxymethano-prostaglandin F2α (U46619, 10-9 - 10-8 M) to produce an active force in the range of 40 - 60% of KPSS-induced contraction. Cumulative concentration-response curves in the range 10-7 - 10-4 M were conducted for vehicle, 3 '-hydroxyflavonol, F3HA, DiOHF3HA, F3P. Experiments were conducted in the presence and absence of 1000U/L BuCHE to cleave the adipate in F3HA and DiOHF3HA. In experiments using F3P 1000U/L phosphatase was used in some experiments to cleave the phosphate.
Effect ofFlavonols andFlavones on Vasorelaxation to ACh in the Presence of Oxidative Stress Control cumulative relaxation responses to ACh. were compared with those obtained fiom endotheiium-intact aortic rings treated with, pyrogallol (2 x 10-5 M). The effects of vehicle (0.1% DMSO), phosphatase (1000U/L) or F3P (IQ^-I0-4 M) on responses to ACh in the rat isolated aortic rings exposed to pyrogallol (2 x 10-5 M) were also determined. Pyrogallol was added when the aortic rings had reached a stahle level of contraction with PE and U44619 at a level between 50 and 70% of KPSS- induced tension and 10 minutes was allowed before determining the cumulative concentration-response curves to ACh. In some experiments using F3P 1000UΛL phosphatase was used to cleave the phosphate.
Effect of DiOHF3HA and F3P in anesthetized rats Male Sprague-Dawley rats (250-350 g) were anaesthetised with pentobarbitone sodium (60 mg kg-1, ip). The trachea was isolated and cannulated with polyethylene tracheal tube (LD. 2.0 mm), and the rat was allowed to breathe spontaneously.
Measurements of arterial yressure and heart rate
The right carotid artery was cannulated and connected with a heparinised saline filled cannula (O,D. 0.75, LD, 0.58 mm) and connected to a pressure transducer. Mean and phasic arterial pressure were continuously measured and recorded on a polygraph. The heart rate was derived from the phasic arterial pressure using a tachometer.
Antioxidant and vascular effects of flavonol and dihydroxyflavone
Flavonol and dihydroxyflavone (DiOHFne) caused concentration dependent decreases in superoxide levels generated by rat aortic rings. At the highest concentration tested (0J mM) flavonol and DiOHFne both reduced the superoxide levels to 36±3% of control. Flavonol did not affect the relaxant effects of ACh or SNP. DiOHFne caused concentration-dependent relaxation of rat aorta which was weaker than the effect of DiOHF. Flavonol caused concentration dependent decreases in calcium-induced contraction of rat aortic rings which, were relatively weak in comparison to previous observations with DiOHF.
Antioxidant and vascular effects offlavone-3-hemiadipate CF3HA)
F3HA (10~7 M-I0-4 M) had no inhibitory effect on superoxide generation by rat aorta but the presence of butyryl choHnesterase (BuCHE, 100- 1000 U/ml) caused a concentration dependent increase in the inhibitory effect of F.3HA (Figure 6-). F3HA only inhibited contractile responses to increasing concentrations of extracellular calcium at the highest concentration tested (0.1 mM).
Antioxidant and vascular effects ofdihydroxy ilavone-3-hemiadϊpate (DiOHF3HA) . DIQHF3HA (10-7M-IC4M) had no inhibitory effect on superoxide generation by rat aorta but the presence of butyryl cholitiesterase (BuCHE, 1000 U/ml) τevealed a concentration dependent inhibitory effect. DiOHF3HA alone had no effect on relaxant responses to ACh or SNP. In contrast, in the presence of BuCHE (1000 U/ml) DiOHF3HA significantly increased the sensitivity of the relaxant response to SNP, Similarly DiOHF3HA alone had little effect on calcium-induced contraction of rat aorta, but in the presence of BuCHE (1000 U/ml) DiOHF3HA (0.1 mM) had an equivalent inhibitory effect to DiOHF. This suggests that when the adipate was removed by the esterase the hemiadipate was equally active to the parent DiOHF. DiOHF3HA was also found to cause direct relaxation of pre-contracted rat aortic rings only in the presence of the esterase (Figure 11).
DiOHF3HA (0.1, 0.3, 1, 3 mg/kg) was injected intravenously, allowing at least 30 min between injections, and the peak changes in mean arterial pressure and heart rate measured. DiOHF3HA caused dose-dependent decreases in arterial pressure (Figure 12a) and heart rate (Figure 12b), In a separate group of experiments ACh (0.3 rπg/kg iv) and phenylephrine (PE, 30 rng/kg W) were injected before and 30 minutes after DiOHF3HA (3 mg/kg iv), a time when arterial pressure and heart rate had returned to control levels. D1OHF3HA significantly enhanced the depressor response to ACh and attenuated the PE-induced increase in arterial pressure (Figure 13). In rat aortic rings DJOHF3HA (0.1 mM), in the absence or presence of cholinesterase, had no effect on endothelium-dependent relaxation in response to the calcium Ionophore A23187 or to isoprenaline. DiOHF3HA (0.1 mM) given alone had no effect on PE-induced contraction but caused marked inhibition in the presence of esterase. The level of inhibition was similar to that observed in response to the presence of the same concentration (0-1 mM) of DiOHF-
Antioxidant and vascular effects offiavone-3-phosphate (FiP) F3P or phosphatase (1000 U/l) had no effect on superoxide generation by rat aortic segments whereas F3P caused a concentration -dependent inhibition of superoxide levels in the presence of phosphatase. F3P, in the presence of phosphatase, increased the sensitivity of rat aortic rings to relaxation by ACh but not SNP, Oxidant stress, caused by the presence of pyrogallol (2x10-5 M), significantly reduced the maximum response to ACh but the response was restored by the' presence of F3 P plus phosphatase. Responses to SNP were unaffected by any of those treatments. F3P caused a small inhibition of calcium-induced contraction but the effect was significantly enhanced by the presence of phosphatase.
F3P (0-1, 0.3, 1, 3, 10 mg/kg) was injected intravenously, allowing at least 30 minutes between injections, and the peak changes in mean arterial pressure and heart rate measured (Figure 16a). DiOHF3HA caused dose-dependent decreases in arterial pressure and heart rate (Figure 12 a and 12b) but the depressor response was small compared to DiOHF (1 mg/kg iv).
Summary These $rudies involved an assessment of the vascular and antioxidant activity of flavonols, 3', 4>-dihydroxyflavcne (DiOHFne), 3', 4'-dihydroxyflavonot (DiOHF), flavøne-3- hemiadipate (F3HA), 3', 4'-dihydroxy flavone-3-hemiadIpate (D£OHF3HA) and flavone-3-phosphate.
Flavone-3-herniadipate (F3HA) alone had no antioxidant or vascular activity when applied alone but the presence of a cholinesterase to cleave the adipate substitution revealed the ability of F3HA to inhibit calcium-induced contraction.
Dihydroxy fiavone-3-hemiadipate (D1OHF3HA) had no antioxidant or vascular activity when applied alone but the presence of a cholinesterase to cleave the adipate substitution revealed the ability of DIOHF3HA to inhibit superoxide levels produced by ' rat aorta, to inhibit calcium-induced contraction and to cause direct relaxation of rat aortic rings. In the presence of the esterase the level of activity of D1OHF3HA was similar to DiOI-IF. In the anaesthetized rat DiOHF3HA caused concentration dependent decreases in arterial pressure and heart rate.
Flavone-3-phosphate (F3P) alone had no antioxidant or vascular activity but the presence of a phosphatase to cleave the phosphate substitution revealed the ability of F3P to inhibit superoxide levels produced by rat aorta, to inhibit calcium-induced contraction and to enhance endothelium-dependent relaxation in the presence of oxidant stress. In the presence of the phosphatase the level of activity of F3P was similar to DiOHF. In the anaesthetized rat F3P caused only small concentration dependent decreases in arterial pressure and heart rate. The effects were much smaller than seen with DiOHF.
Cardioprotective of 3',4'-dihydroxy flavonol adipate (0iOHF3HA) following myocardial ischacmia rcperfusioπ
The ability of the synthetic flavonol, 3 ',4' dihydroxy flavonol adipate (DiOHF3HA) to prevent myocardial ischaemia and reperfusion injury in anaesthetised sheep was assessed. Unlike the parent compound DiOHF, the adipate derivative was soluble in. aqueous solution, particularly water.
DiOHF3HA administered in aqueous solution caused a dose-related reduction in infarct size, which was similar to that caused by a similar molar dose of DiOHF when dissolved an DMSO. Intravenous DiOHFSHA infusion did not alter haemodynamic indices (arterial blood pressure, heart rate, left ventricular-end diastolic pressure (LV-EDP).
Since DiOHF3HA caused an equivalent degree of cardioprotection to the parent compound following cardiac ischaemia-ieperfusion injury in anaesthetised sheep, these data support the hypothesis that this novel derivative compoimd is effectively converted to the parent compound in vivo. Surgical Preparation
Five groups of anaesthetised adult merino sheep (35-45 kg wethers) were examined:
(1) Control (n=5) (2) DiOHF (2 mg/kg, n=2)
(3) DiOHF3HA (2.7 rag/kg, n=3)
(4) DiOHF (5 mg/kg, n=3)
(5) DJOHF3HA (6.6 rog/kg, n=4).
Anaesthesia was induced by intravenous thiopentone sodium (15 mg/kg) and following tracheal intubation was maintained by isoflurane (1.5-2%). A catheter was • inserted in the right facial artery for arterial blood sampling and monitoring arterial pressure. Intravenous infusions were made via a catheter insetted into the jugular vein. The heart was exposed through a left thoracotomy performed at the fourth intercostal space. A 4F catheter-tipped manometer was inserted through the left atrium into the left ventricle to measure left ventricular pressure (LVP). An additional silastic cannula was inserted into the left atrial appendage for the injection of lignocaine and for infusion of Evans Blue. The left anterior descending coronary artery (LAD) was dissected from, the epicardixiTH immediately distal to its second diagonal branch, and a transit-time 2 mm flow probe was placed around it to monitor the LAD blood flow. A silk suture was passed under the LAD proximal to the probe and both ends of the silk were threaded through a plastic tube to form a vascular snare. Exyerimental Design
The animals were allowed to stabilise for 10-15 minutes after the completion of the surgical procedure. Sheep were then randomly divided into different treatment groups. All sheep had 30 minute baseline recording followed by 1 hour ischaemia and 3 hours reperfusion,
During the course of the experiment, hemodynamic measurements were recorded at 5 minute intervals and blood samples were taken at designated time-points. After 30 minutes of ischaemia, flavonol treatment was administered. DiOHF was dissolved in 2 ml DMSO plus 14 ml polyethylene glycobwater (1:1). DiOHF3HA was dissolved in 20 ml 0.1 M Na2Cθ3- The drugs were given at 1 rrύVmin i.v.. The two doses of DiOHF3HA (2.7 mg/kg and 6.6 mg/kg) were chosen to achieve equivalent molar do$es to the parent DiOHF compound (at 2 mg/kg and 5 mg/kg, respectively). Control animals did not receive any intravenous solutions. Lignocaine was used, as required, to ameliorate arrhythmias.
Determination of the area at risk and infarct size
The area of myocardium at risk and infarct size were delineated by Evan's blue and triphenyltetraβolium chloride (TTC) staining. After 3 hours of reperfusion, the LAD was re-occluded at the original occlusion site. Immediately after intravenous injection of pentobarbitone (100 mg kg-1) to arrest the heart, Evan's blue dye (1.5%, 40 ml) was injected into the left atrium to define the myocardium at risk. The heart was rapidly xemoved and the left ventricle was sliced into transverse sections about 1 cm thick. The unstained risk area was traced onto the same transparencies. The sections were then incubated in 0.1 M sodiuro phosphate buffer containing 1% TTC for 20 min (37"C, pH 7.4). The infarcted area was traced onto transparencies. The area of myocardium, at risk, and infarct size, were measured by computerised planimetry. The former was expressed as a percentage of total left ventricular volume (AR/LV%) and infarct size was expressed as a percentage of the area of myocardium at risk (IS/AR%). Plasma markers for myocardial infarction Arterial blood samples (5 ml) were collected into chilled heparinised tubes at baseline, during ischaemia and at three time points during the reperfusion period (1 hour, 2 hour and 3 hour). Following centrifugation at 4°C, plasma samples were stored at -20°C until measurement to determine levels of lactate dehydrogenase and creatinine kinase. Results
In the following summary of results, myocardial infarct size in the 5 different treatment groups is reported. Given the effectiveness of the highest dose of DiOHF3HA, changes in all other parameters are only reported with respect to the Control group of animals versus the DiOHF3HA (6.6 mg/kg) group of animals. In the Control group, one of the sheep died due to ventricular fibrillation in the first 10 minutes of reperfusion. Thus, control data are based on n=4 sheep.
Myocardial infarct size
In this study, the area of left ventricle subjected to ischaemia (AR) among the 5 different treatment groups of sheep was similar, (11%-20%, Figure 17, left panel), in contrast, the infarct size, normalised to the AR, was smaller in the DiOHF and DiOHF3HA treated groups compared to control animals (Figure 17, right panel). Specifically, the infarct size normalized to the area at risk (IS/AR) was reduced from 83±4% in controls to 49±8% by DiOHF3HA (6.7 mg/kg) and to 47±8% by DiOHF (5 mg/kg). With the lower doses of DiOHF3HA (2.7 mg/kg) and DiOHF (2 mg/kg) IS/AR was 64% and 73%, respectively. LAD flow
Baseline LAD flow was similar in the Control and DIOHF3HA (6.6 mg/kg) groups of sheep (7-9 ml/min). During ischaemia, LAD flow fell to zero in all animals. During the early stage of reperfusion, coronary hyperperfusioα occurred in all sheep. Generally, this transient increase in LAD flow returned to baseline levels after 30-60 mins of reperfusion. The regression of flow appeared to be more rapid in the DiOHF3HA group. Haemodynamic response to ischaemia/reperfusion
Baseline arterial pressure was not different between the two groups of sheep (average over 30 mins, ~80 mmHg). In contrast, resting HR was lower (P<0.05) in the control sheep (90±4 bpm) compared to the DiOHF3HA -treated sheep (105±3 bpm). This difference remained throughout the course of the experiment Both MAP and HR were unchanged during the 20-min infusion period of DiOHF3HA administration. Moreover, no marked change in arterial pressure or HR was observed in either group of sheep during myocardial ischaemia and reperfusion.
Resting LV-EDP was not different between the two groups of sheep (-11 mmHg) but the maximal positive value of the first derivative of LVP (dP/dtmax) was lower (P<0.05) in the control sheep (1454±62 mmHg/s) compared to DiOHF3HA- treated sheep (1967±103 mmHg/s). This difference remained throughout the course of the experiment. Both LV-EDP and dP/dtmax were unchanged during the 20-min infusion period of DiOHF3HA administration. Moreover, no marked change in LV-EDP and dP/dtmax was observed in either group of sheep during myocardial ischaemia reperfusion. Haemodynamic benefits of the drug showed up more clearly after 24 hours of reperfusion.
In anaesthetized sheep, following 1 hour isohaemia and 3 hours reperfusion, plasma lactate dehydrogenase increased by 227 ± 141 U/L in the control group (n=3) and by 67 ± 32 U/L in the group treated with DiOHF3HA (n=4). In these sheep plasma creatine kinase increased by 2411 ± 958 U/L in the control group and by 1579 ± 936 U/L in the group treated with DiOHF3HA.
Recovery from ischaemic stroke in rats using synthetic flavonoids
Plasma markers for myocardial infarction Ischaemic stroke was studied in conscious rats, with daily monitoring of neurological function and post mortem morphological assessment of cerebral infarcts at 72 hours after stroke. Unilateral, transient cerebral ischaemia and reperfusion was induced in conscious rats by injection of the potent vasoconstrictor endothelin-1 outside but close to the right middle cerebral artery MCA, (via a pre-implanted guide tube). The ensuing stroke was graded on a scale of 0 to 5 by immediate behaviour, and potential neuroprotective compounds were injected intravenously 3 h after the stroke, and at 24 hour intervals thereafter. Surgical Preparation
Male Hooded Wistar rats (280-340 g) were anaesthetised with pentobarbitone sodium in a volume of 0.6 ml (60 mg/kg i.p.) for insertion of an intravenous (i.v.) catheter into the jugular vein for acute drug administration, A 23-gauge stainless steel guide cannula was then stereotaxically implanted into the piriform cortex 2 mm dorsal to the right MCA (0-2 mm anterior, -5.2 mm lateral and -5.9 mm ventral). The cannula was secured with dental acrylate cement and two small screws inserted into the skull.
The scalp was closed with sutures. Rats were housed individually on a 12h daytaight cycle at a temperature of 18-22°C and allowed to recover for 5 days before induction of stroke.
Stroke Induction
Vaso constriction of the right middle cerebral artery (MCA) was induced in conscious rats by administration of the potent vasoconstrictor agent endothelin-1 (ET- 1) (60 pmol in 3 μl of saline over 10 min) via a 30-gauge injector that protruded 2mm beyond the end of the previously implanted stereotaxic guide cannula. The injector was held in place by a poly-tubing cuff and the rat was placed in a clear Plexiglass box for observation during ET-1 injection. During stroke induction we observed counterclockwise circling, clenching and dragging of the contralateral forepaw, validating the correct placement of the cannula. These behavioural changes occurred within 2 to 10 minutes of the commencement of the ET-1 injection and similar behaviours have been reported by other researchers employing this model. We have assigned a rating scale of stroke severity based on these behavioural changes during stroke and have shown that vehicle-treated rats assigned with higher stroke ratings have greater infarct volumes and neurological deficits. Rats that did not display any behavioural change were deemed not have had a stroke arid were excluded from the study. Sham-injected rats underwent cannula implantation but did not receive any ET-1 injection. Rectal temperatures were taken with a thermistor probe, prior to stroke and at 30- or 60-minute intervals for 3 hours after stroke. Assessment of Functional Outcome All behavioural tests were conducted prior to any procedures (pre-surgery. day
1), immediately prior to ET-1-ind.uced MCA occlusion (pre-ischemia, day 6) and 24, 48 and 72 hours after ET-1-iiiduced MCA occlusion. The behaviour of each rat was compared to pre-stroke, thus each rat acted as its own control. All rats were coded so that the investigator was blinded to treatment condition. Neurological abnormalities were evaluated with the use of a neurological deficit score based on detection of abnormal posture and hemiplegia. Abnormal postures were assessed by suspending rats by the tail and scoring twisting of the thorax and extension of the forelimbs. Hemiplegia was evaluated when rats were placed on a raised platform. Deficits were deemed to be present when the hind limb contralateral to the infarcted hemisphere slipped off the edge of the platform and/or when the contralateral forelimb slipped off when the snout and whiskers were not in contact with the surface. All behaviours were scored on the following scale: 0 = no deficit; 1 = slight; 2 = moderate; and 3 = severe. Thus, when scores were totalled the maximum neurological deficit score was 12. A score of 0 was considered normal. Sensory hemi-neglect was evaluated using a test consisting of placing adhesive tapes (Avery adhesive label, 100 mm diameter circles) on the distal-radial region of each wrist. Placement of the first tape was randomised between contralateral and ipsilateral limbs. The tape on both forepaws was touched simultaneously prior to placing the animal in a plexiglass cage and measuring with a stopwatch, both the latency to touch and the latency to remove each stimulus from the contralateral and ipsilateral forepaws were recorded. The test was terminated at 180 seconds if tapes had not already been removed. Drug treatment All compounds were given intravenously as a single bolus dose 3 hours post- stroke at a concentration which yielded 37 μmol/kg. Vehicle controls were also used and were specific for each compound. After the first dose 3 hours post-stroke, the animals were injected once daily with either drug, or vehicle at 24 and 48 h. The total injection volume for each compound was approximately 300 μl for a 300 g rat, with a 200 μl straight saline flush to ensure full drug administration. Quantification of Ischemic Damage
Rats were decapitated 72h after ischemia and their brains were removed and frozen in liquid nitrogen, and stored at -80°C. Coronal cryostat sections (16 μm) were cut at eight pre-determined coronal planes throughout the brain from -3.2 to 6.8 mm relative to Bregma. Infarct was measured in triplicate unstained sections based on the observation that damaged areas in unstained slide-mounted brain sections are visible to the naked eye as clearly defined frosted or dark areas, while normal tissue is essentially translucent. By applying the principle of ballistic light propagation and using a simple apparatus combined with a computerised image analysis system, the unstained slide mounted section showing damaged areas was clearly visible on the monitor. Light passes directly through the transparent, undamaged tissue to the camera, whereas light rays are diffracted by the damaged tissue. The areas of damage can then easily be outlined, selected and recorded using the image analysis system. Total infarct volume was calculated by integrating the cross-sectional area of damage at each stereotaxic level with the distances between levels. The influence of edema on the infarct area was conrected by applying the following formula.* (area of normal hemisphere/area of infarcted hemisphere) x area of infarct. Slides were also coded so that the investigator was blinded to treatment condition. Stroke Rating
Rats showed neurological behavioural deficits indicative of stroke within 2-10 minutes of ET- 1 injection but not after an equal volume of saline alone. These deficits included specific behavioural responses such as clenching and failure to extend the contralateral forepaw, and circling in the direction contralateral to the occlusion. Grooming behaviour preceded circling and was observed in almost all rats. Grooming occurred in a stereotypical manner with facial grooming being followed by -Roll body grooming in one continuous movement. Other behaviours such as teeth chattering, biting of the cage and bedding or tongue poking, were observed less frequently. These behavioural responses observed at the time of stroke could be ranked based on their degree and severity. We have also shown that there is a positive correlation between stroke rating and neurological deficit score and stroke rating and infarct volume, in vehicle treated rats (n=40). Following ranking, stroke rats were paired based on equal stroke rating so that stroke ratings were evenly distributed between vehicle and Drug treatment groups. These rats were then coded so that the remaining assessments could be performed blind to treatment. Stratifying Drιi£ treatment Prognostic models are used to predict functional outcome and survivability in human stroke patients in order to support clinical management of stroke patients and to correctly stratify treatment groups hi clinical trials. The use of similar models in experimental stroke animals has not previously been attempted. In the ET-1 model of MCA occlusion it is possible to observe behavioural responses during stroke induction and assign a rating scale of stroke severity based on these responses. Therefore it is possible to predict which animals will have severe strokes and which animals will have mild to moderate strokes. This process also allows for some predication of the area of risk, which is potentially salvageable by neuroprotective agents after stroke. Severe strokes leave little area of risk for neuroprotection given that the infarct occupies greater the 70% of total hemisphere volume. Mild to moderate strokes however reveal a greater area of risk for salvage, and therefore present a greater opportunity for neuroprotection. Indeed clinical MRI studies in patients are now being used to stratify patients in a similar manner in order to determine who is more likely to benefit from foture drug treatment. For this reason we removed animals that had severe stroke ratings of 4 or 5 at the end of drug treatment analysis, and re-analysed data in mild to moderate stroke groups (ratings 1-3) for all future compounds tested. 3',4'-Dihydroxyflavonol (DiOHF)
Initial experiments conducted in our laboratory assessed the delayed neuroprotective potential of DiOHF (10 mg/kg) given intravenously 3 hours post-stroke onset. Each rat received 3 bolus doses of DiOHF dissolved in 20% DMSO, 40% Polyethylglycol and 40% sterile water for injection. 3',4'-Dihydroxyflavonol (DiOHF) administration in rats with modest strokes (scores 2-3, n=6 and 5, compound and vehicle, respectively) reduced the neurological deficits at 48 and 72h, and abolished the increase in hemineglect scores ("sticky tape test") after stroke, that were observed in the control rats given endothelin plus drug vehicle alone. Importantly, DiOHF reduced the volume of infarct produced in the cerebral cortex, and completely prevented an infarct developing in the striatum of the brain.
DiOHF (10 mg/kg) treatment in mild to moderate stroke rats significantly reduced the area of infarct throughout the cortex and the striatum compared with vehicle treatment. DiOHF treatment also significantly improved neurological outcome in mild to moderate stroke rats, in comparison to vehicle treated rats. 3'.4'-Dihydroxyflavone-3-hemiadipate (DiOHF3HA) for treatment of Stroke
Each rat received 3 bolus doses of DiOHF3HA (15mg/kg/day i.v.) dissolved in a Na2CO3 buffered saline (0.1M, pH 7.8) for injection.
Figure imgf000055_0001
Following stroke, there was no significant weight loss in either treatment group. Core temperature prior to stroke in both treatment groups was within normal physiological limits. Following stroke there was a significant increase in temperature at
30 minutes in both treatment groups, however temperature returned to within normal levels after this time. Following intravenous injection of vehicle or DiOHF3HA, temperature appeared to increase in both treatment groups but this was not significantly different from pre-stroke temperature. Following stroke rats in both treatment groups exhibited significantly higher neurological deficit scores 24, 48 and 72 hours post-stroke when compared to pre- stroke scores. Treatment with DiOHF3HA (15 mg/kg/day) measurably improved neurological deficit scores at 24, 48 or 72 hours post-stroke when compared with vehicle treated rats. Vehicle treated rats showed increased latency to remove sticky labels from the stroke affected contralateral forepaw when compared with the ipsilateral side (P<0.05, two-way RM-ANOVA with 2-factor repetition, hours after stroke and side). This effect was abolished after treatment with DiOHF3HA (15 mg/kg/day). Infarct area through the cortex was significantly reduced following treatment with DiOHF3HA (15 mg/kg i.v.) when compared with vehicle.
In summary, DiOHF3HA (15mg/kg) treatment significantly improved neurological function in the hemineglect test, and also reduced the area of damage in the striatum following stroke compared with vehicle treatment. Effect of DiOHF3HA in mild to moderate strokes
A selected group of rats were studied with mild to moderate strokes.
Figure imgf000056_0001
Rats did not lose weight following mild to moderate stroke in either treatment group. Core temperature prior to stroke in both treatment groups was within normal physiological limits. Following mild to moderate stroke there was a significant increase in temperature at 30 minutes in both treatment groups, but temperature returned to within normal levels after this time. following mild to moderate strokes, rats in both treatment groups exhibited significantly higher neurological deficit scores pre-stroke and 24, 48 and 72h post- stroke when compared to pre-surgery scores. Treatment with DiOHF3HA (15 mg/kg/day) had no effect on neurological deficit scores when compared with vehicle treated rats. Vehicle treated rats with mild to moderate strokes showed an increased latency to touch sticky labels from the stroke affected contralateral forepaw when compared with the ipsilateral side, at 24 and 48 hours (P<0.05, two-way RM-ANOVA with 2-factor repetition, h after stroke and side). Vehicle treated rats also showed an increased latency to remove sticky labels at 24 hr (P<0.05, two-way RM-ANOVA with 2-factor repetition, hours after stroke and side). These effects were abolished following treatment with DiOHF3HA (15 mg/kg/day) (Figure 18). Infarct area in mild to moderate stroke rats through the cortex was significantly reduced following treatment with DiOHF3HA (15 mg/kg i.v. per day) when compared with vehicle (Figure 19). DiOHF3HA treatment also significantly reduced the area of infarct through the striatum, In summary, DiOHF3HA (15 mg/kg) treatment in mild to moderate stroke rate significantly reduced the area of infarct through the cortex and the striatum compared with -vehicle treatment DiOHF3HA treatment also significantly restored neurological function in the hemineglect test
Unless otherwise indicated, all values in graphs are means with s.e. mean shown by vertical lines.
Any discussion of documents, acts, materials, devices, articles or the like which has been included in the present specification is solely for the purpose of providing a context for the present invention. It is not to be taken as an admission that any or all of these matters form part of the prior art base or were comnron general knowledge in. the field Televant to the present invention as it existed before the priority date of each claim of this application.
Throughout this specification the word "comprise", or variations such as
"comprises" or '"comprising", will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.
It will be appreciated by persons skilled in the art that numerous variations and/or modifications may be made to the invention as shown in the specific embodiments without departing from the spirit or scope of the invention as broadly described. The present embodiments are, therefore, to be considered in all respects as illustrative and not restrictive.

Claims

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:- 1. A pharmaceutically and/or veterinary composition comprising a pharmaceutically and/or veterinarily acceptable carrier or diluent together with at least one compound of the general Formula 1:
Figure imgf000058_0002
wherein:
= denotes a single or double bond; and
R1, R2, R3, R4- R5 are independently selected from H, OH or a group according to Formula (Ia):
Figure imgf000058_0001
in which
O is oxygen;
L is a linker group which is covalently linked to the oxygen and D, if present, or is covalently linked to the oxygen and E, or is absent; D is a spacer group having a chain length equivalent to about 1 to 20 carbon atoms, or is absent; and E is a solubilizing group; provided that at least one of R1, R2, R3, R4, R5 is other than H or OH.
2. The composition according to claim I, wherein E is selected from an ester, a carboxylic acid, sulfonic acid, phosphonic acid, phosphate ester, sulfamate, sulfonic ester, phosphamate, phosphonate ester, sulphonate, zwitterionic species, amino acid, amino phosphonate, acyclic amine, cyclic amine, quaternary ammonium cation, polyethylene glycol, oligosaccharide or dendrimer.
3. The composition according to claim 1 or claim 2. wherein E is a selected from an ester, carboxylic acid, sulfonic acid, phosphonic acid, phosphate esteτ, polyethylene glycol, oligosaccharide or dendrimer.
4. The composition according to any one of the preceding claims, wherein E is selected from an ester, carboxylic acid or phosphate ester.
5. The composition according to any one of the preceding claims, wherein E is group according to Formula (Ib):
Figure imgf000059_0002
wherein
W is O, NH, S, O-, NH- or S-; and
X is H, a mono- or divalent cationic salt, or an ammonium cationic salt
6. The composition according to claim 5, wherein W is O.
7. The composition according to claim 5 or claim 6, wherein X is H.
8. The composition according to any one of claims 1 to 4, wherein E is an ester according to the Formula (Ic):
Figure imgf000059_0001
wherein
Q is a substituted or unsubstituted alkylene, alkenylene, alkynylene, optionally interrupted by one or more heteroatom(s);
W is O,NH, S, O; NH-, or S-; and
X is H, substituted or unsubstituted alkyl, alkylbenzyl, a mono- or divalent cationic salt, or an ammonium cationic salt.
9. The composition according to claim 8, wherein Q is substituted or unsubstituted lower alkylene.
10. The composition according to claim 8 or claim 9 wherein W is O.
11. The composition according to any one of claims 1 to 4, wherein E is a phosphate ester according to the Formula (Id):
Figure imgf000060_0001
wherein.
Y is O, NH, S, O',NH', or S-; Z is O or S; and R6 and R7 are independently selected from H, substituted or unsubstituted alkyl, a mono- or divalent cationic salt, or an ammonium cationic salt.
12. The compound according to claim 11, wherein Y and Z are O.
13. The compound according to any one of the preceding claims, wherein at least one of R1, R2, R3, R4 and R5 is phosphate ester according to the Formula (Ie):
Figure imgf000060_0002
wherein R6 and R7 are independently selected from H, a substituted or unsubstituted alkyl, a mono- or divalent cationic salt, or an ammonium cationic salt.
14. The composition according to any one of the preceding claims, wherein L is present and selected from -CO-, ester, phenol, phosphonate ester, carbamate, carbonate or a Mannich base.
15. The composition according to any one of the preceding claims, wherein L is -CO-.
16. The composition, according to any one of the preceding claims, wherein D present and selected from substituted or unsubstituted alkylene, alkenylene, alkynylene, optionally interrupted by one or more heteroatom(s), aryl, heteroaryl, cycloatkyl or heterocycloalkyl.
17. The composition according to claim 16, wherein D is a substituted or unsubstituted alkylene, optionally interrupted by one or more heteroatom(s).
18. A pharmaceutically and/or veterinary composition comprising a pharmaceutically and/or veterinarily acceptable carrier or diluent together with at least one compound of the general Formula II:
Figure imgf000061_0001
wherein
= denotes a single or double bond; and
R1, R2 and R3 are as defined in any one of the preceding claims.
19. A pharmaceutically and/or veterinary composition comprising a pharmaceutically and/or veterinarily acceptable carrier or diluent together with at least one compound of the general Formula III:
Figure imgf000061_0002
wherein R3 is defined as in any one of the preceding claims.
20. A pharmaceutically and/or veterinary composition comprising a pharmaceutically and/or veterinarily acceptable carrier or diluent together with at least one compound of the general Formula IV:
Figure imgf000061_0003
wherein Q is substituted or unsubstituted alkylene, optionally interrupted by one or more heteroatom(s) X is H, a mono- or divalent cationic salt, or an ammonium cationic salt
21. The composition of claim 20, wherein Q is substituted or unsubstituted lower alkylene, optionally interrupted by one or more heteroatom(s).
22. A pharmaceutically and/or veterinary composition comprising a pharmaceutically and/or vcterinarily acceptable carrier or diluent together with at least one compound selected from the group comprising 3-
(Benzyloxycarbonylbutylcarbonyloxy)flavone; 3-Hydroxyflavone 3- hemiadipate; 4' -(Benzyloxy)-3-(benzyloxycarbonylbutylcarbonyloxy)flavone; 4'-Hydroxyflavone 3-hemiadipate; 3'-4'-Dibenzyloxy-3- (benzyloxycarbonylbutylcarbonyloxy)flavone; 3'-4'-Dihydroxyflavone 3- hemiadipate;3 ,4'-Di-(benzyloxycarbonylb-utylcarbonyloxy)flavone; flavone
3,4'-his(hemiadipate); 3,7-Di-(benzyloxycarbonylbutylcarbon.yloxy)flavone; 3- (Dibenzyloxyphosphoryloxy)flavone; 3-7-Dihydroxyflavone 3,7- bis(hemiadipate); 4'-Hydroxy-3-Hydroxyflavone-3-quaternary ammounium ester; Flavone-3-phosphate disodium salt; 4'-(Benzyloxy)-3- (dibenzyloxyphosphoryloxy)flavone or 3-HydroxyfIavone-3-phosphate disodium salt.
23. A method of preventing and/or treating a disease(s) in a subject associated with the presence of reactive oxidative species (ROS), the method comprising: administering an effective amount of at least one compound specified in any one of the preceding claims.
24. The method according to claim 23, wherein the subject in need of such treatment is at risk of developing ischaemia.
25. The method according to claim 23, wherein the subject is suffering ischaemia and/or reperfusion injury as a result of an acute or chronic condition.
26. The method according to claim 25, wherein the chronic condition is selected from cancer, cerebrovascular disease, pulmonary vascular disease, atherosclerosis, artery disease, congestive heart disease, coronary disease, peripheral vascular disease, diabetes, hypertension, migraine, burns, chronic obstructive pulmonary disease and retinal vascular disease.
27. The method according to claim 25, wherein the acute condition is selected from stroke, myocardial infarction, mechanical trauma resulting from crush injury or surgery.
28. The method according to claim 27, wherein the surgery is vascular surgery.
29. The method according to claim 27, wherein the vascular surgery is heart bypass and/or transplant surgery.
30. The method according to any one of claims 27 to 29, wherein the compound is administered to the subject before and/or during the surgery.
31. A method of preventing, delaying the onset of and/or slowing the progression of atherosclerosis and/or coronary heart disease in a subject comprising administering an effective amount of at least one compound specified in any one of the preceding claims.
32. A therapeutic and/or prophylactic method of preventing and/or treating a disease(s) in a subject associated with the presence of reactive oxidative species (ROS), the method comprising: adrniήistering an effective amount of at least one compound specified in any one of claims 1 to 22.
33. A method of preventing and/or at least ameliorating the damage to a subj ect caused by ischaemia and/or reperfusion injury, the method comprising administering an effective amount of at least one compound specified in any one of claims 1 to 22.
34. A method of preventing and/or at least ameliorating damage to a subject caused by the administration of a therapeutic agent, the method comprising coadministering to a subject; i) a therapeutic agent; and ii) administering an effective amount of at least one compound specified in any one of claims 1 to 22,
35. The method according to claim 34, wherein the therapeutic agent is an oxidative therapeutic agent.
36. The method according to claim.34, wherein, the therapeutic agent is an anti- cancer agent.
37. The method according to claim 36, wherein the anticancer agent is anthracycline and homologies thereof.
38. The method of any one of claims 23 to 37, wherein tine compound is administered orally, topically, subcutaneous, parenterally, intramuscular, intra- arterial and/or intravenously.
39. The use of a compound as specified in any one of claims 1 to 22 for the preparation of a medicament.
40. A compound of the general Formula I:
Figure imgf000064_0001
wherein;
= denotes a single or double bond; and
R1, R2, R3, R4, R5 are independently selected from H, OH or a group according to Formula (Ia):
wherein:
Figure imgf000064_0002
O is oxygen; L is a linker group which is covalently linked to the oxygen and D, if present, or is covalently linked to the oxygen and E, or is absent;
D is a spacer group having a chain length equivalent to about 1 to 20 carbon atoms, or is absent; and E is a solubilizing group; provided that at least one of R1, R2, R3, R4, R5 is other than H or OH, with the proviso that the compound is not flavone, 3 -hydroxy-, acetate; Flavone, 4'-hydroxy-, acetate; Flavone, 3-hydroxy-, acetate; (±)-41- Acetoxyflavanone; Flavanone, 3,4',7-trihydroxy-; 3-acetate; 4H-1-Benzopyran- ,4-one, 3,7-bis(acetyloxy)-2,3-dihydro-2-phenyl-, (2R-trαns)-; 4H-1 - Benzopyran-4-one, 7-(acetyloxy)-2-[4-(acetyloxy)phenyl]-2,3-dihydro-, (±); (+)-4',7-Diacetoxyflavanone; (2S,3S)3,7-Dihydroxyflavanone diacetate; Flavanone, 3,4'-dihydroxy-, diacetate; Flavanone, 3',4'-dihydroxy-, diacetate; Flavanone, 3,7-di hydroxy-, diacetate; 4H-1-Benzopyran-4-one, 3,7- bis(acetyloxy)-2-(3,4-dihydroxyphenyl)-2,3-dihydro-, (2R-trans)-; Flavone, 3,3' - dihydroxy-, diacetate; Flavone, 4',7-dihydroxy-, diacetate; Flavone, 3,7- dihydroxy-, diacetate; Flavone, 3,3',7-trihydroxy-, triacetates; Flavone, 3,3',4'- trihydroxy-, triacetate; 4H-1-Benzopyran-4-one, 7-(acetyloxy)-2-[3,4- bis(acetyloxy)phenyl]-; Flavone, 3 ,4', 7-trihydroxy-, triacetate; Flavanone, 3',4'7, -trihydroxy-, triacetate; 4H-1-Benzopyran-4-one, 7-(acetyloxy)2-[3,4- bis(acetyloxy)phenyl]-2,3-dihydro-, (S)-; Flavanone, 3,4',7-trihydroxy-, triacetate; Flavanone, 3,4',7-trihydroxy , triacetate, trans-(t)-; 4H-1-Benzopyran- 4-one, 3,7-bis(acetyloxy)-2-[3,4-bis(acety]oxy)phenyl]-; Fustin, tetraacetate; 4H-1-Benzopyran-4-one, 3,7-bis(acetyloxy)-2-[3,4-bis(acetyloxy)phenyl]-2,3- dihydro-, (2R-trαns)-; 4H-1-Benzopyran-4-one, 3,7-bis(acetyloxy)-2-[3,4- bis(acetyloxy)phenyl]-2,3-dihydro-, trans-; Flavanone, 3,3',4',7-tetrahydroxy-, tetraacetate; 4H-1-Benzopyran-4-one, 3-(l-oxopropoxy)-2-phenyl-; Propanoic acid, 2-methyl-, 4-oxo-2-phenyl-4H-1-benzopyran-3-yl ester; Propanoic acid, 2,2-dimethyl-, 4-oxo-2-phenyl-4H-1-benzopyran-3-yl ester; Benzeneacetic acid, 4-oxo-2-phenyl-4H-1-benzopyran-3-yl ester; Benzenepropanoic acid, 4-oxo-2- phenyl-4H-1-benzopyran -3-yl ester; Benzeneacetic acid, a-phenyl-, 4-oxo-2- phenyl-4H-1-benzopyran -3 yl ester; Phosphorothioic acid, o-[4-[3- [(dicthoxyphosphinothioyl)oxy]-4-oxo-4H-1--benzopyran-2-yl]phenyl] o,o- diethyl ester; Phosphorothioic acid, o-[3-[3-[(diethoxyphosphinothioyl)oxy]-4- oxo-4H-1-benzopyran-2-yl]phenyl] o,o -diethyl ester; Phosphoric acid, diethyl 4-
(4-oxo-4H-1-benzopyran-2-yl)phenyI ester; 4H-1-Benzopyran -4-one , 2-phenyl- 3-(phosphonooxy)-; Flavone, 3 -hydroxy-, dihydrogen phosphate diammonium salt; 4H-1-Benzopyran-4-crae, 2-phenyl-3-(phosphonooxy)-, magnesium salt (1:1), pentahydrate; 4H-1-Benzopyran-4-one, 2-[3-hydroxy-4- (phosphonooxy)phenyl]-; 3',4'-dihydroxyflavone-4'-phosphate; 3 ',4'- dihydroxyflavone-4'-β-D-glucopyranoside sodium salt; 3', 4'-dihydroxyflavone-
4'-β-D-ribofluranoside sodium salt; and pharmaceutically and/or veterinaxily acceptable salts or solvates thereof.
41. The compound according to claim 40, wherein E is selected from an ester, a carboxylic acid, sulfonic acid, phosphonic acid, phosphate ester, sulfamate, sulfonic ester, phosphamate, phosphonate ester, sulphonate, zwitterionic species, amino acid, amino phosphonate, acyclic amine, cyclic amine, quaternary ammonium cation, polyethylene glycol, oligosaccharide or dendrimer.
42. The compound according to claim 40 or claim 41, wherein E is a selected from an ester, carboxylic acid, sulfonic acid, phosphonic acid, phosphate ester, polyethylene glycol, oligosaccharide or denάrimer.
43. The compound according to any one of claims 40 to 42, wherein E is selected from an ester, carboxylic acid or phosphate ester.
44. The compound according to any one of claims 40 to 43, wherein E is group according to Formula (Ib):
Figure imgf000066_0001
wherein
W is O, NH, S, O-, NH- or S-; and
X is H, a mono- or divalent cationic salt, or an ammonium cationic salt
45. The compound according to claim 44, wherein W is O .
46. The compound according to claim 44 or claim 45, wherein X is H.
47. The compound according to any one of claims 40 to 44, wherein E is an ester according to the Formula (Ic) :
Figure imgf000067_0001
wherein
Q is a substituted or unsubstituted alkylene, alkenylene, alkynylene, optionally interrupted by one or more heteroatom(s); W is O, NH, S, O-, NH-, or S-; and
X is H, substituted or unsubstituted alkyl, alkylbenzyl, a mono- or divalent cationic salt, or an. ammonium cationic salt.
48. The compound according to claim 47, wherein Q is substituted or unsubstituted lower alkylene.
49. The compound according to claim 47 or claim 48 wherein W is O.
50. The compound according to any one of claims 39 to 44, wherein E is a phosphate ester according to the Formula (Id):
Figure imgf000067_0002
wherein
Y is O, NH, S, O-, NH-, or S-; Z is O or S; and
R6 and R7 are independently selected from H, substituted or unsubstituted alkyl, a mono- or divalent cationic salt, or an ammonium cationic salt
51. The compound according to claim 50, wherein Y and Z are O.
52. The compound according to any one of claims 40 to 51, wherein at least one of R1, R2, R3, R4 and R5 is phosphate ester according to the Formula (Ie);
Figure imgf000067_0003
wherein R6 and R7 are independently selected from H, a mono- or divalent cationic salt, or an ammonium cationic salt.
53. The compound according to any one of claims 40 to 52, wherein L is present and selected from -CO-, ester, phenol, phosphonate ester, carbamate, carbonate or a Mannich base.
54. The compound according to any one of claims 40 to 53, wherein L is -CO-.
55. The compound according to any one of claims 40 to 54, wherein D present and selected from substituted or unsubstituted alkylene, alkenylene, alkynylene, optionally interrupted by one or more heteroatom(s), aryl, heteroaryl, cycloalkyl or heterocycloalkyl.
56. The compound according to claim 55, wherein D is a substituted or unsubstituted alkylene, optionally interrupted by one or more heteroatom(s).
57. A compound according to the general Formula (II):
Figure imgf000068_0001
wherein
= denotes a single or double bond; and R1, R2 and R3 axe as defined in any one of claims 40 to 56.
58. A compound according to the general Formula (III):
Figure imgf000068_0002
wherein R3 is defined as in any one of claims 40 to 56.
59. A compound according to the general Formula (IV):
Figure imgf000069_0001
wherein
Q is substituted or unsubstituted alkylene, optionally interrupted by one or more heteroatom(s) X is H, a mono- or divalent calionic salt, or an ammonium cationic salt
60. The compound of claim 59, wherein Q is substituted or unsubstituted lower alkylene, optionally interrupted by one or more heteroatom(s).
61. A compound according to the general Formula V:
Figure imgf000069_0002
wherein R3 and R5 axe defined as in any one of claims 40 to 56.
62. A compound selected from the group comprising 3- (Benzyloxycarbonylbutylcarbonyloxy)flavone; 3-Hydroxyflavone 3- hemiadipate; 4'-(Benzyloxy)-3-(benzyloxycarbonylbutylcarbonyloxy)flavone; 4'-Hydroxyflavone 3-hemiadipate; 3 ',4'-Dibenzyloxy-3- (benzyloxycarbonylbutylcarbonyloxy)flavone; 3'-4'-Dihydroxyflavone 3- hemiadipate;3,4'-Di-(benzyloxycarbonylbutylcarbonyloxy)flavone; flavone 3,4'-bis(hemiadipate); 3,7-Di-(benzyloxycarbonylbutylcarbonyloxy)flavone;
3,7-Dihydroxyflavone 3,7-bis(hemiadipate); 4'-Hydroxy-3-Hydroxyflavone-3- quaternary ammounium ester; 4'-(Benzyloxy)-3- (dibenzyloxyphosphoryloxy)flavone or 3 -Hydroxyflavone-3 -phosphate disodium salt.
62. A method for synthesizing compounds in accordance with any one of claims 1 to 22.
63. A uutraceutical composition comprising a nutraceutically acceptable carrier or diluent together with at least one compound of the general Formula I:
Figure imgf000070_0002
wherein
= denotes a single or double bond; and
R1, R2, R3, R4, R5 are independently selected from H, OH or a group according to Formula (Ia):
Figure imgf000070_0001
in which
O is oxygen;
L is a linker group which is covalently linked to the oxygen and D, if present, or is covalently linked to the oxygen and E, or is absent;
D is a spacer group having a chain length equivalent to about 1 to 20 carbon atoms, or is absent; and
E is a solubilizing group; provided that at least one of R1, R2, R3, R4, R5 is other than H or OH.
PCT/AU2006/000314 2005-03-11 2006-03-10 Flavonoid compounds and uses thereof WO2006094357A1 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
BRPI0608402A BRPI0608402B8 (en) 2005-03-11 2006-03-10 flavonoid compounds and compositions comprising them
AU2006222556A AU2006222556B2 (en) 2005-03-11 2006-03-10 Flavonoid compounds and uses thereof
KR1020077023356A KR101397510B1 (en) 2005-03-11 2006-03-10 Flavonoid compounds and uses thereof
US11/885,736 US8017649B2 (en) 2005-03-11 2006-03-10 Flavonoid compounds and uses thereof
NZ560633A NZ560633A (en) 2005-03-11 2006-03-10 Flavonoid compounds and uses thereof
CN2006800078033A CN101137639B (en) 2005-03-11 2006-03-10 Flavonoid compounds and uses thereof
CA2601028A CA2601028C (en) 2005-03-11 2006-03-10 Flavonoid compounds and uses thereof
JP2008500009A JP5380069B2 (en) 2005-03-11 2006-03-10 Flavonoid compounds and uses thereof
ES06704987.4T ES2552108T3 (en) 2005-03-11 2006-03-10 Flavonoid compounds and uses thereof
EP06704987.4A EP1856085B1 (en) 2005-03-11 2006-03-10 Flavonoid compounds and uses thereof
DK06704987.4T DK1856085T3 (en) 2005-03-11 2006-03-10 FLAVONOID COMPOUNDS AND APPLICATIONS THEREOF

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2005901214A AU2005901214A0 (en) 2005-03-11 Flavonoid compounds and uses thereof
AU2005901214 2005-03-11

Publications (1)

Publication Number Publication Date
WO2006094357A1 true WO2006094357A1 (en) 2006-09-14

Family

ID=36952879

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU2006/000314 WO2006094357A1 (en) 2005-03-11 2006-03-10 Flavonoid compounds and uses thereof

Country Status (15)

Country Link
US (1) US8017649B2 (en)
EP (1) EP1856085B1 (en)
JP (1) JP5380069B2 (en)
KR (1) KR101397510B1 (en)
CN (1) CN101137639B (en)
AU (1) AU2006222556B2 (en)
BR (1) BRPI0608402B8 (en)
CA (1) CA2601028C (en)
DK (1) DK1856085T3 (en)
ES (1) ES2552108T3 (en)
NZ (1) NZ560633A (en)
RU (1) RU2431634C2 (en)
SG (1) SG162773A1 (en)
WO (1) WO2006094357A1 (en)
ZA (1) ZA200707427B (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008150085A3 (en) * 2007-06-07 2009-02-26 Dong A Pharm Co Ltd 3',4',5-trimethoxy flavone derivatives as stimulant of mucus secretion, method of the same, and pharmaceutical composition comprising the same
WO2010042886A2 (en) * 2008-10-10 2010-04-15 Limerick Biopharma, Inc. Pyrone analogs for therapeutic treatment
US7947733B2 (en) 2007-07-31 2011-05-24 Limerick Biopharma Phosphorylated pyrone analogs and methods
US8017649B2 (en) 2005-03-11 2011-09-13 Howard Florey Institute Of Experimental Physiology And Medicine Flavonoid compounds and uses thereof
AU2006233256B2 (en) * 2006-10-30 2012-01-19 Armaron Bio Pty Ltd Improved flavonols
WO2014056038A1 (en) 2012-10-11 2014-04-17 Neuprotect Pty Ltd Novel flavonoid compounds and uses thereof
EP2902399A1 (en) * 2014-02-03 2015-08-05 Versitech Limited Water-soluble derivatives and prodrugs of acacetin and methods of making and using thereof
CN113045527A (en) * 2021-03-22 2021-06-29 广东省科学院动物研究所 Dihydrothromone derivative and synthesis method and application thereof

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010514790A (en) * 2006-12-28 2010-05-06 リメリック バイオファーマ， インコーポレイテッド Methods and compositions for therapeutic treatment
AU2008282273A1 (en) * 2007-07-31 2009-02-05 Limerick Biopharma, Inc. Pyrone analog compositions and methods
WO2009018326A2 (en) * 2007-07-31 2009-02-05 Limerick Biopharma, Inc. Soluble pyrone analogs methods and compositions
US8034838B2 (en) * 2008-05-29 2011-10-11 Daryl Lee Thompson Composition and method for the treatment of neurological disorders
KR101586992B1 (en) * 2009-03-20 2016-01-20 건국대학교 산학협력단 A composition for the improvement of embryo development comprising flavonoid and the method thereof
WO2011013735A1 (en) * 2009-07-31 2011-02-03 国立大学法人 岡山大学 Novel flavanone derivative
JP6047092B2 (en) * 2010-07-27 2016-12-21 トラスティーズ オブ ボストン ユニバーシティ Aryl hydrocarbon receptor (AhR) modifier as a novel cancer therapy
CN102464642B (en) * 2010-11-18 2014-04-23 谢联金 Compound, preparation method thereof and application thereof as feed additive
KR101459712B1 (en) * 2012-09-10 2014-11-12 건국대학교 산학협력단 Flavonoid derivatives selectively inhibiting the activity of Janus kinase 3
CN102861053B (en) * 2012-10-27 2013-07-10 南京大学 Application of Houttuynoid D in leukemia treating medicine
CN104592246A (en) * 2013-10-30 2015-05-06 周亚伟 Flavonoid compound, preparation method and application thereof
US10729668B2 (en) 2014-06-30 2020-08-04 The Regents Of The University Of California Ketobutyrate compounds and compositions for treating age-related symptoms and diseases
CN104387360B (en) * 2014-11-21 2016-10-05 潍坊医学院 Naringenin fatty acid ester, its preparation method and the pharmaceutical composition with this compound as active component and application thereof
US10123991B2 (en) 2015-05-15 2018-11-13 Global Biolife Inc. Electrophilically enhanced phenolic compounds for treating inflammatory related diseases and disorders
CN105153254B (en) * 2015-08-29 2018-03-30 西南民族大学 A kind of flavone compound
CN105153093B (en) * 2015-08-29 2017-07-21 西南民族大学 A kind of flavone compound and its production and use
CN106632479B (en) * 2016-12-22 2018-10-23 贵州大学 O, O '-dialkyl group-O "-(substitution flavones -3- bases) phosphoric acid ester derivant, preparation method and application
WO2019005829A1 (en) * 2017-06-26 2019-01-03 Wayne State University Methods and compositions relating to steroid hormone receptor-dependent cancers
CN107382941B (en) * 2017-07-10 2020-05-08 石家庄学院 Flavone derivative and preparation method and application thereof
US20200164079A1 (en) * 2017-07-18 2020-05-28 Pvac Medical Technologies Ltd Anti-bacterial substance and composition thereof, medical and non-medical uses using the same, and products comprising said substance and compositions
CN109280067B (en) * 2017-07-21 2022-07-05 南京正大天晴制药有限公司 Diosmin derivative, preparation method and medical application thereof
CN107550902A (en) * 2017-10-31 2018-01-09 上海华堇生物技术有限责任公司 The medicinal usage of young fustic
CN108752378A (en) * 2018-07-12 2018-11-06 四川福思达生物技术开发有限责任公司 A kind of synthetic method of methyl hypophosphorous acid monoalkyl ester
CN108997426B (en) * 2018-07-19 2020-11-13 大连理工大学 Flavone alkoxy phosphoramidate derivative targeting Hsp60, preparation and application
CN114656579A (en) * 2020-12-22 2022-06-24 安庆北化大科技园有限公司 Low-toxicity flavonol sulfonate photoinitiator, visible light initiation system and application
CN113321633B (en) * 2021-05-21 2022-03-15 湖北工业大学 Quercetin-3-O-acetic acid- (3-chloro-4-thioamino) -phenyl ester and application thereof in preparation of diabetes drugs
CN115504970B (en) * 2022-10-18 2023-04-18 黑龙江中医药大学 Flavonoid derivative for treating myocardial ischemia and preparation method thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995025733A1 (en) * 1994-03-18 1995-09-28 Ferrer Internacional, S.A. 4-p-fluorobenzoyl-1-piperidinyl-propoxy-chromen-4-one derivatives, their preparation and their use in the treatment of psychosis and schizophrenia
WO1999066062A1 (en) * 1998-06-18 1999-12-23 Consiglio Nazionale Delle Ricerche Biocatalytic process for the preparation of 3-0-acyl-flavonoids
WO2001021608A2 (en) * 1999-09-23 2001-03-29 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Novel flavonoids
US6506792B1 (en) * 1997-03-04 2003-01-14 Sterix Limited Compounds that inhibit oestrone sulphatase and/or aromatase and methods for making and using
US20030055103A1 (en) * 2001-07-04 2003-03-20 Horacio Heinzen Utilization of achyrocline satureoides ("Marcela") extracts and liposomal preparations of natural and semi-synthetic flavonoids for the prevention and treatment of the consequences of stroke and neurodegenerative diseases

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US650846A (en) * 1899-05-10 1900-06-05 Heiman H Levy Branding-machine.
US3509026A (en) * 1967-01-19 1970-04-28 Litton Systems Inc Method of and apparatus for indicating the sensitivity of microorganisms to antibiotics
GB1461777A (en) * 1973-06-08 1977-01-19 Fisons Ltd 2-phenyl-4-oxo-4h-1-benzopyran derivatives
CA1309672C (en) * 1983-01-27 1992-11-03 Jannis G. Stavrianopoulos Methods and structures employing non-radioactive chemically-labeled polynucleotide probes
DE3442639A1 (en) * 1984-11-22 1986-05-22 Dr. Madaus & Co, 5000 Köln FLAVOLIGNANE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
US5070018A (en) * 1986-11-07 1991-12-03 The Board Of Trustees Of The Leland Stanford Junior University Method of controlling gene expression
JPH01153695A (en) * 1987-12-11 1989-06-15 Showa Denko Kk Production of rutin or quercetin phosphoric acid ester
JPH01308476A (en) * 1988-06-06 1989-12-13 Showa Denko Kk Ultraviolet ray absorber
GB8926715D0 (en) * 1989-11-28 1990-01-17 Haessle Ab Improvements relating to the administration of pharmaceutical agents
DE4134384A1 (en) * 1991-10-17 1993-04-22 Ruetgerswerke Ag MODIFIED HUMINATES, METHOD FOR THEIR PRODUCTION AND USE
FR2719467B1 (en) * 1994-05-05 1996-05-31 Oreal Use of flavonoids to preserve and / or strengthen the mechanical properties of the hair and method of protecting hair using these compounds.
WO1996021440A1 (en) * 1995-01-09 1996-07-18 Alpha-Therapeutics, Inc. Methods for increasing the bioavailability of biological active agents
US6921776B1 (en) * 1996-02-16 2005-07-26 Sterix Limited Compound
FR2764889B1 (en) 1997-06-20 2000-09-01 Sod Conseils Rech Applic NOVEL 2- (IMINOMETHYL) AMINO-PHENYL DERIVATIVES, THEIR PREPARATION, THEIR USE AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US6180661B1 (en) * 1997-04-28 2001-01-30 Marigen, S.A. Bioflavonol-glycoside peresters and their incorporation into pharmacologically active concentrates and ultramicroemulsions
US5972995A (en) * 1997-10-16 1999-10-26 Children's Hospital Medical Center Of Northern California Compositions and methods for cystic fibrosis therapy
FR2778663B1 (en) * 1998-05-15 2001-05-18 Coletica NOVEL ESTERS OF FLAVONOIDS, THEIR USE IN COSMETICS, DERMOPHARMACY, PHARMACY AND AGRI-FOOD
JP2002523501A (en) 1998-09-01 2002-07-30 エルジ ケミカル リミテッド Novel CDK inhibitor having flavone structure
WO2000023073A1 (en) * 1998-10-20 2000-04-27 Korea Institute Of Science And Technology Bioflavonoids as plasma high density lipoprotein level increasing agent
JP2002535410A (en) * 1999-01-27 2002-10-22 ザィエリンスキ，ラブラトリー Hesperetin proform with enhanced bioavailability
EP1055408A1 (en) * 1999-05-26 2000-11-29 Nutrinova Nutrition Specialties & Food Ingredients GmbH Sorbate preserved compositions, process for their manufacture and their use
WO2001003681A2 (en) * 1999-07-08 2001-01-18 Prendergast Patrick T Use of flavones, coumarins and related compounds to treat infections
DE10003786A1 (en) * 2000-01-28 2001-08-02 Merck Patent Gmbh Galenic formulation
EP1127572A3 (en) * 2000-02-25 2003-05-02 Basf Aktiengesellschaft Use of flavones for treating cycloxygenase-2 mediated diseases
GB2348371B (en) * 2000-03-14 2001-04-04 Soares Da Silva Patricio Compositions comprising blockers of L-DOPA renal cell transfer for the treatment of Parkinson's disease
EP1136073A1 (en) * 2000-03-22 2001-09-26 N.V. Nutricia Compositions suitable for the treatment of damage caused by ischemia/reperfusion or oxidative stress
KR100833805B1 (en) * 2000-04-19 2008-05-30 니치유 가부시키가이샤 Cosmetic composition
DE10031457C2 (en) * 2000-06-28 2002-12-12 Jean Krutmann Use of O-beta-hydroxyethylrutoside or its aglycon for the systemic treatment and prophylaxis of UV-induced dermatoses and undesirable long-term consequences of UV radiation
WO2002009699A2 (en) * 2000-07-28 2002-02-07 Immupharm Aps Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract
DE10056400A1 (en) * 2000-11-14 2002-05-23 Merck Patent Gmbh Galenic formulation
FR2820974B1 (en) * 2001-02-21 2004-02-13 Pharmascience Lab TOPICAL COMPOSITION COMPRISING A TRUE SOLUTION CONTAINING A CHROMANE OR CHROMENE DERIVATIVE, ITS PREPARATION METHOD AND ITS COSMETIC AND THERAPEUTIC USE
JP3691764B2 (en) * 2001-03-07 2005-09-07 オリンパス株式会社 Autoclave equipment
WO2004001058A2 (en) * 2001-05-04 2003-12-31 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
FI20011507A0 (en) 2001-07-10 2001-07-10 Orion Corp New compounds
ATE476178T1 (en) * 2001-09-06 2010-08-15 Synorx Inc INHIBITION OF T-LYMPHOCYTE ACTIVATION BY 3-DEOXYFLAVONOIDS AND RELEVANT THERAPIES
ITRM20010600A1 (en) * 2001-10-04 2003-04-04 Brane Tech S R L FLAVONOID COMPOUNDS CAPABLE OF MODIFYING THE PHYSICAL AND / OR DYNAMIC STATE OF BIOLOGICAL MEMBRANES AND OF STIMULATING THE ENDOGENIC SYNTHESIS OF PROTEIN
GB0125532D0 (en) * 2001-10-24 2001-12-12 Burton Michael Enzyme activity indicators
US20030125264A1 (en) * 2001-12-29 2003-07-03 Kimberly-Clark Worldwide, Inc. Methods For Treating Wounds
US20050032882A1 (en) * 2002-03-06 2005-02-10 Sophie Chen Botanical extract compositions and methods of use
US8945518B2 (en) * 2002-04-30 2015-02-03 Unigen, Inc. Formulation of dual eicosanoid system and cytokine system inhibitors for use in the prevention and treatment of oral diseases and conditions
KR100946822B1 (en) * 2002-05-01 2010-03-09 가부시끼가이샤 하야시바라 세이부쓰 가가꾸 겐꾸조 Calcium-containing tissue strengthening agents and use thereof
FR2841784B1 (en) 2002-07-08 2007-03-02 COMPOSITION BASED ON SUBSTITUTED 1,3-DIPHENYLPROP-2EN-1-ONE DERIVATIVES, PREPARATION AND USES
US20050080021A1 (en) * 2002-08-15 2005-04-14 Joseph Tucker Nitric oxide donating derivatives of stilbenes, polyphenols and flavonoids for the treatment of cardiovascular disorders
US20050080024A1 (en) * 2002-08-15 2005-04-14 Joseph Tucker Nitric oxide donating derivatives for the treatment of cardiovascular disorders
DE10244282A1 (en) * 2002-09-23 2004-04-01 Merck Patent Gmbh Preparation with antioxidant properties
CN1717227A (en) * 2002-10-24 2006-01-04 伊穆法姆公司 Pharmaceutical compositions comprising flavonoids and menthol
WO2004069233A1 (en) * 2003-02-04 2004-08-19 Kabushiki Kaisha Yakult Honsha Breast cancer-resistant protein inhibitor
RU2366447C2 (en) * 2003-10-09 2009-09-10 Медигене Аг Therapeutic agent for treatment of precancerous skin lesions
US20050079235A1 (en) * 2003-10-09 2005-04-14 Eggert Stockfleth Use of a polyphenol for the treatment of actinic keratosis
AU2004279644A1 (en) * 2003-10-10 2005-04-21 Resverlogix Corp. Treatment of diseases associated with the egr-1 enhancer element
KR20070020036A (en) * 2004-05-18 2007-02-16 브라이트 퓨처 파마수티컬 라보라토리스 리미티드 Compositions for sleeping disorders
US20060014705A1 (en) * 2004-06-30 2006-01-19 Howitz Konrad T Compositions and methods for selectively activating human sirtuins
US20060105967A1 (en) * 2004-11-18 2006-05-18 Advanced Gene Technology, Corp. Flavone derivatives as TNFalpha inhibitors or antagonists
RU2431634C2 (en) 2005-03-11 2011-10-20 Говард Флори Инститьют Оф Експериментл Физиолоджи Энд Медсин Flavonoid compounds and use thereof
TWI282276B (en) * 2005-04-12 2007-06-11 Univ Taipei Medical Pharmaceutical composition containing flavonoids which possess selective inhibition on phosphodiesterase 4 or 3/4
EP1803809A3 (en) * 2005-08-12 2007-12-19 Abgenomics Corporation Modulation of peroxisome proliferator-activated receptors
US20090124688A1 (en) 2006-01-06 2009-05-14 Rong-Hwa Lin Prostaglandin reductase inhibitors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995025733A1 (en) * 1994-03-18 1995-09-28 Ferrer Internacional, S.A. 4-p-fluorobenzoyl-1-piperidinyl-propoxy-chromen-4-one derivatives, their preparation and their use in the treatment of psychosis and schizophrenia
US6506792B1 (en) * 1997-03-04 2003-01-14 Sterix Limited Compounds that inhibit oestrone sulphatase and/or aromatase and methods for making and using
WO1999066062A1 (en) * 1998-06-18 1999-12-23 Consiglio Nazionale Delle Ricerche Biocatalytic process for the preparation of 3-0-acyl-flavonoids
WO2001021608A2 (en) * 1999-09-23 2001-03-29 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Novel flavonoids
US20030055103A1 (en) * 2001-07-04 2003-03-20 Horacio Heinzen Utilization of achyrocline satureoides ("Marcela") extracts and liposomal preparations of natural and semi-synthetic flavonoids for the prevention and treatment of the consequences of stroke and neurodegenerative diseases

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
DATABASE CA [online] BARRERO A.F., XP008114721, accession no. STN Database accession no. (127:229311) *
DATABASE CA [online] MARTINI H. ET AL., XP008114720, accession no. STN Database accession no. (127:290447) *
DATABASE REGISTRY [online] *
DATABASE REGISTRY [online] XP008114736 *
FITOTERAPIA, vol. 68, no. 3, 1997, pages 281 - 283 *
HERGERT H.L. ET AL.: "The Infrared Spectra of Lignin and Related Compounds. I. Characteristic Carbonyl and Hydroxyl Frequencies of Some Flavanones, Flavones, Chalcones and Acetophenones", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 75, 1953, pages 1622 - 1625, XP008120039 *
KAMKHALIA N.H. ET AL.: "Synthesis of (plus or minus) Fustin and its Derivatives", CURRENT SCIENCE, vol. 32, no. 3, 1963, pages 112 - 113, XP008120270 *
MYCOLOGICAL RESEARCH, vol. 101, no. 8, 1997, pages 920 - 922 *
See also references of EP1856085A4 *
SHEN WANG; GREGORY DUSTING; CLIVE MAY; OWEN WOODMAN, BRITISH JOURNAL OF PHARMACOLOGY, vol. 142, 2004, pages 443 - 452

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8017649B2 (en) 2005-03-11 2011-09-13 Howard Florey Institute Of Experimental Physiology And Medicine Flavonoid compounds and uses thereof
AU2006233256B2 (en) * 2006-10-30 2012-01-19 Armaron Bio Pty Ltd Improved flavonols
US8203011B2 (en) 2007-06-07 2012-06-19 Dong-A Pharm. Co., Ltd. 3′,4′,5-trimethoxy flavone derivatives as stimulant of mucus secretion, method for the same, and pharmaceutical composition comprising the same
CN101679341B (en) * 2007-06-07 2012-06-06 东亚制药株式会社 3',4',5-trimethoxy flavone derivatives as stimulant of mucus secretion, method of the same, and pharmaceutical composition comprising the same
WO2008150085A3 (en) * 2007-06-07 2009-02-26 Dong A Pharm Co Ltd 3',4',5-trimethoxy flavone derivatives as stimulant of mucus secretion, method of the same, and pharmaceutical composition comprising the same
US7947733B2 (en) 2007-07-31 2011-05-24 Limerick Biopharma Phosphorylated pyrone analogs and methods
WO2010042886A3 (en) * 2008-10-10 2010-11-11 Limerick Biopharma, Inc. Pyrones for the treatment of metabolic disorders
WO2010042886A2 (en) * 2008-10-10 2010-04-15 Limerick Biopharma, Inc. Pyrone analogs for therapeutic treatment
CN102438614A (en) * 2008-10-10 2012-05-02 利默里克生物制药公司 Pyrone analogs for therapeutic treatment
WO2014056038A1 (en) 2012-10-11 2014-04-17 Neuprotect Pty Ltd Novel flavonoid compounds and uses thereof
KR20150096376A (en) * 2012-10-11 2015-08-24 아르마론 바이오 피티와이 리미티드 Novel flavonoid compounds and uses thereof
AU2013330222B2 (en) * 2012-10-11 2016-05-12 Armaron Bio Pty Ltd Novel flavonoid compounds and uses thereof
RU2647842C2 (en) * 2012-10-11 2018-03-21 Армарон Байо Пти Лтд New compounds of flavonoids and their application
US10316053B2 (en) 2012-10-11 2019-06-11 Armaron Bio Pty Ltd Flavonoid compounds and uses thereof
KR102169002B1 (en) * 2012-10-11 2020-10-23 아르마론 바이오 피티와이 리미티드 Novel flavonoid compounds and uses thereof
EP2902399A1 (en) * 2014-02-03 2015-08-05 Versitech Limited Water-soluble derivatives and prodrugs of acacetin and methods of making and using thereof
CN113045527A (en) * 2021-03-22 2021-06-29 广东省科学院动物研究所 Dihydrothromone derivative and synthesis method and application thereof

Also Published As

Publication number Publication date
BRPI0608402B1 (en) 2020-10-13
AU2006222556B2 (en) 2011-09-29
KR101397510B1 (en) 2014-05-22
CA2601028C (en) 2014-05-27
NZ560633A (en) 2011-08-26
BRPI0608402A2 (en) 2009-12-29
ES2552108T3 (en) 2015-11-25
SG162773A1 (en) 2010-07-29
DK1856085T3 (en) 2015-10-05
US8017649B2 (en) 2011-09-13
JP5380069B2 (en) 2014-01-08
BRPI0608402B8 (en) 2021-05-25
CA2601028A1 (en) 2006-09-14
CN101137639B (en) 2012-05-23
JP2008532951A (en) 2008-08-21
US20090130051A1 (en) 2009-05-21
RU2431634C2 (en) 2011-10-20
EP1856085A1 (en) 2007-11-21
CN101137639A (en) 2008-03-05
AU2006222556A1 (en) 2006-09-14
EP1856085B1 (en) 2015-07-08
EP1856085A4 (en) 2010-11-03
ZA200707427B (en) 2008-11-26
KR20070114315A (en) 2007-11-30
RU2007137659A (en) 2009-04-20

Similar Documents

Publication Publication Date Title
AU2006222556B2 (en) Flavonoid compounds and uses thereof
EP0765160B1 (en) Dexanabinol derivatives and their use as neuroprotective pharmaceutical compositions
US6096740A (en) Dexanabinol derivatives and their use as neuroprotective pharmaceutical compositions
FR2543550A1 (en) NOVEL TETRAHYDROXY-3 &#39;, 4&#39;, 5.7 FLAVONE DERIVATIVES, THEIR PREPARATION METHOD AND THEIR THERAPEUTIC USE
KR0185717B1 (en) Glycyrrhetic acid derivatives
JP2009046486A (en) Analogue or derivative of quercetin (prodrug)
PT92299B (en) PROCESS FOR THE PREPARATION OF TOCOFEROL ANALOGS WITH CARDIOPROTECTIVE ACTIVITY
JP2018184414A (en) Novel flavonoid compounds and uses thereof
BR9814053B1 (en) lipophilic diesters of chelating agents.
EP0423366B1 (en) Phospholipid derivatives
US6323238B1 (en) Benzopyranyl guanidine derivatives, process for preparation thereof, and pharmaceutical compositions containing them
WO2016147185A1 (en) Adenosine thiophosphate derivatives and uses thereof
US20210139447A1 (en) Lipophenolic Flavonoid Derivatives Useful To Reduce Carbonyl And Oxidative Stresses (COS)
JPH10203976A (en) Medicine comprising isoflavones or xanthones

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2006222556

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 560633

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2006222556

Country of ref document: AU

Date of ref document: 20060310

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006222556

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006704987

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200680007803.3

Country of ref document: CN

Ref document number: 2008500009

Country of ref document: JP

Ref document number: MX/a/2007/011086

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2601028

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 3769/KOLNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2007137659

Country of ref document: RU

Ref document number: 1020077023356

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2006704987

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11885736

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0608402

Country of ref document: BR

Kind code of ref document: A2